

**University of Miami  
Curriculum Vitae**

**1. Date:** June 06, 2022

**I. PERSONAL**

**2. Name:** Isildinha M. Reis, Dr.PH

**3. Office Phone:** (305) 243-5884

**4. Office address:** University of Miami School of Medicine, Dept. of Public Health Sciences  
Clinical Research Building (R669)  
1120 NW 14th Street 10<sup>th</sup> Floor, Room 1045  
Miami, FL 33136, USA

**5. Current Academic Rank:** Professor

**5A. Current Track of Appointment:** Research Track

**6. Primary Department:** Public Health Sciences (Formerly "Epidemiology and Public Health",  
name change date 3/29/2013.)

**7. Secondary or Joint Departmental Appointments:** NA

**II. HIGHER EDUCATION**

**8. Institutional:**

University of California at Los Angeles School of Public Health	DrPH in Biostatistics	03/1996
University of São Paulo, Brazil School of Public Health	<i>Lato sensu</i> M.S in Public Health	12/1991
Institute of Mathematics and Statistics	M.S. in Statistics	11/1989
Institute of Mathematics and Statistics	B.S. in Statistics	02/1981

**9. Non-Institutional:**

Statistics in Health. Summer course of the University of Reading Statistical Service Centre, Reading, United Kingdom.	07-09/1989
Variance Estimation in Complex Surveys. Short-course promoted by the International Association of Survey Statisticians, Paris, France.	08/1989

**10. Certification, licensure:**

*Institutional Review Board Educational Seminar.*  
Accreditation required for performing research on human subjects.  
University of Miami School of Medicine, Human Subjects Office. 11/2000



### **III. EXPERIENCE**

#### **11. Academic:**

<b>Research Professor</b>	06/2017 - present
<b>Research Associate Professor</b>	06/2006 - 05/2017
<b>Research Assistant Professor</b>	04/1999 - 05/2006
Department of Public Health Sciences Leonard M. Miller School of Medicine, University of Miami	
<b>Faculty Biostatistician</b>	04/1999 - present
Sylvester Biostatistics and Bioinformatics Shared Core Resource Sylvester Comprehensive Cancer Center Leonard M. Miller School of Medicine, University of Miami	
<b>Director</b>	04/2012 - 06/2015
<b>Interim co-Director</b>	04/2008 - 11/2008
<b>Interim co-Director</b>	07/2004 - 12/2006
Division of Biostatistics, Sylvester Biostatistics and Bioinformatics Shared Core Resource Sylvester Comprehensive Cancer Center Leonard M. Miller School of Medicine, University of Miami	
<b>Professora Doutora (Assistant Professor)</b>	03/1996 - 01/1999
<b>Assistente (Assistant)</b>	04/1989 - 03/1996
<b>Auxiliar de Ensino (Lecturer)</b>	07/1985 - 04/1989
Department of Epidemiology School of Public Health, University of São Paulo, Brazil	

#### **12. Hospital Appointments: N/A**

#### **13. Non-Academic:**

<b>Research Assistant</b>	08/1993 - 06/1995
Section of Public Health Dentistry School of Dentistry, University of California at Los Angeles	
<b>Junior Systems Analyst</b>	12/1983 - 06/1985
Department of Nutrition, School of Public Health, University of São Paulo, Brazil	

**Statistical consultant**

1984 -1985

Department of Nutrition, School of Public Health,  
University of São Paulo, Brazil.

Study 1: "Nutrition and health conditions of the children in the city of São Paulo"

Principal Investigator: Carlos Augusto Monteiro, MD

Study 2: "Prevalence of anemia in health centers of São Paulo state"

Principal Investigator: Sophia Cornbluth Szarfac

Study 3: "The use of vitamin C to combat anemia"

Principal Investigator: Sophia Cornbluth Szarfac

**Biostatistician**

12/1981 - 11/1983

Indústrias Farmacêuticas [Pharmaceutical Industry]  
Fontoura-Wyeth S.A., São Paulo, Brazil

**14. Military:** N/A

#### **IV. PUBLICATIONS**

**15. Books and monographs published:** None

**16. Juried or refereed journal articles and exhibitions:** (127 publications)

1. Saul EE, Alderuccio J, Reis IM, Zhao W, Iyer SG, Rodriguez G, Desai A, Chapman JR, Markoe AM, Isrow DM, Lossos I. Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma. *Am J Hematol.*, 2022 May 21. doi: 10.1002/ajh.26591. Online ahead of print. PMID: 35560252. **Impact Factor 10.05.**
2. Venkatramani V, **Reis IM**, Gonzalgo ML, Castle EP, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Parekh DJ. Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence A Secondary Analysis of a Randomized Clinical Trial. *JAMA Network Open.* 2022 Feb 1;5(2):e2148329. doi:10.1001/jamanetworkopen.2021.48329 Online ahead of print. PMID: 35171260. **Impact Factor 8.483.**
3. Alderuccio JP, Kuker RA, Barreto-Coelho P, Martinez BM, Miao F, Kwon D, Beitinjaneh A, Wang TP, **Reis IM**, Lossos IS, Moskowitz CH. Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma. *Leuk Lymphoma.* 2022 Jan;63(1):43-53. doi: 10.1080/10428194.2021.1966786. Epub 2021 Aug 17. PMID: 34414842. **Impact Factor 2.891.**
4. Jiang X, Lu X, Gentles A, Zhao D, Wander S, Zhang Y, Natkunam Y, Slingerland J, **Reis IM**, Rabinovich B, Abdulreda M, Moy V, Lossos I. HGAL inhibits lymphoma dissemination by interacting with multiple Cytoskeletal proteins. *Blood Advances.* 2021 Dec 14; 5(23):5072-5085. doi: 10.1182/bloodadvances.2021004304. PMID: 34543391. **Impact Factor 6.799.**
5. Smith DH, Raslan S, **Reis IM**, Al-Awady A, Buitron I, Perez M, Liu H, Halgowich J, Gordon C, Webb Hooper M, Barengo NC, Franzmann EJ. Decreased Levels of Soluble CD44 in a High-Risk Population following a Smoking Cessation Program. *Int J Environ Res Public Health.* 2021 Dec 14;18(24):13174. doi: 10.3390/ijerph182413174. PMID: 34948786. **Impact Factor 3.39.**
6. Florindez JA, Alderuccio JP, **Reis IM**, Lossos IS. Primary thyroid lymphoma: survival analysis of SEER database (1995-2016). *Leuk Lymphoma.* 2021 Nov; 62(11):2796-2799. doi: 10.1080/10428194.2021.1933479. Epub 2021 May 27. PMID: 34039243. **Impact Factor 3.093.**
7. Kwon D, Reddy RRS, **Reis IM**. ABCMETAapp: R shiny application for simulation-based estimation of mean and standard deviation for meta-analysis via approximate Bayesian computation. *Res Synth Methods.* 2021 Jun 20. doi: 10.1002/jrsm.1505. Online ahead of print. PMID: 34148300. **Impact Factor 5.273.**
8. Alderuccio JP, Florindez JA, Reis IM, Zhao W, Izidore S, Lossos IS. Treatments and Outcomes in Stage I Extranodal Marginal Zone Lymphoma in the United States. *Cancers.* 2021 Apr 9;13(8):1803. PMID: 3391880, PMCID: PMC8069638. DOI: 10.3390/cancers13081803. **Impact Factor 6.126.**
9. Horodyski L, Ball B, Emile C, Rhodes A, Miao F, **Reis IM**, Carasquillo M, Livingstone J, Matadial C, Ritch CR, Deane LA. Safe transition to opioid-free pathway after robotic-assisted laparoscopic prostatectomy. *J Robot Surg.* 2021 Apr 15. doi: 10.1007/s11701-021-01237-0. Online ahead of print. PMID: 33855681. **Impact Factor 2.**

10. Alderuccio JP, Saul EE, Iyer SG, **Reis IM**, Alencar AJ, Rosenblatt JD, Lossos IS. R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - long term follow up results. *Am J Hematol.* 2021 Mar 18. doi: 10.1002/ajh.26163. PMID: 33735476. **Impact Factor 6.973.**
11. Bell EB, **Reis IM**, Cohen ER, Almuhaimeid T, Smith DH, Alotaibi F, Gordon C, Gomez-Fernandez C, Goodwin WJ, Goodwin WJ, and Franzmann EJ. Green salad intake is associated with improved oral cancer survival and lower soluble CD44 levels. *Nutrients.* 2021 Feb; 13(2): 372. Published online 2021 Jan 26. doi: 10.3390/nu13020372. PMID: 33530399. **Impact Factor 4.546.**
12. Martos MP, Katz JE, Parmar M, Jain A, Soodana-Prakash NP, Punnen S, Gonzalgo ML, **Reis IM**, Smith NA, Shah HN. Impact of peri-operative factors on nadir serum prostate-specific antigen levels after holmium laser enucleation of prostate. *BJUI Compass* 2020, WJUR-D-20-01750 - Submission Notification to co-author) **Impact Factor 5.588.**
13. Martin L, Ossin D, Schachar J, Devakumar H, Alas A, Davila GW, **Reis IM**, Miao F, Hurtado E. Comparison of methods to identify stress urinary incontinence in women with pelvic organ prolapse. *Female Pelvic Med Reconstr Surg.* 2021 Jan 1; 27(1):e127-e132. doi: 10.1097/SPV.0000000000000858. PMID: 33369965. **Impact Factor 1.503.**
14. Punnen S, Stoyanova R, Kwon D, **Reis IM**, Soodana-Prakash N, Ritch CR, Nahar Bm Gonzalgo ML, Kava B, Liu Y, Arora H, Gaston SM, Castillo RP, DalPra A, Abramowitz M, Kryvewenko ON, Davicioni E, Pollack A, Parekh D. Heterogeneity in genomic risk assessment from tissue based prognostic signatures used in the biopsy setting and the impact of MRI targeted biopsy. *J Urol.* 2020, JU-20-2188. PMID: 33356482. **Impact Factor 5.925.**
15. Florindez JA, Alderuccio JP, **Reis IM**, Lossos IS. Survival analysis in treated plasmablastic lymphoma patients: a population-based study. *Am. J. of Haematol.* 2020;95(11):1344-1351, doi: 10.1002/ajh.25955. PMID: 32777103. **Impact Factor 5.020.**
16. Florindez JA, Alderuccio JP, **Reis IM**, Lossos IS. Splenic marginal zone lymphoma: A US population-based survival analysis (1999-2016). *Cancer.* 2020 Nov 1; 126(21):4706-4716. doi: 10.1002/cncr.33117. PMID: 32767702. **Impact Factor 5.742.**
17. Lossos IS, **Reis IM**, Rosenblatt JD, Alderuccio JP. Long-term outcomes of frontline <sup>90</sup>Y-ibritumomab tiuxetan in marginal zone lymphoma. *Leuk Lymphoma.* 2020 Dec; 61(13):3234-3238. doi:10.1080/10428194.2020.1802449. PMID: 32755329. **Impact Factor 3.093.**
18. Johnson, AL., Medina H, **Reis IM**, Schlumbrecht M, Pinheiro, PS. The Role of Histology on Endometrial Cancer Survival Disparities in Diverse Florida. Accepted for publication in *PLOS ONE* (PONE-D-19-33494R2, email 7/8/2020). **Impact Factor 2.870**
19. Liu J, Medina H, **Reis IM**, Sussman DA, Pinheiro, PS. Disadvantages for non-Hispanic Whites in gastric carcinoma survival in Florida. *Cancer Causes Control.* 2020 Sep;31(9):815-826. doi: 10.1007/s10552-020-01320-1. PMID: 32462560. **Impact Factor 2.300.**
20. Cohen ER, **Reis IM**, Gomez-Fernandez C, Smith D, Pereira L, Freiser ME, Marotta G, Thomas GR, Sargi ZB, Franzmann EJ. CD44 and associated markers in oral rinses and tissues from oral and oropharyngeal cancer patients. *Oral Oncol.* 2020 Jul;106:104720. doi: 10.1016/j.oraloncology.2020.104720. PMID: 32325304. **Impact Factor 3.98.**
21. Husnain M, Kuker R, **Reis IM**, Iyer SG, Zhao W, Chapman JR, Vega F, Lossos IS, Alderuccio JP. Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis. *Cancer Med.* 2020 Jul;9(14):5051-5064. doi: 10.1002/cam4.3096. PMID: 32452658;PMCID: PMC7367627. **Impact Factor 3.362.**

22. Ramasamy R, Masterson TA, Best J, Bitran J, Ibrahim E, Molina M, Kaiser U, Miao F, **Reis IM**. Effect of Natesto on Reproductive Hormones, Semen Parameters and Hypogonadal Symptoms: A single-center, open-label, single-arm trial. *J Urol*. 2020 Sep; 204(3):557-563. doi: 10.1097/JU.0000000000001078. PMID: 32294396. **Impact Factor 5.925**.  
[Reply by Authors](#). Ramasamy R, Masterson TA, Best JC, Bitran J, Ibrahim E, Molina M, Kaiser UB, Miao F, Reis IM. *J Urol*. 2020 Sep;204(3):563. doi: 10.1097/JU.0000000000001078.03. PMID: 32574104.
23. Becerra MF, Venkatramani V, **Reis IM**, Soodana-Prakash N, Punnen S, Gonzalgo ML, Raolji S, Castle EP, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Parekh DJ. Health-Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial - A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy. *J Urol*. 2020 Sep;204(3):450-459. doi: 10.1097/JU.0000000000001029. PMID: 32271690. **Impact Factor 5.925**.
24. Patel P, Katz J, Lokeshwar SD, Molina M, **Reis IM**, Clavijo R, Ramasamy R. Phase II Randomized, Clinical Trial Evaluating 2 Schedules of Low-Intensity Shockwave Therapy for the Treatment of Erectile Dysfunction. *Sex Med*. 2020 Jun;8(2):214-222. doi: 10.1016/j.esxm.2020.01.010. PMID: 32184082; PMCID: PMC7261672. **Impact Factor 3.151**.
25. Nahar B, Bhat A, **Reis IM**, Soodana-Prakash N, Becerra MF, Lopategui D, Venkatramani V, Patel R, Madhusoodanan V, Kryvenko ON, Ritch CR, Gonzalgo ML, Punnen S, Parekh DJ. Prospective Evaluation of Focal High-Intensity Focused Ultrasound (HIFU) for Patients with Localized Prostate Cancer. *J Urol*. 2020 Sep;204(3):483-489. doi: 10.1097/JU.0000000000001015. PMID: 32167866. **Impact Factor 5.925**.
26. Alderuccio JP, Isrow D, **Reis IM**, Iyer SG, Meshman JJ, Zhao W, Vega F, Chapman JR, Markoe AM, Lossos IS. Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not? *Blood*. 2020 Apr 9;135(15):1299-1302. doi: 10.1182/blood.2019003236. PMID: 31978219; PMCID: PMC7265788. **Impact Factor 16.601**.
27. Pollack A, Chinea FM, Bossart E, Kwon D, Abramowitz MC, Lynne C, Jorda M, Marples B, Patel VN, Wu X, **Reis I**, Studenski MT, Casillas J, Stoyanova R. Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy, *Int J Radiat Oncol Biol Phys*, (Feb 2020), doi: 10.1016/j.ijrobp.2020.01.052. PMID: 32084522. **Impact Factor 6.203**.
28. Alghamdi SA, Krishnamurthy K, Garces Narvaez SA, Algashaamy KJ, Aoun J, **Reis IM**, Recine MA, Jorda M, Poppiti RJ, Gomez-Fernandez CR. Low-grade ductal carcinoma in situ: Improving Interobserver Reproducibility on the Path to Surveillance Strategies. *Am J Clin Pathol*., 2020 Feb 8;153(3):360-367. doi: 10.1093/ajcp/aqz179. PMID:31769792. **Impact Factor 2.413**.
29. Venkatramani V, **Reis IM**, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Soodana-Prakash N, Becerra MF, Swain S, Kendrick K, Smith JA Jr, Thompson IM, Parekh DJ. Predictors of recurrence, progression-free and overall survival following open versus robotic radical cystectomy: Analysis from the RAZOR trial with a 3-year follow-up. *J Urol*. 2020 Mar; 203(3):522-529. doi: 10.1097/JU.0000000000000565. PMID: 31549935; PMCID: PMC7487279. **Impact Factor 5.647**.
30. Soodana-Prakash N, Castillo RP, **Reis IM**, Stoyanova R, Kwon D, Velasquez MC, Nahar B, Kannabur P, Johnson TA, Swain SK, Ben-Yakar N, Venkatramani V, Ritch C, Satyanarayana

- R, Gonzalgo ML, Parekh DJ, Bittencourt L, Punnen S. Validation of dominant and secondary sequence utilization in PI-RADS v2 for classifying prostatic lesions. *Can J Urol*. 2019 Jun; 26(3):9763-9768. PMID: 31180306. **Impact Factor 5.157.**
31. Weed DT, Zilio S, **Reis IM**, Sargi Z, Abouyared M, Gomez CR, Civantos FJ, Rodriguez CP, Serafini P. The reversal of immune exclusion mediated by Tadalafil and an anti-tumor vaccine also induces PDL1 upregulation in recurrent head and neck squamous cell carcinoma: interim analysis of a phase I clinical trial. *Frontiers in Immunology* 2019 May; 10:1206-1204. PMID: 31214178. **Impact Factor 6.429.**
  32. Lee E, Nelson OL, Puyana C, Takita C, Wright JL, Zhao W, **Reis IM**, Lin RY, Hlaing WM, Bakalar JL, Yang GR, Hu JJ. Association between C-reactive protein and radiotherapy-related pain in a tri-racial/ethnic population of breast cancer patients: A prospective cohort study. *Breast Cancer Research* 2019 May 28;21(1):70. PMID: 31138314. **Impact Factor 6.142.**
  33. Birnbaum MD, Zhao N, Moorthy BT, Patel DM, Kryvenko ON, Heidman L, Kumar A, Morgan WM, Ban Y, **Reis IM**, Chen X, Gonzalo ML, Jorda M, Burnstein KL, Zhang F. Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis. *Oncogene* 2019 Feb;38(6):838-851. PMID: 30177837. **Impact Factor 40.137.**
  34. Alderuccio JC, **Reis IM**, Zhao W, Lossos IS. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. *Am J Hematol*. 2019 May;94(5):585-596. PMID: 30784098. **Impact Factor 5.303.**
  35. Rich BJ, Perlow H, Kodiyan J, Portelance L, **Reis IM**, Pearson JM, Slomovitz B, Wolfson A. Impact of Greater than Three Cycles of Adjuvant Chemotherapy plus Vaginal Brachytherapy on Outcome of Patients with At-Risk Stage I-II Endometrial Carcinoma. *Annals of Clinical Oncology* 2019;1(1):1-7 (doi:10.31487/j.ACO.2018.01.005). **Impact Factor 14.196**
  36. de la Fuente MI, Alderuccio JC, Reis, IM, Omuro A, Markoe A, Echegaray JJ, Davis JL, Harbour JW, Lossos IS. Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. *Am J Hematol*. 2019;94:455-460. PMID: 30663807. **Impact Factor 5.303.**
  37. Alderuccio, J, Zhao, W, Desai A, Gallastegui N, Ramdial J, Kimble E, de la Fuente MI, Rosenblatt JD, Chapman JR, Vega F, Reis IM, Lossos, I. Risk factors for transformation to higher grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution. *J Clin Oncol*. 2018 Oct 12. [Epub ahead of print] PMID: 30312133. **Impact Factor 26.303.**
  38. Ramey SJ, Yechieli R, Zhao W, Kodiyan J, Asher D, Chinea FM, Patel V, **Reis IM**, Wang L, Wilky BA, Subhawong T, Trent JC 2nd. Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER. *Cancer Med*. 2018 Sep;7(9):4228-4239. PMID: 30030882. **Impact Factor 3.362.**
  39. Kwon D, **Reis IM**, Breto AL, Tschudi Y, Gautney N, Zavala-Romero O, Lopez C, Ford JC, Punnen S, Pollack A, Stoyanova R. Classification of Suspicious Lesions on Prostate multiparametric MRI using Machine Learning. *J Med Imaging (Bellingham)*. 2018 Jul;5(3):034502. PMID: 30840719. **Impact Factor NA.**
  40. Stoyanova R, Chinea F, Kwon D, **Reis IM**, Tschudi Y, Parra NA, Breto AL, Padgett KR, Pra AD, Abramowitz MC, Kryvenko ON, Punnen S, Pollack A. An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam



- Radiotherapy Boost Volumes. *Int J Radiat Oncol Biol Phys*. 2018 Nov 15;102(4):821-829. PMID: 29908220. **Impact Factor 5.133.**
41. Parekh D, **Reis IM**, et al. Effect of robot-assisted radical cystectomy versus open radical cystectomy on progression-free survival in patients with bladder cancer: the RAZOR (Randomized Open versus Robotic Cystectomy) clinical trial. *The Lancet* 2018 Jun; 391: 2525–2536. PMID: 29976469. **Impact Factor 44.002.**
  42. Malpica L, Pimentel A, Reis IM, Gotuzzo E, Lekakis L, Komanduri K, Harrington T, Barber GN, Ramos JC. Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States. *Blood Adv*, 2018, 2(6), 607-620. PMID: 29545256. **Impact Factor ~10.**
  43. Palacio S, Hosein PJ, **Reis I**, Akunyili II, Ernani V, Pollack T, Macintyre J, Restrepo MH, Merchan JR, Rocha Lima CM. The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. *J Gastrointest Oncol*. 2018 Feb;9(1):135-139. PMID: 29564179. **Impact Factor NA.**
  44. Mahmoud O, **Reis IM**, Samuels MM, Elsayyad N, Bossart E, Both J, ELGhoneimy E, Moustafa M, AbdAllah M, Takita C. Prospective Pilot Study Comparing the Need for Adaptive Radiotherapy in Unresected Bulky Disease and in Postoperative Patients With Head and Neck Cancer. *Technol Cancer Res Treat*. 2017;16(6):1014-1021, PMID: 28671024. **Impact Factor 2.204**
  45. Cohen E, **Reis IM**, Perez A, Gomez C, Pereira L, Frazier ME, Hoosien G, Franzmann EJ. Immunohistochemistry Analysis of CD44, EGFR, and p16 in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. *Otolaryngology–Head and Neck Surgery*, 2017;157(2):239-251. PMID: 28397583. **Impact Factor 2.276.**
  46. Greer S, Han T, Dieguez C, McLean N, Saer R, **Reis I**, Levi J, Marquez VE. Enzyme-driven chemo- and radiation-therapy with 12 pyrimidine nucleoside analogs not yet in the clinic. *Anticancer Agents Med Chem*. 2017;17(2):250-264. PMID: 27745548. **Impact Factor 2.722.**
  47. Wright JL, Saigal K, **Reis I**, Zhao W, Takita C, Ambros T, Saeed AM, Sujoy V, Hurley J. Locoregional and overall recurrence after neoadjuvant endocrine therapy versus chemotherapy in post-menopausal women with estrogen receptor positive HER2 negative breast cancer. *Am J Clin Oncol*. 2017; 490-497. PMID:26017482. **Impact Factor 2.61.**
  48. Gomez-Arteaga A, DeGennaro V, George S, **Reis IM**, Santamaria E, Westin GFF, Gabriel D, Hurley JD. Presentation, treatment and outcomes of Haitian women with breast cancer in Miami and Haiti: Disparities in breast cancer. A retrospective cohort study. *Journal of Global Oncology*, 2016;3(4):389-399. PMID: 28831447. **Impact Factor NA.**
  49. Wu ES, Park JY, Zeitouni JA, Gomez CR, **Reis IM**, Zhao W, Kwon D, Lee E, Nelson OL, Lin HY, Franzmann EJ, Savell J, McCaffrey TV, Goodwin WJ, Hu JJ. Effect of actionable somatic mutations on racial/ethnic disparities in head and neck prognosis. *Head & Neck* 2016; 38(8):1234-41. PMID:27028310. **Impact Factor 2.641.**
  50. Pereira LHM, **Reis IM**, Reategui EP, Gordon C, Saint-Victor S, Duncan R, Gomez C, Bayers S, Fisher P, Perez A, Goodwin WJ, Hu JJ, Franzmann EJ. Risk stratification system for oral cancer screening. *Cancer Prevention Research* 2016; 9(6):445-55. PMID: 27020654. **Impact Factor 4.444.**
  51. Wolfson AH, **Reis IM**, Portelance L, Diaz DA, Zhao W, Gibb RK. Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis. *Gynecologic Oncology* 2016; 141(2):255-9. PMID:26970567. **Impact Factor 3.774.**

52. Fan YS, Casas CE, Peng J, Watkins M, Fan L, Chapman J, Ikpat OF, Gomez C, Zhao W, **Reis IM**. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. *Breast Cancer Research and Treatment* 2016; 155:457-462. PMID: 26895325. **Impact Factor 3.94.**
53. Lee E, Takita C, Wright JL, **Reis IM**, Zhao W, Nelson OL, Hu JJ. Characterization of risk factors for adjuvant radiotherapy-associated pain in a tri-racial/ethnic breast cancer population. *Pain* 2016; 157(5): 1122-1131. PMID: 26780493. **Impact Factor 5.21.**
54. Wright JL, Takita C, **Reis IM**, Zhao W, Lee E, Nelson OL, Hu JJ. Prospective evaluation of radiation-induced skin toxicity in a race/ethnically diverse breast cancer population. *Cancer Med* 2016; 5(3):454-64. PMID: 26763411. **Impact Factor 2.5.**
55. Kallungal GJS, Weinberg JM, **Reis IM**, Nehra A, Venkatachalam MA, Parekh DJ. Long-term response to renal ischemia in the human kidney after partial nephrectomy: results from a prospective clinical trial. *BJU International*. 2016; 117(5):766-74. PMID:26053785. **Impact Factor 3.533.**
56. Diaz DA, **Reis IM**, Weed DT, Elsayyad N, Samuels M, Abramowitz MC. Head and neck second primary cancer rates in the HPV era: A population based analysis. *Head & Neck* 2016; 38(Suppl 1): E873-83. PMID: 25966421. **Impact Factor 3.0.**
57. Kwon D, **Reis IM**. Simulation-based estimation of mean and standard deviation for meta-analysis via Approximate Bayesian Computation (ABC). *BMC Med Res Methodol*. 2015;15:1-12. PMID: 26264850. **Impact Factor 2.27.**
58. Arsenault D, Hurley J, Takita C, **Reis IM**, Zhao W, Rodgers S, Wright JL. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy. *Am J Clin Oncol*. 2015; 38(4):348-352. PMID: 23799288. **Impact Factor 2.206.**
59. **Reis IM**, Ramachandran K, Speer C, Gordian E, Singal R. Serum GADD45a methylation is a useful biomarker to distinguish benign versus malignant prostate disease. *British Journal of Cancer* 2015; 113(3):460-468. PMID:26171936. **Impact Factor 4.82.**
60. Weed DT, Vella JL, **Reis IM**, De La Fuente AC, Gomez C, Sargi Z, Nazarian R, Califano J, Borello I, Serafini P. Tadalafil reduces myeloid derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. *Clin Cancer Res*. 2015; 21(1):39-48. PMID: 25320361. **Impact Factor 8.193.**
61. Diaz, DA, Pollack A, **Reis I**, Mahmoud O, Gonzalgo MA, Ishkanian A, Fernandez G, Manoharan M, Abramowitz MC. Neoadjuvant radiotherapy improves survival in patients with T2b/T3 bladder cancer: a population based analysis. *Clin Genitourin Cancer*. 2015; 13(4):378-384. PMID: 25907230. **Impact Factor 2.322.**
62. Hosein PJ, Sandoval-Sus JD, Goodman D, Gomez-Arteaga A, **Reis I**, Hoffman J, Stefanovic A, Rosenblatt JD, Lossos IS. Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. *Am J Hematol*. 2015; 90(6):E111-E116. PMID: 25737247. **Impact Factor 3.477.**
63. Register S, Takita C, **Reis IM**, Zhao W, Amestoy W, Wright J. Deep inspiration breath-hold technique for left-sided breast cancer: An analysis of predictors for organ-at-risk sparing. *Med Dosim*. 2015; 40(1):89-95. PMID: 25534166. **Impact Factor 0.76.**

64. Singal R, Ramachandran K, Gordian E, Quintero C, Zhao W, **Reis IM**. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. *Clin Genitourin Cancer* 2015; 13(1): 22-31. Epub 2014 Aug 1. PMID: 25178642. **Impact Factor 1.884.**
65. Diaz-Pardo A, Hurley J, **Reis IM**, Takita C, Zhao W, Wright J. Locoregional outcomes in clinical stage IIb breast cancer after neoadjuvant therapy and mastectomy with or without radiation. *Medicine* 2014; 93(29): e230. PMID: 25546661. **Impact Factor 4.233.**
66. Wright JL, Takita C, **Reis IM**, Zhao W, Lee E, Hu JJ. Racial variations in radiation-induced skin toxicity severity: data from a prospective cohort receiving postmastectomy radiation. *Int J Radiat Oncol Biol Phys.* 2014; 90(2):335-343. PMID: 25304794. **Impact Factor 4.258.**
67. Rodriguez-Gil JL, Takita C, Wright J, **Reis I**, Zhao W, Lally BE, Hu JJ. Inflammatory biomarker C-reactive protein and radiotherapy-induced early adverse skin reactions in breast cancer patients. *Cancer Epidemiol Biomarkers Prev.* 2014; 23(9):1873-1883. PMID: 24917184. **Impact Factor 4.559.**
68. Rojas CP, Castle SM, Llanos CA, Santos JA, Bird V, Rodriguez S, **Reis IM**, Zhao W, Gomez-Fernandez C, Leveille RJ, Jorda M. Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. *Urol Oncol.* 2013; 31(8):1696-1700. PMID: 22819696. **Impact Factor 2.819.**
69. Saigal K, Hurley J, Takita C, **Reis IM**, Zhao W, Rodgers SE, Wright JL. Risk factors for locoregional failure in inflammatory breast cancer patients treated with trimodality therapy. *Clin Breast Cancer* 2013; 13(5):335-343. PMID: 23850216. **Impact Factor 2.375.**
70. Ramachandran K, Speer CG, Fiddy, S, **Reis IM**, Singal R. Free Circulating DNA as a biomarker of prostate cancer: comparison of quantitation methods. *Anticancer Res.* 2013; 33(10): 4521-4529. PMID: 24123025. **Impact Factor 1.725.**
71. Desai S, Hurley J, Takita C, **Reis IM**, Zhao W, Rodgers SE, Wright JL. Impact of surgery-radiation interval on locoregional outcome in patients receiving neo-adjuvant therapy and mastectomy. *Breast J.* 2013; 19(4):427-430. PMID: 23750652. **Impact Factor 1.831.**
72. Hosein PJ, Lopes Jr GD, Pastorini VH, Gomez CM, Macintyre J, Zayas G, **Reis IM**, Montero AJ, Merchan JR, Rocha Lima CM. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. *Am J Clin Oncol.* 2013; 36(2):151-156. PMID: 22307213. **Impact Factor 2.206.**
73. Hurley J, **Reis IM**, Rodgers SE, Gomez-Fernandez C, Wright J, Leone JP, Larrieu R, Pegram MD. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. *Breast Cancer Res Treat.* 2013; 138(3):783-794. PMID: 23542956. **Impact Factor 4.431.**
74. Wright JL, Takita C, **Reis IM**, Zhao W, Saigal K, Wolfson A, Markoe A, Moller M, Hurley J. Predictors of locoregional outcome in patients receiving neoadjuvant therapy and post-mastectomy radiation. *Cancer* 2013; 119(1):16-25. PMID: 22736498. **Impact Factor 5.131.**
75. Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, **Reis IM**, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM. Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. *Clin Cancer Res.* 2012; 18(21):5911-5923. PMID: 22896656. **Impact Factor 7.742.**
76. Yasir S, Herrera L, Gomez-Fernandez C, **Reis IM**, Umar S, Leveillee R, Kava B, Jorda M. Positive CD10(+) and CK7/RON(-) immunophenotype distinguishes renal cell carcinoma

- conventional type with eosinophilic morphology from its mimickers. *Appl Immunohistochem Molecular Morphol.* 2012; 20(5):454-461. PMID: 22417859. **Impact Factor 1.411.**
77. Subbarayan, PR, Sarkar M, Nagaraja Rao S, Philip S, Kumar P, Altman N, Reis I, Ahmed M, Ardalan A, Lokeshwar BL. Achyranthes aspera (Apamarg) leaf extract inhibits human pancreatic tumor growth in athymic mice by apoptosis. *J. Ethnopharmacol.* 2012; 142(2):523-530. PMID: 22640722. **Impact Factor 2.466.**
  78. Wright JL, **Reis IM**, Zhao W, Panoff JE, Takita C, Sujoy V, Gomez CR, Jorda M, Francheschi D, Hurley J. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy. *Breast* 2012; 21(3):276-283. PMID: 22178596. **Impact Factor 2.089.**
  79. Franzmann EJ, Reategui EP, Pereira LHM, Pedroso F, Joseph D, Allen GO, Hamilton K, **Reis IM**, Duncan R, Goodwin WJ, Hu JJ, and Lokeshwar VB. Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. *Head Neck* 2012; 34(5):687-695. PMID: 22294418. **Impact Factor 2.182.**
  80. Lewin AA, Derhagopian R, Saigal K, Panoff JE, Abitbol A, Wieczorek DJ, Mishra V, **Reis I**, Ferrell A, Moreno L, Takita C. Accelerated partial breast irradiation is safe and effective using intensity-modulated radiation therapy in selected early-stage breast cancer. *Int J Radiat Oncol Biol Phys.* 2012; 82(5):2104-2110. PMID: 21640490. **Impact Factor 4.503.**
  81. Panoff JE, Takita C, Hurley J, **Reis IM**, Zhao W, Rodgers SE, Gunaseelan V, and Wright JL. Higher chest wall dose results in improved locoregional outcome in patients receiving post mastectomy radiation. *Int J Radiat Oncol Biol Phys.* 2012; 82(3):1192-1199. PMID: 21514739. **Impact Factor 4.503.**
  82. Ramamoorthy S, Tufail R, Jorda M, Zhao W, **Reis I**, Nawaz N. Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis. *Breast Cancer Research and Treatment* 2012; 132(1):97-108. **Impact Factor 4.859.**
  83. Tufail R, Jorda M, Zhao W, **Reis IM**, and Nawaz Z. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. *Breast Cancer Research and Treatment* 2012; 131(3):743-750. PMID: 21399893. **Impact Factor 4.859.**
  84. Saigal K, Weed DT, **Reis IM**, Markoe A, Wolfson AH, and Nguyen-Sperry J. Mucosal melanomas of the head and neck: the role of postoperative radiation therapy. *ISRN Oncology* 2012; Article ID 785131, 7 pages. PMID: 22577582. **Impact Factor 2.**
  85. Han HS, **Reis I**, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip A, Gluck S. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. *European Journal of Cancer* 2011; 47(17):2537-2545. PMID: 21741825. **Impact Factor 4.944.**
  86. Smith TR, Liu-Mares W, Van Emburgh BO, Levine EA, Allen GO, Hill JW, **Reis IM**, Kresty LA, Pegram MD, Miller MS, Hu JJ. Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer. *Carcinogenesis* 2011; 32(9): 1354-1360. PMID: 21700777. **Impact Factor 5.702.**
  87. Panoff JE, Hurley J, Takita C, **Reis IM**, Zhao W, Sujoy V, Gomez CR, Jorda M, Koniaris L, Wright JL. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. *Breast Cancer Research and Treatment* 2011; 128(3):899-906. PMID: 21475999. **Impact Factor 4.859.**
  88. Solomon N, Mezentssev D, **Reis I**, Lima M, Rios J, Avisar E, Franceschi D, Livingstone A, Podolsky L, Ardalan B. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-

- fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma. *Jpn J Clin Oncol*. 2011; 41(4):469-476. PMID: 21258083. **Impact Factor 1.856.**
89. Ascunce G; Ribeiro A, **Reis I**, Rocha-Lima C, Sleeman D, Merchan J, Levi J. EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video). *Gastrointestinal Endoscopy*. 2011; 73(2): 267-274. PMID: 21295640. **Impact Factor 5.647.**
  90. Pereira LH, Adebisi IN, Perez A, Wiebel M, **Reis I**, Duncan R, Goodwin WJ, Hu JJ, Lokeshwar VB, and Franzmann EJ. Salivary markers and risk factor data: A multivariate modeling approach for head and neck squamous cell carcinoma detection. *Cancer Biomarkers* 2011/2012;10(5): 241-249. PMID: 22699785. **Impact Factor 2.418.**
  91. Cook N, Kobetz E, **Reis I**, Fleming L, Loer-Martin D, Amofah, SA. Role of patient race/ethnicity, insurance and age on PAP smear compliance across 10 community health centers in Florida. *Ethnicity & Disease* 2010; 20(4): 321-326, PMID: 21305816. **Impact Factor 1.**
  92. Lobo C, Lopes G, Baez O, Castrellon A, Ferrell A, Higgins C, Hurley E, Hurley J, **Reis IM**, Richman S, Seo P, Silva O, Slingerland J, Tukia K, Welsh C, Glück S. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. *Breast Cancer Research and Treatment* 2010; 123(2):427-435. PMID: 20585851. **Impact Factor 4.859.**
  93. Gordian E, Ramachandran K, **Reis IM**, Manoharan M, Soloway MS, Singal R Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. *Cancer Epidemiology, Biomarkers & Prevention*. 2010; 19(8):1984-1991. PMID: 20647404. **Impact Factor 3.919.**
  94. Ardalan B, Subbarayan PR, Ramos Y, Gonzalez M, Fernandez A, Mezentssev D, **Reis I**, Duncan R, Podolsky L, Lee K, Lima M, Ganjei-Azar P. A phase I study of 5- fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. *Clin Cancer Res*. 2010; 16(11):3019-3027. PMID: 20501625. **Impact Factor 7.338.**
  95. Krishan A, Ganjei-Azar P, Hamelik R, Sharma D, **Reis I**, Nadji M. Flow immunocytochemistry of marker expression in cells from body cavity fluids. *Cytometry: Part A* 2010; 77(2):132-143. PMID: 19899128. **Impact Factor 3.753.**
  96. Webb, MS, de Ybarra DR, Baker EA, **Reis IM**, Carey MP. Cognitive-behavioral therapy to promote smoking cessation among African American smokers: a randomized clinical trial. *J Consult Clin Psychol*. 2010; 78(1):24-33. PMID: 20099947. **Impact Factor 5.227.**
  97. Jabiev AA, Ikeda MH, **Reis IM**, Solorzano CC, Lew JI. Surgeon-performed ultrasound can predict differentiated thyroid cancer in patients with solitary thyroid nodules. *Ann Surg Oncol*. 2009; 16(11):3140-3145. PMID: 19655201. **Impact Factor 3.943.**
  98. Abdel-Wahab M, **Reis IM**, Wu J, Duncan R. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data. *Urology* 2009; 74(4):866-871. PMID: 19628258. **Impact Factor 2.273.**
  99. Hatoum GF, Patton B, Takita C, Abdel-Wahab M, LaFave K, Weed D, **Reis IM**. Small Cell Carcinoma of the Head and Neck: The University of Miami Experience. *Int J Radiat Oncol Biol Phys*. 2009; 74(2):477-481. PMID: 19004574. **Impact Factor 4.176**

100. Ramachandran K, Gopisetty G, Gordian E, Navarro L, Hader C, **Reis IM**, Schulz WA, Singal R. Methylation-mediated repression of GADD45 $\alpha$  in prostate cancer and its role as a potential therapeutic target. *Cancer Research* 2009; 69(4):1527-1535. PMID: 19190346. **Impact Factor 9.284.**
101. Abdel-Wahab, M, **Reis, IM**, Hamilton-Nelson, K. Second Primary Cancer after radiation therapy- a SEER analysis of brachytherapy versus external beam radiation. *Int J Radiat Oncol Biol Phys.* 2008; 72(1):58-68. PMID: 18374503. **Impact Factor 4.441.**
102. Silva O, Lopes G, Morgenzstern D, Lobo C, Doliny P, Santos E, Abdullah S, Gautam U, **Reis I**, Welsh C, Slingerland J, Hurley J, Gluck S. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. *Clin Breast Cancer* 2008; 8(2):162-167. PMID: 18621613. **Impact Factor 2.628.**
103. Ramos JC, Ruiz Jr P, Ratner L, **Reis IM**, Brites C, Pedroso C, Byrne Jr GE, Toomey NL, Andela V, Harhaj EW, Lossos I, Harrington Jr WJ. IRF-4 and c-Rel expression in antiviral resistant adult T-cell leukemia/lymphoma. *Blood* 2007; 109:3060-3068. PMID: 17138822. **Impact Factor 9.775.**
104. Krishan A, Ganjei-Azar P, Jorda M, Nadji M, Hamelik RM, **Reis IM**, Nadji M. Detection of tumor cells in body cavity fluids by flow cytometric and immunocytochemical analysis. *Diagnostic Cytopathology* 2006; (34):528-541. PMID: 16850481. **Impact Factor 1.52.**
105. Das PM, Ramachandran K, Vanwert J, Ferdinand L, Gopisetty G, **Reis IM**, Singal R. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. *Mol Cancer* 2006; 18:5-28. PMID: 16848908. **Impact Factor 5.40.**
106. Schlesselman JJ, **Reis IM**. Phase II clinical trials in oncology: strengths and limitations of two-stage designs. *Cancer Investigation* 2006; 24(4):404-412, Review. PMID: 16777694. **Impact Factor 2.094.**
107. Hurley J, Doliny P, **Reis IM**, Silva O, Gomez-Fernandez C, Velez P; Pauletti, G; Pegram MD; Slamon DJ and Powell, Jodden E. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. *J Clin Oncol.* 2006; 24(12):1831-1838. PMID: 1659824. **Impact Factor 17.96.**
108. Voti L, Richardson LC, **Reis IM**, Fleming LE, Mackinnon J, Coebergh JW. The effect of race/ethnicity and insurance in the administration of standard therapy for local breast cancer in Florida. *Breast Cancer Research and Treatment* 2006; 95(1):89-95. PMID: 16244785. **Impact Factor 2.975.**
109. Voti L, Richardson LC, **Reis IM**, Fleming LE, Mackinnon J, Coebergh JW. Treatment of local breast carcinoma in Florida: The role of the distance to radiation therapy facilities. *Cancer* 2006; 106(1):201-207. PMID: 16311987. **Impact Factor 4.901.**
110. Richardson LC, Tian L, Voti L, Hartzema AG, **Reis IM**, Fleming L E, Mackinnon J: The role of teaching hospitals, insurance status, and race/ethnicity in receipt of adjuvant therapy for regional-stage breast cancer in Florida. *Am J Public Health* 2006; 96(1):160-166. PMID: 16317209. **Impact Factor 3.93.**
111. Singal R, Das PM, Manoharan M, **Reis IM**, Schlesselman JJ. Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. *Oncol Reports* 2005; 14(2):569-573. PMID: 16012746. **Impact Factor 2.301.**
112. Hurley J, **Reis IM**, Silva O, Gomez C, DeZarraga F, Velez P, Welsh C, Powell J, Doliny P. Weekly Docetaxel/Carboplatin as primary systemic therapy for HER2-negative locally

- advanced breast cancer. *Clin Breast Cancer* 2005; 5(6):447-454. PMID: 15748465. **Impact Factor 2.628.**
113. Lee YL, Doliny P, Gomez-Fernandez C, Powell, J, **Reis IM**, Hurley J. Docetaxel and Cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. *Clin Breast Cancer* 2004; 5(5):371-376. PMID: 15585076. **Impact Factor 2.628.**
  114. Singal R, Ferdinand L, Das PM, **Reis IM**, Schlesselman JJ. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. *Int J Oncol.* 2004; 25(5):1465-1471. PMID: 15492840. **Impact Factor 2.170.**
  115. Singal R, Ferdinand L, **Reis IM**, Schlesselman JJ. Methylation of multiple genes in prostate cancer and relationship with clinicopathological features of disease. *Oncol Reports* 2004; 12:631-637. PMID: 15289848. **Impact Factor 2.868**
  116. Raez LE, Rosado MF, Santos ES, **Reis IM**. Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer - experience from a prematurely closed phase II study. *Lung Cancer* 2004; 131-132. PMID: 15196746. **Impact Factor.**
  117. Landy H, Markoe A, Potter P, Lasalle G, Marini A, Savaraj N, **Reis I**, Heros D, Wangpaichitr M, Feun L. Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma. *J Neurooncol.* 2004; 67:215-220. PMID: 15502470. **Impact Factor 6.180**
  118. Landy HJ, Markoe AM, Wu X, Patchen SJ, **Reis IM**, Takita C, Abdel-Wahab MM, Wen BC, Wolfson AH, Huang DT. Safety and efficacy of tiered limited-dose Gamma Knife stereotactic radiosurgery for unilateral acoustic neuroma. *Stereotactic and Functional Neurosurgery* 2004; 82:147-152. PMID: 15467382. **Impact Factor 1.66.**
  119. McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, **Reis I**, Lee KP, Boise LH. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. *Molecular Cancer Therapeutics* 2003; 2:1155-1164. PMID: 14617789. **Impact Factor 5.72.**
  120. Bahlis NJ, Grad JM, Jordan-McMurry I, Neil J, **Reis IM**, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. *Clinical Cancer Research* 2002; 8:3658-3668. PMID: 12473574. **Impact Factor Impact Factor 8.193.**
  121. Hurley J, Franco S, Gomez-Fernandez C, Powell J, **Reis IM**, Velez P, Harrington W, Wilkinson J, Kanhouh R, Lee, Y. Breast cancer and human immunodeficiency virus: treatment and outcomes of 20 cases. *Clin Breast Cancer* 2001; 2:215-220. (Commentary by Guth AA on page 221). PMID: 11899415. **Impact Factor 2.628.**
  122. Grad JM, Bahlis NJ, **Reis IM**, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. *Blood* 2001; 98:805-813. PMID: 11468182. **Impact Factor 9.775**
  123. Schwartz GG, **Reis IM**. Is cadmium a cause of human pancreatic cancer? *Cancer Epidemiology Biomarkers & Prevention* 2000; 9:139-145. PMID: 10698473. **Impact Factor 4.324**
  124. **Reis IM**, Hirji KF, Afifi AA. Exact and asymptotic tests for homogeneity in several 2x2 tables. *Stat Med* 1999; 18:893-906. PMID: 10363329. **Impact Factor 2.037**

125. **Reis IM**, Flack VF, Atchison KA, White SC. Findings of clinical and radiographic caries among several adult age groups. *Oral Surg Oral Med Oral Pathol* 1998; 86:760-764. PMID: 9868739. **Impact Factor 1.640.**
126. Monteiro CA, Mondini L, Torres AM, **dos Reis IM**. Patterns of intra-familial distribution of undernutrition: Methods and applications for developing societies. *Eur J Clin Nutr.* 1997; 5:800-803. PMID: 9426353. **Impact Factor 2.95**
127. Hirji KF, Vollset SE, **Reis IM**, Afifi AA. Exact tests for interaction in several 2x2 tables. *Journal of Computational and Graphical Statistics* 1996; 5(3):209-224. PMID: **Impact Factor 1.803**
128. da Silva NN, **dos Reis IM**. Delineamento amostral para a implantação de um Sistema Nacional de Informações de Demanda Ambulatorial. [Sampling design for the implementation of a National Information System on the demand for ambulatory services.] *Rev. Saúde Pública* 1989;23:298-306. PMID: 2631184. **Impact Factor 1.328**
129. Szarfarc SC, Monteiro CA, Meyer M, Tudisco ES, **dos Reis IM**. Estudo das condições de saúde das crianças do município de São Paulo, SP (Brasil), 1984/1985. X. Consumo alimentar. [The health status of children in the municipality of São Paulo, SP (Brazil), 1984/1985. X. Food intake.] *Rev. Saúde Pública* 1988;22:266-272. PMID: 3241949. **Impact Factor 1.328**
130. Monteiro CA, Benício MH, **Reis Lamonica IM**, L'Abbate S, Stefanini ML, Oshiro JH, Pires HB, Alves MC. Avaliação do impacto da suplementação alimentar a gestantes no controle do baixo peso ao nascer no município de São Paulo, SP (Brasil). [Evaluation of the impact of supplementary feeding to pregnant women in the control of low birth weight rates in the municipality of São Paulo, SP (Brazil)]. *Rev. Saúde Pública* 1985; 19: 458-474. PMID: 3836500. **Impact Factor 1.328**
131. Benício MH, Monteiro CA, Souza JM, Castilho EA, **Reis Lamonica IM**. Análise multivariada de Fatores de risco para o baixo peso ao nascer em nascidos vivos do município de São Paulo, SP (Brasil). [Multivariate analysis of risks factors for low birthweight in livebirths in the city of São Paulo, SP (Brazil)]. *Rev. Saúde Pública* 1985; 19: 311-320. PMID: 3832376. **Impact Factor 1.328**
132. Roncada MJ, Marucci M. de F, **Reis Lamonica IM**. Níveis sanguíneos de vitamina A e caroteno em indivíduos de meia-idade e idosos, em onze localidades do estado de São Paulo, Brasil. [Blood levels of vitamin A and carotene in middle-aged and elderly individuals, in eleven localities of the state of S. Paulo, Brazil]. *Rev. Saúde Pública* 1985; 19: 336-343. PMID: 3832377. **Impact Factor 1.328.**
133. Monteiro CA, **dos Reis IM**, Benício MH, Gandra YR. Estudo Antropométrico-nutricional de pré-escolares de áreas de baixa renda do estado de São Paulo, Brasil. [Antropometric nutritional study of preschool children in low income areas of the state of S. Paulo, Brazil.] *Rev. Saúde Pública* 1984; 18: 1-18. PMID: 6427911. **Impact Factor 1.328.**
134. Levy MSF, **Reis IM**, Santos JLF, Godinho RE. Aplicação de uma técnica de parturição a dados brasileiros. [Application of a demographic technique for giving birth analysis to Brazilian data.] *Anais do VIII Encontro Nacional de Estudos Populacionais* 1992;1:75-88. **Impact Factor NA.**
135. Natal D, Marucci D, **Reis IM**, Galatti AB. Modificação da armadilha CDC com testes para coletas de Flebotomíneos (Diptera). [Sand flies collecting trials with a modified CDC trap (Diptera, Psychodidae).] *Revta bras. Ent.* 1991; 35: 697-700. **Impact Factor NA.**
136. Martinez TLR, Auriemo CRC, Feres MC, **Reis IM**, Piageti ALA, Camano L, Bertini-Oliveira AM. Resultados dos níveis de colesterol, lipo-proteínas e triglicídeos em gestantes normais.



[Serum levels of cholesterol, triglycerides and lipoproteins in normal pregnant women.] *Rev. Bras. Ginecol. Obstet* 1986; 8:117-124. **Impact Factor NA.**

137. Martinez TLR, Elias IJ, Auriemo CRC, Almeida FFF, Liviero L, **Reis IM**, Camano L, Bertini-Oliveira AM. Modelo de planejamento utilizado na caracterização sócio-econômico-cultural das gestantes do pré-natal da Escola Paulista de Medicina, São Paulo. [A technique model used to characterize social, economic and culturally the pregnant women.] *J. Bras. Ginec.* 1985; 95: 493-498. **Impact Factor NA.**
138. Martinez TLR, Martinez Filho EE, Auriemo CRC, Maldjian S, **Reis IM**, Camano L, Bertini-Oliveira AM. Lipoproteínas e índices de risco cardiovascular em gestantes normais. [Lipoprotein and index of risk for coronary heart disease in normal pregnant women.] *Rev. Bras. Ginecol. Obstet.* 1985; 7: 221-225. **Impact Factor NA.**
139. Nobrega FJ, Lopez FA, **Reis IM**. Estudo comparativo do efeito terapêutico e tolerabilidade da associação trimetoprim-sulfametoxipirazina versus ampicilina no tratamento de infecções respiratórias em crianças. [Comparison of trimethoprim plus sulfamethopyrazine (sulfalene) versus ampicillin for efficacy and safety in the treatment of children's respiratory infections -] *Arq. Bras. Med.* 1983; 57: 139-141. **Impact Factor NA.**

## 17. Other works, publications, and abstracts:

### 18a. Patent submitted

Franzmann E, Pereira L, **Reis IM**, Duncan RC. "Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma." University of Miami patent, publication number US 20150219656 A1, application number US 14/688,221, publication date 2015/08/06 <http://www.google.com/patents/US20150219656> (co-inventor).

### 18b. Letters to the Editor

Lebrão ML, Silva NN, **Reis IM**, Latorre MRO, Hamerly I. Sistema Nacional de Informações de Demanda Ambulatorial. [National health care information system.] *Rev. Saúde Pública* 1988; 22:344-45.

### 18c. Technical reports

**Reis IM**, Singer JM. Uso do SOC para ajuste de modelos log-lineares a dados categorizados. [The use of SOC software to fit log-linear models for categorical data.] EMBRAPA/ NTIA, CT-NTIA-8904, Campinas, 1989. (Technical Report)

Lebrão ML, Silva NN, **Reis IM**, Latorre MRO, Hamerly I. Sistema Nacional de Informações de Demanda Ambulatorial. FSP/USP, convênio FSP/USP/INAMPS, São Paulo, 1987. (Technical Report)

### 18d. Abstracts of Oral or Poster Presentations (165)

Abbreviations:

AACR: American Association for Cancer Research

ASCO: American Society of Clinical Oncology

AAO-HNSF: American Academy of Otolaryngology-Head and Neck Surgery Foundation

AHNS: American Head and Neck Society  
 ASTRO: American Society for Radiation Oncology  
 ASA: American Statistical Association  
 ARS: American Radium Society  
 ASH: American Society of Hematology  
 AUA: American Urological Association  
 COSM: Combined Otolaryngology Spring Meetings  
 ECHNO: European Congress on Head and Neck Oncology  
 ENAR: Eastern North American Region of the Biometrics Society  
 ISMRM: International Society for Magnetic resonance in Medicine  
 NAACCR: North American Association of Central Cancer Registries  
 SESAUA: Southeastern Section of the AUA  
 SABCS: San Antonio Breast Cancer Symposium  
 SUO: Society of Urologic Oncology  
 USCAP: United States and Canadian Academy of Pathology

1. Atluri VS, Zucker I, **Reis IM**, Kwon D, Soodana-Prakash N, Tewari A, Patel V, Wagaskar V, Konety B, Kasraeian A, Czarniecki S, Thoreson G, Kim E, and Punnen S. MRI, Biomarker, or both? Results from a large multi-institutional study of 1111 men with 4Kscore, multiparametric MRI and prostate biopsy. AUA Meeting. Las Vegas, NV, Sept 10-13, 2021. (Abstract submission #).
2. Almeida R, Zucker I, **Reis IM**, Kwon D, Soodana-Prakash N, Tewari A, Patel V, Wagaskar V, Konety B, Kasraeian A, Czarniecki S, Thoreson G, Kim E, and Punnen S. MRI, Establishing the best threshold for biopsy in mpMRI negative or indeterminate men using data from a large multi-institutional cohort of men undergoing mpMRI, 4KScore and prostate biopsy. AUA Meeting. Las Vegas, NV, Sept 10-13, 2021. (Abstract submission #).
3. Almeida R, Soodana-Prakash N, Kwon D, **Reis IM**, Castilho RP, Kryvenko O, Stoyanova R, Pollack A, Nahar B, Gonzalgo M, Ritch C, Parekh DJ, and Punnen S. The performance of mpMRI and the 4Kscore for predicting progression on Active Surveillance; results from a single-institution prospective study AUA Meeting. Las Vegas, NV, Sept 10-13, 2021. (Abstract submission #).
4. Buitron E, Smith DH, **Reis IM**, Liu H, Halgowich J, Gordon C, Franzmann EJ. Family history of cancer does not influence a change of CD44 levels in oral rinses. AHNS Annual Meeting. 2021 AHNS Annual Meeting at COSM April 7–11, 2021 | Virtual; or AHNS 10th International Conference on Head and Neck Cancer July 22-25, 2021 | Chicago, Illinois.
5. Smith DH, Raslan S, **Reis IM**, Liu H, Halgowich J, Gordon C, Franzmann EJ. 12-month smoking cessation program lowers soluble CD44 levels in a high-risk population. AHNS Annual Meeting. 2021 AHNS Annual Meeting at COSM April 7–11, 2021 | Virtual; or AHNS 10th International Conference on Head and Neck Cancer July 22-25, 2021 | Chicago, Illinois.
6. Weed DT, Zilio S, **Reis IM**, Sargi Z, Abouyared M, Gomez CR, Civantos FJ, Rodriguez CP, Serafini P. The reversal of immune exclusion mediated by tadalafil and an anti-tumor vaccine also induces PDL1 up regulation in recurrent head and neck squamous cell carcinoma: final analysis including clinical outcomes of a phase I clinical trial. AHNS Annual Meeting. 2021 AHNS Annual Meeting at COSM April 7–11, 2021 | Virtual; or AHNS 10th International Conference on Head and Neck Cancer July 22-25, 2021 | Chicago, Illinois.
7. Alderuccio JP, Kuker RA, Barreto-Coelho P, Martinez BM, Miao F, Beitinjane A, Wang TP, **Reis IM**, Lossos IS, Moskowitz CH. Prognostic Value of PET/CT Metrics in Patients with Relapsed and Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Platinum-Based

- Chemotherapy: An Intent-to-Treat Analysis. 62nd ASH Annual Meeting. San Diego, California, December 5-8, 2020 – will be presented as **an all-virtual event**, given the continuing threat of the COVID-19 pandemic. Virtual Poster Publication Number: 1209, Submission ID: 141098.
8. Alderuccio JP, **Reis IM**, Zhao W, Lossos IS. Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis. 62nd ASH Annual Meeting. San Diego, California, December 5-8, 2020 – will be presented as **an all-virtual event**, given the continuing threat of the COVID-19 pandemic. Virtual Poster Publication Number: 2050, Submission ID: 137620.
  9. Takita C, Kesmodel S, Marples B, Stoyanova R, Gomez C, Net J, Yepes M, **Reis IM**. Phase I Study to Evaluate the Safety and Feasibility of Preoperative Ablative Radiotherapy (SABER) for Selected Early Stage Breast Cancer. 2020 San Antonio Breast Cancer Symposium®, December 8-12, 2020. Poster presentation, Abstract #1330.
  10. Wang K, Hu JJ, **Reis IM**, Zhao W, Yang GR, Herna S. Breast Cancer Survival Disparities by Insurance Status or Race/Ethnicity in Specific Patient Populations. AACR Virtual conference: 13th AACR Conference on The Science Of Cancer Health Disparities In Racial/Ethnic Minorities And The Medically Underserved. Oct 2-4, 2020. Control/Tracking Number: xxx-AACR.
  11. Wang K, Hu JJ, **Reis IM**, Zhao W, Yang GR, Herna S. Predicting Breast Cancer Survival Outcomes in a Tri-Racial/Ethnic Population. AACR Virtual conference: 13th AACR Conference on The Science Of Cancer Health Disparities In Racial/Ethnic Minorities And The Medically Underserved. Oct 2-4, 2020. Control/Tracking Number: xxx-AACR.
  12. Liu, J, Medina HN, Reis IM, Pinheiro, PS. Disadvantages for non-Hispanic Whites in Gastric Carcinoma survival in Florida. NAACCR 2020 Conference in Philadelphia, PA June 21 - 26, 2020. Abstract # 109.
  13. Johnson, AL, Medina HN, Reis IM, Schlumbrecht M, Pinheiro, PS. The role of histology on endometrial cancer survival disparities in diverse Florida. NAACCR 2020 Conference in Philadelphia, PA June 21 - 26, 2020. Abstract # 106.
  14. Weed DT, Zilio S, **Reis IM**, Sargi Z, Abouyared M, Gomez CR, Civantos FJ, Rodriguez CP, Serafini P. The reversal of immune exclusion mediated by tadalafil and an anti-tumor vaccine also induces PDL1 up regulation in recurrent head and neck squamous cell carcinoma: final analysis including clinical outcomes of a phase I clinical trial. AHNS Annual Meeting. Chicago, IL, Jul 18, 2020.
  15. Bell EB, Almuhaimeid T, Cohen ER, Alotaibi F, Gordon C, **Reis IM**, Gomez C, Goodwin WJ, and Franzmann EJ. Green Salad Intake is Associated with Improved Oral Cancer Survival and Lower Soluble CD44 Levels. AHNS Annual Meeting. Chucago, IL, Jul 18, 2020.
  16. Yang GR, **Reis IM**, Hu JJ. Comorbidities and C-reactive protein in predicting all-cause mortality in breast cancer patients. AACR Annual Meeting. April 24-29, 2020; San Diego, CA. Control/Tracking Number: xxx-AACR.
  17. Mihyu MM, **Reis IM**, Takita C, Wright JL, Lee E, Nelson OL, Yang GR, Bakalar JL, Hu JJ. Association between DNA Oxidative Damage and Radiotherapy-Induced Skin Toxicities in Breast Cancer Patients. AACR Annual Meeting. April 24-29, 2020; San Diego, CA. Control/Tracking Number: 20-A-6581-AACR.
  18. Hu X, **Reis IM**, Hu JJ. Immune-Cell Profiling among Female Breast Cancer Patient with Different Clinical Characteristics. 2020 Eastern-Atlantic Student Research Forum (ESRF). University of Miami, M, Miami, FL.

19. Venkatramani V, **Reis IM**, Soodana-Prakash N, Becerra MF, Gonzalgo ML, Castle EP, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DL, Quek ML, Dash A, Parekh DJ. Urologic complications after robotic and open radical cystectomy: An analysis from the RAZOR trial. AUA Meeting. Wahington,DC, May 15-18, 2020. (Abstract submission #20-8154).
20. Venkatramani V, **Reis IM**, Soodana-Prakash N, Becerra MF, Gonzalgo ML, Castle EP, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DL, Quek ML, Dash A, Parekh DJ. Readmission rates and their predictors after robotic and open radical cystectomy: An analysis from the RAZOR trial. AUA Meeting. Wahington,DC, May 15-18, 2020. (Abstract submission #20-8141).
21. Venkatramani V, **Reis IM**, Soodana-Prakash N, Becerra MF, Gonzalgo ML, Castle EP, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DL, Quek ML, Dash A, Parekh DJ. Predictors of postoperative complications after robotic and open radical cystectomy: An analysis from the RAZOR trial. AUA Meeting. Wahington,DC, May 15-18, 2020. (Abstract submission #20-7396).
22. Horodyski L, Ball B, Emile C, Rhodes A, Miao F, **Reis IM**, Carasquillo M, Acosta M, Ji L, Mouzannar A, Sinha V, Livingstone J, Kamat A, Baumgard D, Matadial C, Swain S, Punnen S, Ritch C, Deane L. Implementing a Pathway for the Safe Reduction of Opioids in Patients Undergoing Robotic Assisted Laparoscopic Prostatectomy: A Retrospective Analysis of a US Veterans Affairs Medical Center Patient Cohort. AUA Meeting. Washington, DC, May 15-18, 2020. (Abstract submission #20-4803).
23. Meshman J, Farnia B, Stoyanova R, **Reis I**, Abramowitz M, Dal Pra A, Horwitz E, Pollack A. Biopsy positivity in prostate cancer patients undergoing mpMRI-targeted radiation dose escalation. 102nd American Radium Society (ARS) National Meeting; May 2020; Scottsdale, Arizona. (Oral Presentation).
24. Meshman J, Farnia B, Stoyanova R, **Reis I**, Abramowitz M, Dal Pra A, Horwitz E, Pollack A. Biopsy positivity in prostate cancer patients undergoing mpMRI-targeted radiation dose escalation. JCO. 2020;38 (6\_suppl):336-336. [ASCO Genitourinary Cancer Symposium Feb. 2020: San Francisco, CA [Poster Presentation]
25. Horodyski L, Ball B, **Reis IM**, Miao F, Carasquillo M, Ji L, Livingstone J, Matadial C, Ritch CR, Deane LA. Safe Transition to Opioid-Free Pathway in Patients Undergoing Robotic-Assisted Laparoscopic Prostatectomy: A Retrospective Analysis of a US Veterans Affairs Medical Center Patient Cohort. American College of Surgeons Clinical Congress. Oct 27-31 San Francisco, CA. 2019. [Poster Presentation], Urological Surgery, Vol 229, Issue 4, Supplement 2, E248, October 01, 2019.
26. Alderuccio JP, **Reis IM**, Habermann TM, Link BK, Thieblemont C, Conconi A, Larson MC, Cascione L, Zhao W, Cerhan JR, Zucca E, Lossos IS. Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL). ASH Meeting. Orlando, FL, December 7-10, 2019. (ASH abstract submission #125008).
27. Alderuccio JP, Yeir SG, **Reis IM**, Alencar AJ, Rosenblatt JD, Lossos IS. R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma. ASH Meeting. Orlando, FL, December 7-10, 2019. (ASH abstract submission #125004).
28. Alderuccio JP, Isrow D, **Reis IM**, Sunil I, Meshman JJ, Zhao W, Markoe AM, Lossos IS. Omission of Staging Bone Marrow Biopsy Does Not Affect Outcomes in Patients with Stage I

- Extranodal Marginal Zone Lymphoma (EMZL) Treated with Radiation Therapy. ASH Meeting. Orlando, FL, December 7-10, 2019. (ASH abstract submission #124964).
29. Becerra MF, Venkatramani V, **Reis IM**, .....,Parekh DJ. Health related Quality of Life Outcomes by Urinary Diversion: An analysis from the randomized robotic versus open radical cystectomy (RAZOR) trial. AUA Meeting. Chicago, IL, May 3-6, 2019 (Podium presentation).
  30. Venkatramani V, Becerra MF, **Reis IM**, .....,Parekh DJ. Predictors of postoperative health-related quality of life (HRQoL): An analysis from the RAZOR trial. AUA Meeting. Chicago, IL, May 3-6, 2019.
  31. Becerra MF, Miao F, **Reis IM**, Furlong D, Johnson T, Soodana-Prakash N, Punnen S. Can the time interval between MRI and Fusion Biopsy affect the Cancer Detection Rates? AUA Meeting. Chicago, IL, May 3-6, 2019.
  32. Slingerland JM, Lippman ME, Hurley, J, Net JM, Collado-Mesa F, **Reis, IM**, Noriega-Esquivas BS, Pegram M, Yepes, MM, Avisar, E, Jorda M, Aoun J. Results of a randomized double blind trial of neoadjuvant anastrozole plus placebo vs anastrozole plus saracatinib for ER+ postmenopausal breast cancer. 2018 SABCS, San Antonio, TX, Dec 4-8, 2018. " Poster presentation #. Abstract # 1556.
  33. Pollack A, Chinae FM, Bossart E, Kwon D, Abramowitz MC, Lynne C, Jorda M, Marples B, Patel V, Wu X, **Reis IM**, Studenski M, Casillas V, Stoyanova R. Dosimetry and Toxicity of a Phase I Clinical Trial of Men Treated for Prostate Cancer with Lattice Extreme Ablative Dose (LEAD) Radiotherapy. ASTRO Annual Meeting. San Antonio, TX, Oct 21-24, 2018. Poster#: SU\_32\_2316 Abstract xx.
  34. Takita C, **Reis IM**, Yakoub D, Panthaki Z, Boneti C, Kassira W, Moller M, Samuels S, Freedman L, Ahamad A, Kesmodel S, Avisar E. Final Results of Phase I Study of Prophylactic Nipple-Areola Complex (NAC) Radiotherapy after Nipple Sparing Mastectomy (NSM) and Immediate Reconstruction for Breast Cancer or DCIS Patients not Initially Eligible for NSM. ASTRO Annual Meeting. San Antonio, TX, Oct 21-24, 2018. Poster Discussion Session, Oral Presentation # 1144. Abstract xx.
  35. Alderuccio JP, Desai A, Crestani NG, Ramdial J, Kimble E, De La Fuente MI, Chapman J, Vega F, Zhao W, **Reis IM**, Lossos IS. Outcomes in Patients with Marginal Zone Lymphomas Undergoing Transformation to High-Grade Lymphomas. ASCO Annual Meeting. Chicago, IL, Jun 1-5, 2018. Abstract 217525.
  36. Kwon D, Jung J, **Reis IM**. Non-inferiority test for clustered matched-pair binary data using hierarchical Bayesian method. ASA Joint Statistical Meeting (JSM). Vancouver, BC, Canada, Jul 28-Aug 2, 2018. Abstract # 327129.
  37. Stoyanova R., Abramowitz MC, Chinae FM, Kwon D, **Reis IM**, Padgett KR, Punnen S, Kryvenko ON, Pollack A. An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiotherapy Boost Volumes. Joint Annual Meeting ISMRM-ESMRMB, Paris, France, June 16-21 2018. Abstract 6092.
  38. Castillo LEM, Pimentel A, **Reis IM**, Gotuzzo E, Lekakis LJ, Komanduri K, Harrington TJ, Barber GN, Ramos JC. Epidemiology, clinical features, and outcome of HTLV-1 related Adult T-cell Leukemia-lymphoma in a Prevalent Area in the U.S." ASH Annual meeting. Atlanta, GA, Dec 9-12, 2017. Abstract 373.

39. Barboza MP, Prakash NS, **Reis IM**, Miao F, Velasquez MC, Castillo R, Ritch CR, Gonzalgo ML, Kava B, Satyanarayana R, Parekh DJ, and Punnen S. Does MPMRI Perform Differently in Men Undergoing Targeted Biopsy for Evaluation of Prostate Cancer versus those on Active Surveillance? SUO Annual Meeting. Washington, DC, Nov29-Dec1, 2017. Poster 211.
40. Barboza MP, Prakash NS, **Reis IM**, Miao F, Velasquez MC, Castillo R, Ritch CR, Gonzalgo ML, Kava B, Satyanarayana R, Parekh DJ, and Punnen S. Does MPMRI Perform Differently in Men Undergoing Targeted Biopsy for Evaluation of Prostate Cancer versus those on Active Surveillance? SESAUA Meeting. Orlando, FL, Mar 22-25, 2017. Poster 10.
41. Pollack A, Abramowitz MC, Kwon D, Padgett KR, **Reis IM**, Tschudi Y, Chinae FM, Kryvenko ON, Punnen S, Stoyanova R. An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiotherapy Boost Volumes. ASTRO Annual Meeting. San Diego, TX, Sep 24-27, 2017. Abstract 3811. (*Oral presentation*)
42. Vosoughi A, **Reis IM**, Jorda M. Rater agreement of urine cytology characteristics by Cyto Atyp Paris. USCAP Annual Meeting. Charleston, SC. Jan 14-16, 2017. Abstract xxx.
43. Kwon D, Jung J, **Reis IM**. Hierarchical Bayesian Method for Dealing with Uncertainty of Dose-Response Relationship Estimation in Meta-Analysis. ENAR Spring meeting. Washington, DC, Mar 12-15, 2017. (Presenter)
44. Gajjar S, **Reis IM**, Takita C. Identification of predictors of survival in patients with metastatic breast cancer (MBC) may improve patient selection for ablative local therapies. ASTRO Annual Meeting. Boston, MA, Sep 25-28, 2016. Int J Radiat Oncol Biol Phys. 2016 Oct 1; 96(2S).
45. **Reis IM**, Perez A, Pereira L, Freizer M, Cohen E, Hoosien G, Franzmann EJ. Immunohistochemistry analysis of CD44, EGFR and p16 in oral and oropharyngeal squamous cell carcinomas. ECHNO 2016 Annual Meeting. Budapest-Hungary, Sep 7-10, 2016.
46. **Reis IM**, Perez A, Pereira L, Freizer M, Cohen E, Hoosien G, Franzmann EJ. Immunohistochemistry analysis of CD44, EGFR and p16 in oral and oropharyngeal squamous cell carcinomas. AAO-HNSF 2016 Annual Meeting. San Diego, CA, Sep 18-21, 2016.
47. : Cohen E, **Reis I**, Perez A, Pereira L, Gomez C, Freiser M, Hoosien G, Franzmann E. Immunohistochemistry analysis of CD44, EGFR, & p16 in oral & oropharyngeal squamous cell carcinomas. AAO-HNSF. San Diego, CA, Sep 18-21, 2016. (Oral presentation)
48. Cohen ER, A Perez A, Pereira LH, Reategui E, **Reis IM**, Gomez, C, Freiser ME, Franzmann EJ. CD44 and associated markers in oral rinses and tissues from oral cancer patients. AHNS 9th International Conference on Head and Neck Cancer. Seattle, WA, Jul 16-20, 2016. (*Oral presentation*)
49. Kwon D, **Reis IM**. Simulation-based estimation of mean and standard deviation for meta-analysis using Approximate Bayesian Computation (ABC) coupled with model averaging method. ENAR Spring meeting. Austin, TX, Mar 6-9, 2016. (Presenter)
50. Pereira LHM, Reis IM, Reategui EP, Gordon C, Saint-Victor S, Duncan R, Gomez C, Bayers S, Fisher P, Perez A, Goodwin WJ, Hu JJ, Franzmann EJ. Risk stratification system for oral screening. Poster presentation. Global Oral Cancer Forum. New York, NY, Mar 4-5, 2016.

51. Weed DT, Vella J, **Reis IM**, De la Fuente AC, Gomez C, Sargi Z, Nazarian R, Califano J, Noonan K, Borrello I, and Serafini P. Tadalafil reduces myeloid-derived suppressor cells and regulatory t cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma: Cumulative data from two independent trials. Multidisciplinary Head and Neck Cancer Symposium (AHNS, ASCO & ASTRO). Scottsdale, AZ, Feb 18-20, 2016.
52. Almuhaimeid TM, **Reis IM**, Goodwin WJ, Franzmann EJ. Nutritional effect on CD44 in head and neck cancer. AACR Annual Meeting ,Philadelphia, PA, Apr 18-22, 2015. Abstract LB-269.
53. Wright JL, Takita C, Lee E, **Reis I**, Zhao W, Nelson O, Hu JJ. Predictors of radiation-induced skin toxicity in a prospective study of tri-racial/ethnic breast cancer patient population. ASTRO Annual Meeting. San Antonio, TX, Oct 18-21, 2015. Abstract 2134.
54. Kodiyan J, **Reis I**, Portelance L, Pearson M, Slomovitz B, De La Garza J, Nieves-Neira W, Adams B, and Wolfson AH. Impact of adjuvant therapy on patient survival in stage I/II high-risk endometrial cancers. ASTRO Annual Meeting. San Antonio, TX, Oct 18-21, 2015. Abstract 3811.
55. Nelson OL, Wu ES, Park JY, Zeitouni J, Gomez CR, **Reis IM**, Zhao W, Lee E, Lin H-L, Franzman EJ, Savell J, McCaffrey TV, Goodwin WJ, Hu JJ. Actionable somatic mutations in head and neck cancer prognosis. AACR Annual Meeting. April 18-22, 2015; Philadelphia, PA. *Cancer Res.* 2015;75: 3876.
56. Wu ES, Park JY, Gomez CR, **Reis IM**, Zhao W, Lee EY, Nelson OL, Franzmann EJ, Goodwin WJ, Hu JJ. Racial/ethnic-specific somatic mutations in head and neck cancer prognosis. 2015 Miami Winter Symposium "Towards Personalized Cancer Medicine". University of Miami Miller School of Medicine and Sylvester Cancer Center; Miami, FL, Jan 18-21, 2015.
57. Gajjar S, Yoga A, **Reis IM**, Zeidan Y, Takita C. Predictors of outcomes in breast cancer patients with oligometastases. ARS Annual Meeting. Kauai, HI, May 2-5, 2015. *Int J Radiat Oncol Biol Phys.* 2015; 93(3): E21. Abstract 66719.
58. Diaz DA, Mitchell D, **Reis I**, Panoff J. Glioblastoma multiforme outcome comparison between pediatrics and adults: Is there a difference? ARS Annual Meeting. Kauai, HI, May 2-5, 2015. Abstract 66719.
59. Kwon D, **Reis IM**. Simulation-based estimation of mean and standard deviation for meta-analysis via Approximate Bayesian Computation (ABC). ENAR Spring meeting. Miami, FL, Mar 15-18, 2015.
60. Cnossen NR, Orman AG, Kwon D, Ritch C, Gonzalgo M, Ishkanian A, **Reis I**, Pollack A, Abramowitz M. A meta-analysis of health-related quality of life after primary treatment for prostate cancer as measured by the Expanded Prostate Index Composite. ASCO Genitourinary Cancers Symposium. Orlando, FL, Feb 26-28, 2015. *J Clin Oncol* 2015;33(7): abstract 39.
61. Palacios S, Akunyili II, Ernani V, Macintyre J, Merchan JR, Pollack T, **Reis I**, Restrepo MH, Rocha-Lima CMS, Hosein PJ. Gemcitabine (Gem) and nab-Paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer. ASCO Gastrointestinal Cancers Symposium. San Francisco, CA, Jan 15-17, 2015. *J Clin Oncol* 2015; suppl 3; abstr 413.
62. Pimentel A, **Reis I**, Toomey N, Diaz L, Ruiz P, Taylor G, Ramos JC. Using HDAC Inhibitors to eradicate adult t-cell leukemia-lymphoma. ASH Annual Meeting and Exposition. San Francisco, CA, Dec 6-9, 2014. Abstract 76894.

63. Pollack A, Abramowitz M, Bossart E, Lynne C, Jorda M, Casillas V, Ishkanian A, **Reis I**, Stoyanova R. Prostate cancer phase I Lattice Extreme Ablative Dose (LEAD) trial: Feasibility and acute toxicity. ASTRO Annual Meeting. San Francisco, CA, Sep 14-17, 2014.
64. Wright JL, Takita C, Reis IM, Zhao W, Hu JJ. Black patients treated with PMRT are more likely than others to develop moist desquamation in a prospective skin toxicity study. ASTRO Annual Meeting. San Francisco, CA, Sept 14-17, 2014. *Int J Radiat Oncol Biol Phys.* 2014; 90(1): S242.
65. Verma J, Kwon D, **Reis IM**, Takita C. Breast cancer subtype in locoregional outcomes in stage III locally advanced breast cancer. ASTRO Annual Meeting. San Francisco, CA, Sep 14-17, 2014. *Int J Radiat Oncol Biol Phys.* 2014; 90(1): S263.
66. Diaz Pardo DA, Abramowitz M, Mahmoud O, **Reis IM**, Elsayyad N, Samuels M, and Weed DT. Head and neck second primary cancer rates in the HPV era: a SEER analysis. ASTRO Annual Meeting. San Francisco, CA, Sep 14-17, 2014.
67. Shah NN, **Reis I**, Panoff J. Total body radiotherapy dose comparison in patients with relapsed acute lymphoblastic leukemia. ASTRO Annual Meeting. San Francisco, CA, Sep 14-17, 2014.
68. Wright JL, Takita C, **Reis I**, Zhao W, Lee E, Hu JJ. Variation in severity of acute skin toxicity by race and ethnicity in a prospective cohort of patients receiving post-mastectomy radiation. ARS Annual Meeting. St. Thomas, USVI, Apr 26-29, 2014.
69. Takita C, Kwon D, **Reis IM**, Wright JL, Mahamoud O, and Pollack A. Impact of breast cancer subtype in locoregional outcomes in stage III locally advanced breast cancer (LABC) treated with newer multimodality therapy. ARS Annual Meeting. St. Thomas, USVI, Apr 26-29, 2014.
70. Diaz Pardo DA, Abramowitz M, Mahmoud O, **Reis IM**, Elsayyad N, Samuels M, and Weed DT. Head and neck second primary cancer rates in the HPV era: a SEER analysis. (Oral presentation). ARS Annual Meeting. St. Thomas, USVI, Apr 26-29, 2014.
71. Diaz Pardo DA, Xie H, Abramowitz M, Mahmoud O, **Reis IM**, Ishkanian A, Fernandez G, Manoharan M, and Pollack A. Neoadjuvant radiotherapy improves survival in patients with T2b/T3 invasive bladder cancer. ASTRO Annual Meeting. Atlanta, GA, Sep 22-25, 2013.
72. Mahmoud O, **Reis IM**, Samuels MA, Elsayyad N, Both JA, Bossart E, El-Ghoneimy E, Moustafa M, AbdAllah M, Takita C. Prospective pilot study assessing the need for adaptive radiotherapy in unresected bulky disease and in postoperative head/neck cancer patients. ASTRO Annual Meeting. Atlanta, GA, Sep 22-25, 2013. Abstract 1871, oral presentation.
73. Lally B, Zhao W, Monde RA, **Reis IM**, Hu JJ. Non-small cell lung cancer disparities in a tri-racial/ethnic population. ASTRO Annual Meeting. Atlanta, GA, Sep 22-25, 2013. (Abstract 3099, oral presentation)
74. Register S, **Reis IM**, Zhao W, Takita C, Amestoy W, Wright J. Deep inspiration breath-hold technique for left-sided breast cancer: An analysis of OAR sparing. ASTRO Annual Meeting. Atlanta, GA, Sep 22-25, 2013. *Int J Radiat Oncol Biol Phys.* 87(2), Suppl. S226–S227 (Abstract 2058).
75. Wright JL, **Reis IM**, Zhao W, Takita C. Traditional risk factors for locoregional recurrence may not be predictive in post-menopausal women with ER positive breast cancer treated with neoadjuvant therapy. ASTRO Annual Meeting. Atlanta, GA, Sep 22-25, 2013.



76. Pereira LHM, **Reis I**, Duncan R, Wen J, Reategui E, Bayers S, Walters L, Perez A, Hu JJ, Goodwin WJ, Franzmann EJ. CD44, protein, demographics and risk factor data: A combined approach to detect head and neck squamous cell carcinoma. AACR Annual Meeting. Washington, DC, Apr 6-10, 2013.
77. Pereira LHM, **Reis I**, Duncan R, Wen J, Reategui E, Gordon C, Walters L, Perez A, Franzmann EJ. Head and neck squamous cell carcinoma and disparities: A model for early detection. AHNS 2013 Annual Meeting at the Combined Otolaryngology Spring Meetings (COSM). Orlando, FL, Apr 10-11, 2013.
78. Wright JL, Takita C, **Reis IM**, Zhao W, Poitevien M, and Hu JJ. Racial/ethnic disparities in breast cancer radiosensitivity. AACR Annual Meeting, Chicago, IL, Mar 31- Apr 4, 2012.
79. Ly B, Kwon D, **Reis I**, Jauhari S, Wright JL, Gunaseelan V, Takita C. Comparison of clinical outcomes in early stage triple negative breast cancer treated with mastectomy versus breast conserving therapy. ASTRO Annual Meeting. Boston, MA, Oct 28-31, 2012. *Int J Radiat Oncol Biol Phys.* 2012; 84(3): S258-S259.
80. Wright JL, **Reis IM**, Zhao W, Takita C, Poitevien M, Hu JJ. Race and ethnic disparities in quality of life in breast cancer patients receiving adjuvant radiotherapy after conservative surgery. ARS Annual Meeting, Las Vegas, NV, Apr 2012.
81. Diaz DA, Hurley J, Takita C, **Reis IM**, Zhao W, Wright JL. Locoregional outcomes in clinical stage IIB breast cancer after neoadjuvant therapy and mastectomy with or without chest wall and supraclavicular radiation. ASTRO Annual Meeting. Boston, MA, Oct 28-31, 2012. *Int J Radiat Oncol Biol Phys.* 2012; 84(3): S112.
82. Pereira LHM, **Reis I**, Duncan R, Wen J, Reategui E, Walters L, Perez A, Franzmann EJ. Head and neck squamous cell carcinoma and disparities: A model for early detection. AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. San Diego, CA, Oct 27-30, 2012.
83. Wright JL, Takita C, **Reis I**, Zhao W, Hu JJ. Rate of moist desquamation in patients receiving radiation for breast cancer after mastectomy versus breast conserving surgery. ASTRO Annual Meeting, Boston. MA, Oct 28-31, 2012. *Int J Radiat Oncol Biol Phys.* 2011; 84(3): S222.
84. Takita C, Kwon D, Wright JL, Gunaseelan V, **Reis I**. Assessment of prognostic features in treatment decision for ductal carcinoma in situ of the breast. ASTRO Annual Meeting. Boston, MA, Oct 28-31, 2012. *Int J Radiat Oncol Biol Phys.* 2012; 84(3): S262.
85. Hosien G, Perez A, Pereira LM, Reategui E, Wen J, **Reis I**, Duncan D, Morales A, Hu JJ, Goodwin WJ, Franzmann E. Novel analysis of p16 tumor status in the detection of oral and oropharyngeal squamous cell carcinomas using a saliva CD44/protein screening test. AHNS International Conference on Head and Neck Cancer; theme: BRIDGING THE GAP: Caring for the Head and Neck Cancer Patient. Toronto, ON, Canada, Jul 21-25, 2012. Abstract 42256.
86. Ambros T, **Reis I**, Dilprit B, Villasboas JC, Blieden C, Sujoy V, Wright J, Saigal K, Gomez Fernandez C, Hurley J. Neoadjuvant chemotherapy versus neoadjuvant hormonal therapy in post-menopausal women with ER positive, HER-2/neu negative locally advanced breast cancer. ASCO Annual meeting. Chicago, IL, Jun 1-5, 2012. Abstract 595.
87. Pereira LHM, **Reis I**, Duncan R, Perez A, Franzmann EJ. Head and neck squamous cell carcinoma in African Americans: A simple oral rinse detection test using solCD44 and total protein. AACR Annual Meeting. Chicago, IL, Mar 31- Apr 4, 2012. Abstract 3627.

88. Pereira LHM, **Reis I**, Duncan D, Perez A, Franzmann EJ. Salivary markers, demographic and risk factor data in head and neck cancer: Towards a new combined approach to predict head and neck squamous cell carcinoma. AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. Washington, DC, Sep 18-21, 2011. Abstract 122633.
89. Wright JL, Takita C, Panoff JE, **Reis IM**, Zhao W, Sujoy V, Fernandez CG, Jorda M, Franceschi D, Hurley J. The effect of molecular subtype on survival in a racially diverse cohort of patients with high-risk breast cancer receiving trimodality therapy. ASCO Breast Cancer Symposium. San Francisco, CA, Sep 8-10, 2011. J Clin Oncol 29, 2011 (suppl 27; abstract 156)
90. Wright JL, **Reis I**, Zhao W, Panoff JE, Takita C, Gomez C, Sujoy V, Jorda M, Franceschi D, Hurley J. Racial disparity in survival outcome varies with molecular subtype in breast cancer patients receiving trimodality therapy. ASCO Breast Symposium. **Poster Discussion**. San Francisco, CA, Sep 8-10, 2011.
91. Ambros T, Sujoy V, Fernandez CG, **Reis I**, Wright JL, Jorda M, Saigal K, Hurley J. Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor positive breast cancers. ASCO Breast Cancer Symposium. San Francisco, CA, Sep 8-10, 2011. Abstract 86752.
92. Takita C, **Reis IM**, Miao F, LaFave KE, Gunaseelan V, Hurley J, Silva OE, Avisar E, Wright JL. Comparison of locoregional recurrence in triple negative and HER2 positive breast cancer subtype after breast-conserving therapy and modern systemic therapy. ASCO Breast Cancer Symposium. San Francisco, CA, Sep 8-10, 2011. Abstract 86538.
93. Arsenault DM, Hurley J, **Reis I**, Zhao W, Takita C, Gomez C, Jorda M, Cioffi-Lavina M, Villasboas JC, Wright JL. Prognostic factors for locoregional recurrence in HER-2 overexpressing breast cancer patients treated with neoadjuvant chemotherapy. ASTRO Annual Meeting. Miami Beach, FL, Oct 2-6, 2011. Int J Radiat Oncol Biol Phys. 2011; 81(2): S225. Abstract 2026.
94. Panoff JE, Hurley J, Takita C, **Reis I**, Zhao W, Gomez C, Sujoy V, Jorda M, Franceschi D, Wright JL. Racial disparity in survival outcome varies with molecular subtype in breast cancer patients receiving trimodality therapy. ASTRO Annual Meeting. Miami Beach, FL, Oct 2-6, 2011. Int J Radiat Oncol Biol Phys. 2011; 81(2): S224-S225. Abstract 2025.
95. Saigal K, Saeed AM, Hurley J, **Reis I**, Zhao W, Takita C, Sujoy V, Ambros T, Ernani V, Wright JL. Pathologic response and locoregional outcome in post-menopausal ER positive breast cancer patients receiving neoadjuvant endocrine therapy versus cytotoxic chemotherapy. ASTRO Annual Meeting. Miami Beach, FL, Oct 2-6, 2011. Int J Radiat Oncol Biol Phys. 2011; 81(2): S90-S91. Abstract 181.
96. Takita C, **Reis I**, Miao F, LaFave K, Gunaseelan V, Wright JL. Triple Negative but not HER2 positive breast cancer subtype is associated with higher locoregional recurrence after breast-conserving therapy and modern systemic therapy. ASTRO Annual Meeting. Miami Beach, FL, Oct 2-6, 2011. Int J Radiat Oncol Biol Phys. 2011; 81(2): S220.
97. Pereira LHM, **R IM**, Duncan R, Perez A, Adebisi IN and Franzmann EJ. Salivary markers and risk factor data: Towards a new combined approach to predict head and neck squamous cell carcinoma. AACR Conference in the Science of Cancer Health Disparities in Racial/Ethnic Minorities and Medical Undeserved. Miami, FL, Sep-Oct 2010. Abstract B109.

98. Greenfield BJ, Mahmoud O, **Reis, IM**, Wright J, Miao F, Gunaseelan V, Hobeika GA, Takita C. Outcomes of T3N0M0 breast cancer patients in a diverse population. ASCO Breast Cancer Symposium. Washington, DC, Oct 1-3, 2010. Abstract 132.
99. Gordian E, Ramachandran K, **Reis I**, Manoharan M, Soloway M, Singal R. Serum free-circulating DNA as a biomarker of prostate cancer diagnosis. American Urological Association (AUA) Annual Meeting. San Francisco, CA, May 29 –Jun 3, 2010. Paper 52325.
100. Wright JL, Zhao W, **Reis IM**, Takita C, Gunaseelan V, Hurley J. Disparities in survival in African American patients compared to Hispanic White patients with locally advanced breast cancer. ASCO Breast Cancer Symposium. Washington. DC, Oct 1-3, 2010. Abstract 60305.
101. Panoff JE, Zhao W, **Reis IM**, Gunaseelan V, Hurley J, Takita C, Wright JL Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation. ASCO Breast Cancer Symposium. Washington, DC, Oct 1-3, 2010. Abstract 60333
102. Panoff JE, Zhao W, **Reis IM**, Gunaseelan V, Hurley J, Rodgers S, Takita C, Wright JL. Higher chest wall dose results in improved locoregional outcome in patients receiving post mastectomy radiation. ASCO Breast Cancer Symposium. Washington, DC, Oct 1-3, 2010. Int J Radiat Oncol Biol Phys. Vol. 78(3): S205.
103. Desai SC, **Reis I**, Zhao W, Takita C, Hurley J, Gunaseelan V, Rodgers S, Wright JL. Interval of up to 16 weeks between mastectomy and radiation does not impair locoregional outcome in patients receiving neoadjuvant chemotherapy. ASCO Breast Cancer Symposium. Washington, DC, Oct 1-3 2010. Abstract 2027.
104. Saigal K, Palmer JD, **Reis I**, Sperry JN. Mucosal melanomas of the head and neck: a modern experience at the University of Miami. ASCO Breast Cancer Symposium. Washington, DC, Oct 1-3, 2010. Int J Radiat Oncol Biol Phys. Vol. 78(3):S479.
105. Sperry JL, **Reis IM**, Casiano RR, Civantos FG, Weed DT. Esthesioneuroblastoma: A modern experience at the University of Miami. ASTRO Annual Meeting. San Diego, CA, Oct 31-Nov 4, 2010. Int J Radiat Oncol Biol Phys. Vol. 78(3): S217.
106. Wright JL, **Reis IM**, Zhao W, Gunaseelan V, Moller M, Takita C, Hurley J. Relationship between nodal stage, post mastectomy radiation field selection, and clinical outcome after neoadjuvant chemotherapy for breast cancer. ASTRO Annual Meeting. San Diego, CA, Oct 31-Nov 4, 2010. Int J Radiat Oncol Biol Phys. Vol. 78(3): S97.
107. Reyes C, Chapman-Fredricks J, Cioffi-Lavina M, **Reis I**, Gomez-Fernandez C, Jorda M. CXCL-16: a marker for papillary renal cell carcinoma type 2. UM SCCC Annual Zubrod Memorial Lecture and Poster Session. Miami, FL, May 21, 2010. Abstract 39.
108. Gordian E, Ramachandran K, **Reis I**, Manoharan M, Soloway M, Singal R. Serum free-circulating DNA as a biomarker of prostate cancer diagnosis. ASCO Annual Meeting. Chicago, IL, Jun 4-8, 2010. J Clin Oncol 28:15s, 2010 (suppl; abstract 4640).
109. Singal R, Ramachandran K, Gordian E, Reis IM, Zhao W, Quintero C, Mayo C, Auguste F. Phase I study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy. ASCO Annual Meeting. Chicago, IL, Jun 4-8, 2010. Paper 52086.
110. Ardalan B, Subbarayan PR, Ramos Y, Gonzalez M, Mezentsev D, **Reis IM**, Duncan R, Ganjei-Azar P, Lee K. Phase I study of 5-FU and arsenic trioxide (ATO) in patients with

- refractory metastatic colorectal carcinoma. ASCO Annual Meeting. Chicago, IL, Jun 4-8, 2010. Paper 50990.
111. Hosein PJ, Lopes GDL, Gomez CM, Pastorini VH, Macintyre J, Easey M, **Reis IM**, Merchan JR, Bejarano P, Rocha Lima CMS. A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)- based therapy. ASCO Annual Meeting. Chicago, IL, Jun 4-8, 2010. Paper 42443.
  112. Singal R, Gordian E, Ramachandran K, **Reis I**, Manoharan M, Soloway M. Serum free-circulating DNA as a biomarker of prostate cancer diagnosis. Annual Meeting of AUA Education and Research Inc. San Francisco, CA, May 29 –Jun 3, 2010.
  113. Sperry JL, Gomez CR, **Reis IM**, Casiano RR, Weed DT, Hatoum, GF. Small cell carcinoma of nasal cavity and paranasal sinuses: A single institutional experience. ARS Annual Meeting. Cancun, Mexico, May 2010.
  114. Singal R, Gordian E, Ramachandran K, **Reis I**, Manoharan M, Soloway M. Serum free-circulating DNA as a biomarker of prostate cancer diagnosis. ASCO Genitourinary Cancers Symposium. Mar 5-7, 2010, San Francisco, CA. Abstract 203.
  115. Singal R, Ramachandran K, Gordian E, **Reis I**, Zhao W. Phase I study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy. ASCO Genitourinary Cancers Symposium. San Francisco, CA, Mar 5-7, 2010. Abstract 137.
  116. Reyes C, Chapman-Fredricks J, Cioffi-Lavina M, **Reis I**, Gomez-Fernandez C, Jorda M. CXCL-16 is a marker for papillary renal cell carcinoma type 2. USCAP Annual Meeting. Washington, DC, Mar 20-26, 2010. Abstract 1540.
  117. Rojas C, Rodriguez S, Bird V, **Reis I**, Zhao W, Santos J, Leveillee R, Gomez-Fernandez C, Jorda M. Diagnostic accuracy of ureteroscopic biopsies from upper urinary tract carcinomas: does size really matter? USCAP Annual Meeting. Washington, DC. Mar 20- 26, 2010. Abstract 636.
  118. Dauphin-McKenzie N, Kobetz E, **Reis I**, Duncan R, Zhao W, Rosa-Cunha I, Jimenez E, Papadia A, Schuman S, Lucci J. Does the use of HIV protease inhibitors affect cervical dysplasia? *Oral Presentation* under “Cervical Cancer Prevention: 20 years of progress and path to the future”. EUROGIN, Society of Gynecologic Oncology Meeting ([www.eurogin.com/2010](http://www.eurogin.com/2010)). Monte Carlo, Monaco, Feb 17-20, 2010.
  119. Sperry JL, Hall MW, **Reis IM**, Hatoum, GF, Markoe AM, Casiano RR, Weed DT, Franzmann EJ, Arnold DJ, Civantos FJ. Sinonasal neuroendocrine tumors: A single institutional experience. ASTRO Multidisciplinary Head and Neck Cancer Symposium. Chandler, AZ, Feb 2010.
  120. Bayraktar S, Bayraktar UD, **Reis IM**, Pegram M, Welsh C, Silva O, Franchesci D, Gomez CR, Hurley J. Neoadjuvant dose-dense docetaxel, carboplatinum and trastuzumab (ddTCH) chemotherapy for her2 over-expressing breast cancer. ASCO Annual Meeting. Orlando, FL, May 29 –Jun 2, 2009.
  121. Han HS, **Reis I**, Kuroi K, Suzuki E, Toi M, Sizili E, Sume R, Chow L, Yip A, Zhao W, Nimmagadda R, Gluck S. Racial differences in acute toxicities of FEC 100 chemotherapy in patients with breast cancer. ASCO Annual Meeting. Chicago, IL, Jun 4-8, 2010.
  122. LaFave KE, Venkatraman A, **Reis I**, Wright JL, Gunaseelan V, Hatoum G, Avisar E, Silva O, Takita C. Outcome of a Young Minority Breast Cancer Population, 40 Years and

- Younger, in the Modern Era of Systemic Therapy. ASCO Annual Meeting. Chicago, IL, Jun 4-8, 2010. *Int J Radiat Oncol Biol Phys*. Vol. 75(3): S223. Abstract 2094.
123. Wright JL, **Reis I**, Takita C, Pegram MD, Rodgers SE, Leone, JD, Guardiola VD, Gunaseelan V, Hurley J. Locoregional outcomes in an inner city underserved population of triple-negative breast cancer patients receiving induction therapy with platinum salts and docetaxel. ASCO Annual Meeting. Chicago, IL, Jun 4-8, 2010. *Int J Radiat Oncol Biol Phys*. Vol. 75(3): S211-S212.
  124. Panoff JE, Gunaseelan V, Wright JL, Venkatraman A, **Reis I**, Hatoum G, Silva O, Avisar E, Takita C. Capecitabine as a radiation sensitizer for locally advanced breast cancer. (Abstract # 2087) ASCO Annual Meeting, Jun 4-8, 2010, Chicago, IL. *Int J Radiat Oncol Biol Phys*. Vol. 75(3):S220.
  125. Singal R, Navarro L, Gordian E, Ramachandran K, **Reis IM**, Manoharan M, Soloway M. Aberrant promoter methylation in serum of prostate cancer patients and controls. ASCO Annual Meeting. Chicago, IL, Jun 4-8, 2009. *J Clin Oncol* 27, 2009 (suppl; abstr e16046).
  126. Herrera LP, Bird V, **Reis IM**, Sanz D, Viera E, Nadji M. Lymphatic Space Invasion Predicts metastatic behavior in patients with renal cell carcinoma, and it may be an independent prognostic factor for overall survival. USCAP Annual Meeting. Boston, MA, Mar 7-13, 2009. Abstract 451918/2500.
  127. Herrera LP, Jorda M, **Reis IM**, Sanz D, Viera E, Nadji M. The potential value of a simple two-level grading system for renal cell carcinomas. USCAP Annual Meeting. Boston, MA, Mar 7-13, 2009. Abstract 2402.
  128. Jabiev AA, **Reis IM**, Montano R, Solorzano CC, Lew JI. Surgeon performed ultrasound can predict differentiated thyroid cancer in solitary thyroid nodules. Society of Surgical Oncology (SSO) Annual Cancer Symposium. Phoenix, AZ, Mar 5-8, 2009. Abstract 546578.
  129. Han HS, **Reis I**, Kuroi K, Suzuki E, Toi M, Chow L, Syme R, Yip A, Zhao W, Gluck S. Racial differences in acute toxicities of adjuvant chemotherapy in patients with breast cancer. ASCO Breast Cancer Symposium. Washington, DC, Sep 5-7, 2008. Abstract 113.
  130. Gluck S, Lobo C, Hurley J, Lopes G, **Reis IM**, Seo P, Silva O, Slingerland J, Welsh C, Tukia C. Interim results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer (MBC). ASCO Breast Cancer Symposium. Washington, DC, Sep 5-7, 2008. Abstract 167.
  131. Gluck S, Lobo C, Hurley J, Lopes G, **Reis I**, Seo P, Silva O, Slingerland J, Welsh C, Carmody C, Tukia K. Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with Her2-negative metastatic breast cancer (MBC). ASCO Annual Meeting. Chicago, IL, May 30 – Jun 3, 2008. Abstract 1089.
  132. Ardalan B, Spector S, Mezentssev D, Molina MA, **Reis I**, Ganjei-Azar P, Sapp M, Rios J, Franceschi D, Livingstone AS. Phase II study of neo-adjuvant chemotherapy (NAC) with FUdR (F), leucovorin (L), oxaliplatin (O) and docetaxel (D) (FLOD) in chemo-naïve operable esophageal adenocarcinoma (EAC). ASCO Annual Meeting. Chicago, IL, May 30 - Jun 3, 2008. Abstract 15503.
  133. Singal R, Navarro L, Gordian E, Ramachandran K, **Reis I**, Hamilton K, Jorda M, Manoharan M, Soloway M. Methylation of GSTP1, RARB and RASSF1A in free circulating DNA and buffy coat DNA in prostate cancer patients and controls. ASCO Genitourinary Cancers Symposium. San Francisco, CA, Feb 14-16, 2008. Abstract 262.

134. Singal R, Ramachandran K, Reis I, Jorda M, Manoharan M. Methylation of GSTP1, RARB and RASSF1A in free circulating DNA and buffy coat DNA in prostate cancer patients and controls. AUA Annual Meeting. Orlando, FL, May 17-22, 2008. Abstract 1346; *The Journal of Urology*, 179(4): p 461.
135. Abdel-Wahab M, **Reis IM**, Hamilton K. Second Primary Cancer after radiation therapy- a comparison between brachytherapy versus external beam radiation therapy. ASCO Genitourinary Cancers Symposium. San Francisco, CA, Feb 14-16, 2008. Abstract 121.
136. Ardalan B, Spector S, Mezentsev D, Molina MA, **Reis I**, Ganjei-Azar P, Sapp M, Rios J, Franceschi D, Livingstone A. Phase II study: neo-adjuvant chemotherapy (NAC) with FUdR (F), leucovorin (L), oxaliplatin (O) and docetaxel (D) (FLOD) in chemo-naïve operable esophageal adenocarcinoma (EAC). ASCO Gastrointestinal Cancers Symposium. Orlando, FL, Jan 25-27, 2008. Abstract 52.
137. Pochi SR, Ramos Y, Mezentsev D, Ganjei-Azar P, **Reis I**, Lee K, Ardalan B. A continued report on Phase I study of escalating doses of 5-FU and arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) in patients with refractory metastatic colorectal carcinoma. ASCO Gastrointestinal Cancers Symposium. Orlando, FL, Jan 25-27, 2008. Abstract 329.
138. Herrera LP, Gomez-Fernandez C, **Reis IM**, Hamilton K, Jorda M. Limited immunohistochemical panel helps distinguish granular type of conventional renal cell carcinoma from other non-papillary renal oncocyctic neoplasms. UM SCCC Annual Zubrod Memorial Lecture and Poster Session. Miami, FL, May 1, 2008. Abstract 9.
139. Herrera LP, Gomez-Fernandez C, Nicolas M, **Reis I**, Hamilton K, Jorda M. A Limited immunohistochemical panel helps in the distinction of conventional type renal cell carcinoma with granular morphology from other non-papillary renal oncocyctic neoplasms. 2008 USCAP Annual Meeting. Denver, CO, Mar 2-8, 2008. Das PM Herrera LP
140. Pochi SR, Ramos, Y, Mezentsev D, Bongato T, Ganjei-Azar P, **Reis I**, Kozyreva O, Lee K, Ardalan B. A phase I study of 5-FU and arsenic trioxide for patients with refractory metastatic colorectal carcinoma. ASCO Gastrointestinal Cancers Symposium. Orlando, FL, Jan 2007. Abstract 419.
141. Voti L, Richardson LC, **Reis IM**, Fleming LE, Mackinnon J, Coebergh JWW. The effect of race/ethnicity and insurance in the administration of standard therapy for local breast cancer in Florida. International Association of Cancer Registries (IACR) Annual Meeting. Ljubljana, Slovenia, Sep 17-20, 2007.
142. Abdel-Wahab M, **Reis IM**, Wu J. The Effect of Treatment on Development of Second Primary Cancer in Prostate Cancer Patients: an Analysis of SEER Data. ASTRO Annual Meeting. Philadelphia, PA, Nov 5-9, 2006. Int J Radiat Oncol Biol Phys. Vol. 6(3): S334.
143. Huang KT, Abdel-Wahab M, Shouman T, **Reis IM**. Comparison of 5, 7, and 9 field IMRT plans in prostate cancer treatment and structure sparing priorities. ASTRO Annual Meeting. Philadelphia, PA, Nov 5-9, 2006. Abstract 984.
144. Jorda M, Perez A, Gomez C, **Reis IM**, Nadji M. MUC-4 expression in prostate cancer. USCAP Annual Meeting. Atlanta, GA, Feb 11-17, 2006.
145. Krishan A, Ganjei-Azar P, Jorda M, Nadji M, **Reis IM**, Hamelik RM. Detection of tumor cells in body cavity fluids by multiparametric flow cytometry and immunocytochemistry. AACR Annual Meeting. Washington, DC, Apr 1-5, 2006. Abstract 06-AB-1457-AACR.
146. Voti L, Richardson LC, **Reis IM**, Fleming LE, Mackinnon J, Coebergh JWW. Administration of standard therapy for local breast cancer in Florida: the role of

- race/ethnicity and insurance. Latino/Hispanic Cancer Disparity. AACR Annual Meeting. Washington, DC, Apr 1-5, 2006.
147. Singal R, Das PM, **Reis IM**, Schlesselman JJ. Polymorphisms in the DNA methyltransferase 3b (DNMT3b) gene and prostate cancer risk. ASCO Prostate Cancer Symposium. Orlando, FL, Feb 17-19, 2005. Abstract 17.
  148. Dauphin-McKenzie N, Lambrou N, Garg R, Almeida Z, **Reis IM**, Lucci J. Highly active antiretroviral therapy affects survival in human immunodeficiency virus-positive patients with invasive cervical cancer. UM SCCC Annual Zubrod Memorial Lecture and Poster Session. Miami, FL, May 19, 2005. Abstract 4.
  149. Das PM, vanWert J, Ferdinand L, Gopal G, **Reis IM**, Singal R. Methylation mediated silencing of TMS1 – a novel pro-apoptotic gene – in prostate cancer. UM SCCC Annual Zubrod Memorial Lecture and Poster Session. Miami, FL, May 19, 2005. Abstract 24.
  150. Raez LE, Rosado MF, Santos ES, Hamilton K, **Reis IM**. Irinotecan and docetaxel as first-line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. ASCO Annual Meeting. New Orleans, LO, Jun 5-8 2004. ASCO Annual Meeting Proceedings (Post-Meeting Edition) JCO 2004; 22:14S Abstract 7246.
  151. Singal R, Ferdinand L, **Reis IM**, Schlesselman JJ. Methylation of selected genes occurs at a significantly higher frequency in prostate cancers than in benign prostatic hypertrophy specimens and correlates with clinicopathological features of poor prognosis in prostate cancer patients. AACR Annual Meeting. Orlando, FL, Mar 27-31, 2004. Abstract 900.
  152. Das PM, Ferdinand L, **Reis IM**, Schlesselman JJ, Singal R,. Methylation of multiple genes in prostate cancer and relationship with clinico-pathological features. UM SCCC Annual Zubrod Memorial Lecture and Poster Session. Miami, FL, Jun 3, 2004. Abstract 16.
  153. Voti L, Richardson L, Fleming L, Mackinnon J, **Reis I**, Hartzema A. The role of health insurance and teaching hospitals in the treatment of lymph node positive breast cancers diagnosis in Florida, July 1997- December 2000. UM SCCC Annual Zubrod Memorial Lecture and Poster Session. Miami, FL, Jun 3, 2004. Abstract 60.
  154. McCafferty-Grad JM, Bahlis NJ, Aguilar TM, **Reis I**, Lee KP, Boise LH. Mechanisms of action and determinants of sensitivity for arsenic trioxide in Multiple Myeloma. International Myeloma Foundation: IX<sup>th</sup> International Workshop on Multiple Myeloma. Salamanca, Spain, May 23-27, 2003.
  155. Abdel-Wahab M, Schwartz GG, Howard G, **Reis I**, Schlesselman J, Diego J, Willingham M, Hollis B, Markoe A, Calcifediol in recurrent prostate cancer – a phase II trial. ASCO Annual Meeting. Chicago, IL, May 31- Jun 3, 2003. Proceedings: Abstract 1708.
  156. Cho, H-M, Morgensztern D, **Reis I**, Challita-Eid P, Yi KH, Rosenblatt, JD, Shin S-U. Vaccination with B7.1-antibody fusion protein coated tumor cells provides protection *in vivo*. . UM SCCC Annual Zubrod Memorial Lecture and Poster Session. Miami, FL, June, 2003. Abstract 21.
  157. Cho, H-M, Shin S-U, Morgensztern D, **Reis I**, Challita-Eid p, Yi KH, Rosenblatt, JD. Vaccination with B7.1-antibody fusion protein coated tumor cells provides protection *in vivo*. ASCO Annual Meeting. Chicago, IL, May 31- Jun 3, 2003. Proceedings: Abstract 734.

158. Hurley J, Doliny P, **Reis IM**, DeZarraga F, Gomez C, Velez, Powell J. Platinum salts and docetaxel as primary therapy of locally advanced and inflammatory breast cancer: the final report of three sequential studies. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 3-6, 2003. *Breast Cancer Research and Treatment* 2003; 82 (1): 238.
159. De Zarraga F, Doliny P, **Reis IM**, Powell J, Velez P, Gomez-Fernandez C, Tang S-C, Hurley J. Cardiotoxicity of neoadjuvant trastuzumab, docetaxel and cisplatin is related to BMI. ASCO Annual Meeting. Chicago, IL, May 31- Jun 3, 2003. Proceedings: Abstract 227.
160. Doliny P, Velez P, Jorda, Powell J, **Reis IM**, Tang S-C, Shonukan, Hurley J. Weekly Carboplatin and Docetaxel as neoadjuvant therapy in locally advanced and inflammatory breast cancer that do not express HER-2. ASCO Annual Meeting. Chicago, IL, May 31- Jun 3, 2003. Proceedings: Abstract 251.
161. Hurley J, Lunn J, Turnquest T, **Reis IM**, Doliny P, Donenberg T, De Zarraga F, Mirhashemi R. Breast Cancer in the Bahamas: Preliminary evidence for a high incidence of genetic risk. ASCO Annual Meeting. Chicago, IL, May 31- Jun 3, 2003 Proceedings: Abstract 3506.
162. McCafferty-Grad J, Bahlis N, Aguilar T, **Reis I**, Lee K, Boise L. Arsenic trioxide in multiple myeloma. UM SCCC Annual Zubrod Memorial Lecture and Poster Session. Miami, FL, May 29, 2003. Abstract 35.
163. Morrell L, Lee Y, **Reis IM**, Hurley J. MVAC as neoadjuvant therapy in locally advanced and inflammatory breast cancer: ten year update. ASCO Annual Meeting. Chicago, IL, May 31- Jun 3, 2003. Proceedings: Abstract 244.
164. Landy H, Markoe A, Potter P, Marini A, Savaraj N, **Reis IM**, Wangpaichitr M, Feun L. Radiosurgery (RS) plus estramustine in the treatment of patients with malignant primary brain tumors (MBT). ASCO Annual Meeting. Orlando, FL, May 18-21, 2002. Proceedings: Abstract 2093.
165. Franco S, Silva O, Bateman D, Doliny P, Jorda M, Castillo M, **Reis IM**, Velez P, and Hurley J. Neoadjuvant (NEO) treatment of locally advanced and inflammatory breast cancer with weekly taxotere and carboplatin in tumors that do not overexpress HER-2. ASCO Annual Meeting. Orlando, FL, May 18-21, 2002. Proceedings: Abstract 2048.
166. Hurley J, Doliny P, Silva O, Gomez-Fernandez C, **Reis IM**, Velez P, Castillo M, Bateman D, Franco S, and Gautam U. Neoadjuvant herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. ASCO Annual Meeting. Orlando, FL, May 18-21, 2002. Proceedings: Abstract 196.
167. Hurley J, Doliny P, Silva O, Powell J, Shayker M, Velez P, **Reis IM**, and Lee Y. Is there an alternative to anthracycline based chemotherapy: an evaluation of a non-anthracycline containing regimen as neoadjuvant therapy in locally advanced and inflammatory breast cancer? San Antonio Breast Cancer Symposium (SABCS) Annual Meeting. San Antonio, TX, Dec 11-14, 2002. *Breast Can Res Treat* 2002; 76(1): Abstract 155.
168. **Reis I**, Schlesselman JJ. EWOC – A superior dose-finding ALGORITHM for phase I clinical trials. UM SCCC Annual Zubrod Memorial Lecture and Poster Session. Miami, FL, Jun 13, 2002. Abstract 18.
169. Hurley J, Doliny P, Velez P, Guatam U, **Reis IM**, Silva O, Gomez-Fernandez C, Lee Y, and Franco S. High rate of axillary node clearance with neoadjuvant herceptin, taxotere and cisplatin in locally advanced and inflammatory breast cancer. San Antonio Breast Cancer Symposium (SABCS) Annual Meeting. San Antonio, TX, Dec 10-13, 2001. *Breast Cancer Research and Treatment*, 2001; 69(3): Abstract 516.



170. Amed A, Bertini-Oliveira AA, Martinez TLR, Auriemo CRC, **Reis Lamonica IM**, Maldjian S, Feres MC, Miranda EA, Nascimento DJ, Camano L. Perfil lipídico e glicêmico em gestantes que parturiram recém-nascidos macrossômicos. *ANAIS do XIX Congresso Brasileiro de Patologia Clínica*. Sao Paulo, Brazil, 1985. Abstract 31.
171. Martinez TLR, Martinez Fo EE, Auriemo CRC, Delboni Fo H, Camano L, **Reis IM**, Piageti ALA, Liviero L, Freitas FF, Bertini-Oliveira AM. Serum levels of cholesterol, triglycerides and lipoproteins in normal pregnant women. *Archives of Gynecology, XI<sup>th</sup> World Congress of Gynecology and Obstetrics*. Berlim, 1985.

### **18e. Received Acknowledgement**

*(Biostatistician who performed statistical analyses, or biostatistician consultant.)*

1. Organização Pan-americana da Saúde. Fundação Nacional de Saúde/Centro Nacional de Epidemiologia. *Métodos de investigação epidemiológica em doenças transmissíveis*. Vol. I e II: Andrade, A.L.S.S. & Zicker, F. (org), Brasília, 1997. [WHO/PAHO - World Health Organization / Pan American Health Organization. Brazilian National Health Foundation/National Epidemiology Center. Epidemiological research methods in communicable diseases.]
2. White SC, Atchison KA, Hewlett ER, Flack VF. Clinical and historical predictors of dental caries on radiographs. *Dentomaxillofac. Radiol* 1995; 24:121-27.
3. Carmo LCB, Cols. Estudo comparativo duplo cego com fentiazac e acetaminofen no tratamento da dor pós-cirurgia abdominal. *F. Méd. (BR)*, 1984; 88.
4. Pinto JA, Pinheiro JM, Mekhitarian Neto L, Andrade NA. Avaliação de acetaminofen, dipirona e placebo no tratamento da dor pós-amigdalectomia. *Revista Brasileira de Cirurgia*, 74(4), 1984.
5. Molina-López J. Fentiazac in osteoarthritis: comparison of BID and QID regimens. *Clinical Therapeutics*, 1983; 5:462-71.
6. Wortsman AM. Avaliação clínica e ergométrica de pacientes hipertensos tratados com Indoramina e Propanolol. *F. Méd. (BR)*, 1983;87:177-82.
7. Carmo LCB, Cols. Avaliação das propriedades analgésicas do fentiazac. *F. Méd. (BR)*, 1983;87:301-8.
8. Michielin F, Cols. Avaliação clínica comparativa entre indoramina e metildopa: Estudo multicêntrico. *F. Méd. (BR)*, 1983; 87:247-52.
9. Páscoa MP. Avaliação multicêntrica de fentiazac pomada. *F. Méd. (BR)*, 1983;87:195-99.
10. Saviano A, Carvalho ED. Lormetazepam como hipnoindutor na véspera da cirurgia: Estudo controlado com placebo. *F. Méd. (BR)*, 1983; 86:359-63.
11. Mathias Filho AP. Doses altas de fentiazac a longo prazo no tratamento de artrite reumatóide. *F. Méd. (BR)*, 1983; 86:195-99.

**19. Other works accepted for publications****19a. Manuscripts under revision or submitted for publication**

## **V. PROFESSIONAL**

### **20. Funded Research Performed:**

#### **20a. CURRENT GRANTS**

##### **1. THE SYLVESTER CANCER CENTER SUPPORT**

Principal Investigator: Nimer, Stephen  
 Role in Project: Biostatistical Co-Investigator, 5%  
 Grant #: 1P30CA240139  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI), P30  
 Project Period: 07/01/2019 - 06/30/2024  
 Total Award: \$12,133,751

Summary: The major goal of this proposal is for The Sylvester Comprehensive Cancer Center at the University of Miami to seek National Cancer Institute designation to support its mission to reduce the human burden from cancer through research, education, prevention, and the delivery of quality patient care.

##### **2. EPIGENETIC TARGETING OF AFRO-CARIBBEAN VARIANT OF HTLV-1 RELATED ADULT T-CELL LEUKEMIA-LYMPHOMA**

Principal Investigator: Ramos, Juan Carlos  
 Role in Project: Co-Investigator, 3%  
 Grant #: 1R01CA223232-01  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI), R01  
 Project Period: 01/01/18-12/31/22  
 Total Award: \$ 1,721,736

Summary/Aims: This project revolves around a novel clinical approach to treat ATLL, and the study of the biological effects of a new class of drugs in this type of cancer in order to advance the treatment and cure of a fatal neglected disease affecting a U.S. population group. Specific Aim 1: To conduct a clinical trial using a potent HDAC inhibitor in combination with AZT-based maintenance therapy to eradicate ATLL. Specific Aim 2: To investigate the molecular basis of HDAC inhibitors in ATLL.

##### **3. MRI IMAGING AND BIOMARKERS FOR EARLY DETECTION OF AGGRESSIVE PROSTATE CANCER**

Principal Investigator: Pollack, Allan  
 Role in Project: Co-Investigator, 4%  
 Grant #: U01CA239141  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI), U01  
 Project Period: 09/19/19-08/31/22  
 Total Award: \$ 2,977,709

##### **4. IMPACT OF PRECISION INTERVENTION ON REDUCING BREAST CANCER DISPARITIES**

Principal Investigator: Hu, JJ  
 Role in Project: Co-Investigator, 5%  
 Grant #: FP6831 (submitted 02/18/2022)  
 Funding Source: Florida Breast Cancer Foundation (FL-BCF)  
 Project Period: 12 months 06/01/2022- 05/31/2023  
 Total Award: \$ 100,000

## **20b. PENDING GRANTS (12)**

### **1. DEVELOPMENT OF AN EFFECTIVE, LOW-COST, POINT-OF-CARE EARLY DETECTION TEST FOR ORAL CANCER IN LOW RESOURCE SETTINGS**

Principal Investigator: Franzmann, EJ  
Role in Project: Co-Investigator,  
Grant #: (submitted 02/2022)  
Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI), STTR  
Project Period: ?  
Total Award: \$400,000

### **2. ORAL CANCER EARLY DETECTION IN FLORIDA CITY**

Principal Investigator: Franzmann, EJ  
Role in Project: Co-Investigator 2%  
Grant #: (submitted 04/05/2022)?  
Funding Source: SCCC CTA  
Project Period: 4/21-4/24  
Total Award: \$50,000

### **3. TUMOR MUTATION BURDEN AND IMMUNE SIGNATURES IN PREDICTING BREAST CANCER PRECISION INTERVENTIONS**

Principal Investigator: Hu, Jennifer  
Role in Project: Co-Investigator 5%  
Grant #: Submitted 9/2021 FP5544  
Funding Source: FDOH  
Project Period: 7/1/22-6/30/27  
Total Award: \$ 1,499,466

### **4. TRANSFORMATIVE RESEARCH TO ADVANCE PRECISION INTERVENTION OF BREAST CANCER.**

Principal Investigator: Hu, Jennifer  
Role in Project: Co-Investigator (\$5,000 for BBSR)  
Grant #: Submitted 8/2021 FP5250  
Funding Source: NIH  
Project Period: 04/1/22- 3/30/27  
Total Award: \$ 3,660,177

### **5. MOLECULAR DETERMINANTS OF BREAST CANCER DISPARITIES IN TRANSFORMING PRECISION INTERVENTION**

Principal Investigator: Hu, Jennifer  
Role in Project: Co-Investigator  
Grant #: Submitted 2/2021 FP3652  
Funding Source: Florida Breast Cancer Foundation (FL-BCF)  
Project Period: 07/1/21- 6/30/22  
Total Award: \$ 100,000

### **6. EFFECT OF COVID-19 INFECTION ON MALE REPRODUCTION**

Principal Investigator: Ramasamy, Ranjith & Zhang, Fangliang  
Role in Project: Co-Investigator, 5%  
Grant #: 1R01HD110510-01 (submitted 02/2022)

Funding Source: National Institutes of Health (NIH), National Institute of Child Health and Human Development (NICHD), R01  
 Project Period: 07/01/21- 06/30/26  
 Total Award: \$3,834,700.00 (Total Cost)

#### 7. OVARIAN CANCER HEALTH DISPARITIES – ROLE OF HRD IN HIGH GRADE SEROUS CARCINOMA.

Principal Investigator: George, Sophia & Schlumbrecht, Matthew  
 Role in Project: Co-Investigator, 5%  
 Grant #: (submitted 11/2020)  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI), R01  
 Project Period: 07/01/21- 06/30/26  
 Total Award: \$ 2,618,600 (Total Cost)  
 Summary/Aims: Aim 1: Determine the genomic variant landscape and association with clinicopathologic features in Black women with high-grade serous ovarian cancer; Aim 2: Define early genomic events in pre-neoplastic lesions in Black women; Aim 3: Develop neoplastic models of HGSC in Black women.

#### 8. STING-dependent Adjuvants (STAVs) Cell based Therapy for Aggressive Leukemias

Principal Investigator: Ramos, Juan Carlos  
 Role in Project: Co-Investigator, 3%  
 Grant #: (Submitted 10/2020)  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI), R01  
 Project Period: 07/01/21- 06/30/26  
 Total Award: \$ 3,837,501 (Total Cost)  
 Summary/Aims: We aim to evaluate whether STAVs could be useful immunotherapy in combination with DC vaccine for the treatment of aggressive incurable leukemias. Our strategy provides a new therapeutic approach for the treatment this cancer.

#### 9. A PHASE 1 TRIAL OF COMBINED MEK, STAT3 AND PD-1 INHIBITION IN METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Principal Investigator: Merchant, Nipun  
 Role in Project: Co-Investigator, 3%  
 Grant #: NA (Submitted 09/27/2019)  
 Funding Source: The ASCO Foundation  
 Project Period: 07/01/20 – 06/30/23  
 Total Award: \$ 1,938,975

#### 10. UNRAVELING THE INTEGRATIVE EFFECTS OF NEOADJUVANT CHEMOTHERAPY AND IMMUNOTHERAPY ON OVARIAN CANCER TUMOR BIOLOGY

Principal Investigator: Huang, Marilyn  
 Role in Project: Co-Investigator, 3%  
 Grant #: NA (Submission: 09/27/2019)  
 Funding Source: The ASCO Foundation  
 Project Period: 07/01/20 – 06/30/23  
 Total Award: \$ ?

#### 11. GENETIC DETERMINANTS OF NEUROCOGNITIVE AND PSYCHOSOCIAL FUNCTIONING IN LATINO AND NON-LATINO PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION.

Principal Investigator: Rueda-Lara, Maria & Penedo, Frank

Role in Project:	Co-Investigator (\$5,000 for BBSR)
Grant #:	(Submitted 10/2019)
Funding Source:	Sylvester
Project Period:	01/01/20- 12/30/22
Total Award:	\$ 71, 000

## 20c. COMPLETED/ENDED GRANTS (29)

### 1. DOES SEX MATTER? TARGETING SEX DIFFERENCES IN AGE-RELATED LUNG DISEASE

Principal Investigator: Elliot, Sharon J  
 Role in Project: Co-Investigator, Biostatistician, 3%  
 Grant #: 1 R21 AG060338-01  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI), R21  
 Project Period: 02/15/19-12/31/20  
 Total Award: \$ 275,000

Summary/Aims: The research goal is to detect sex-specific differential pathways. *Aim 1*: Determine the activational effects of gonadal hormones/respective receptors and subsequent downstream signaling that contribute to age-associated lung disease. We will compare gonadectomized (GDX) aging male and female BLM-treated mice to determine if estrogens are protective and androgens harmful to lung fibrosis. We will determine the contribution of AR and ER in the development of lung fibrosis using myofibroblasts isolated from lungs of male and female patients with IPF. *Aim 2*: Determine whether sex chromosomes contribute to sex differences in age-associated lung disease using the four core genotypes mouse model. This model separates the effects of gonadal sex (ovaries versus testes) from the sex chromosome complement (XX vs. XY) by producing XX and XY gonadal males and XX and XY gonadal females.

### 2. METABOLOMICS: NOVEL STRATEGIES TO IMPROVE BREAST CANCER RADIOTHERAPY RESPONSES

Principal Investigator: Hu, Jennifer J.  
 Role in Project: Co-Investigator/Biostatistician, 5%  
 Grant #: 1R21 CA234880-01  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI), R21  
 Project Period: 07/01/19-06/30/21  
 Total Award: \$ 437,029 (Total Cost)

Summary/Aims: *Aim 1*: To evaluate global metabolomics-driven models in predicting RT-induced EASRs/pain. Our pilot data support the working hypothesis that at least 7 metabolic pathways contribute to worse RT-induced EASRs/pain; the alanine, aspartate and glutamate metabolism pathway has the highest impact. **We will test 240 pre-RT urine samples (120 high and 120 low EASRs/pain)** for 712 metabolites in building a prediction model of RT-induced EASRs/pain after adjusting for potential confounders in multivariable logistic regression models. *Aim 2*: To validate/quantitate significant metabolites/pathways (pilot and *Aim 1*) in predicting RT-induced EASRs/pain after adjusting for confounders in multivariable logistic regression models. The working hypothesis is that pre-RT metabolomics can predict an individual's risk for RT-induced EASRs/pain. We will target significant metabolites/pathways using **another 240 samples (120 high and 120 low EASRs/pain)** for validation/quantitation. *Aim 3*: To evaluate the performance of metabolites/pathways in clinical application. We will compare the performance of metabolites/pathways (*Aim 2*) and patient/clinic characteristics in predicting RT-induced EASRs/pain using Receiver Operating Characteristic (ROC) curves. Milestone: The comprehensive models with patient/clinic characteristics and metabolomics will accurately predict RT-induced EASRs/pain and impact clinical practice.

### 3. THE ROLE OF ATE1-MEDIATED DEGRADATION OF CYCLIN D1 IN BREAST CANCER PROGRESSION

Principal Investigator: Zhang, Fangliang  
 Role in Project: Co-Investigator, 2%  
 Grant #:   
 Funding Source: Florida Breast Cancer Foundation (FL-BCF)  
 Project Period: 7/01/19 – 06/30/20  
 Total Award: \$ 100,000

Summary/Aims: While our hypothesized mechanism likely operates in all stages of BC, a reduction of Ate1 appears to be more prevalent in ER-negative cells. We will carried out three independent aims covering biochemical, cell-based, and human tissue-based angles. Aim 1. How does Ate1 regulate the half-life of cyclin D1? Aim 2. Is tumor growth or metastasis of BC cells affected by Ate1-dependent degradation of cyclin D1? Aim 3. What is the correlation between Ate1 and cyclin D1 levels in relation to BC malignancy in patients?

### 4. IMPACT OF ETIOLOGY-DRIVEN PRECISION MEDICINE ON REDUCING BREAST CANCER DISPARITIES

Principal Investigator: Hu, Jennifer J.  
 Role in Project: Co-Investigator/Biostatistician, 5%  
 Grant #: 5BC04  
 Funding Source: FL Biomedical Research, Bankhead-Coley (BHC)  
 Project Period: 05/15/15-05/15/18  
 Total Award: \$ 1,290,000

Summary/Aims: The goal is to build a paradigm-shift model system to translate etiology to precision medicine in breast cancer. The study will test the working hypothesis that genetic polymorphisms, dietary factors, metabolomics, and somatic mutations are associated with more aggressive triple negative breast cancer (TNBC) and worse survival. The Specific Aims are: (1) To evaluate gene-gene and gene-diet interaction in TNBC risk utilizing a new OncoArray panel of 250,000 genetic polymorphisms and food frequency questionnaire; (2) To determine metabolomic signatures of TNBC by utilizing a high-throughput technology for >478 metabolites; (3) To investigate impact of gene-gene, gene-diet interactions and metabolomics on somatic mutations.

### 5. AN UNKNOWN ROLE OF ARGINYLATION IN PROSTATE CANCER

Principal Investigator: Zhang, Fangliang  
 Role in Project: Co-Investigator, 3% (3<sup>rd</sup> year fiscal year)  
 Grant #: PC140622  
 Funding Source: Department of Defense (DOD)  
 Project Period: 10/01/15 – 08/30/18  
 Total Award: \$ 225,000

Summary/Aims: We hypothesize that Ate1/arginylation is an essential regulator for the physiological responses to oxidative stress, and that the down-regulation of Ate1 in PC cells allow them to metastasize. Therefore, a lower level of Ate1 in the primary tumor of prostate cancer is a predictive sign for future metastasis. Specific Aims: (1) Testing whether down-regulation of Ate1 promotes the metastasis of prostate cancer cells. (2) Testing the association between the level of Ate1 in primary tumors and clinical outcomes. (3) Identification of targets of arginylation related to its anti-cancer role in response to oxidative stress.



## 6. METHYLATION PROFILING IN FREE CIRCULATING DNA AS A BIOMARKER FOR RISK STRATIFICATION OF PROSTATE CANCER

Principal Investigator: Singal, Rakesh

Role in Project: Biostatistician, 10% (Year 2)

Grant #: 4BB18

Funding Source: FL Biomedical Research, Bankhead-Coley (BHC)

Project Period: 12/1/15-11/30/18

Total Award: \$400,000

Summary/Aims: (1) Identification of methylation markers of aggressive prostate cancer; (2) Determination of methylation of selected genes in plasma of patients prior to radical prostatectomy (RP); (3) Correlation of methylation levels of candidate genes with pathological stage of disease and GS of patients undergoing RP.

## 7. OPTICAL IMAGING OF A CD44 BASED ORAL RINSE WITH FLORESCENT DETECTION TO VISUALIZE ORAL CANCER

Principal Investigator: Reis, Isildinha M (PI-UM) & Franzmann, Elizabeth J (PI-Vigilant)

Role in Project: PI-UM, 10%

Grant #: 1R43DE025797-01

Funding Source: Vigilant Biosciences / National Institutes of Health (NIH) Small Business Innovation Research (SBIR)

Project Period: 02/05/2016 - 10/30/2017

Total Award: \$ 191,538 (UM \$ 63,432) Year 1 \$ 27,916 (UM 16,588) Year 2

Summary/Aims: The goal of this study is to develop an imaging device that will involve a simple rinse and spit solution with an anti-CD44 probe bound to non-absorbable, fluorescent microspheres that will bind to cells expressing abnormally high levels of CD44. Specific Aim#1: Test an in-vitro model for detecting CD44 elevated cells using fluorescent probes on membranes. To do this, we will culture well-characterized cell lines that have been engineered to overexpress or underexpress CD44. Specific Aim #2: Test the system in tumor explants from humans. In this Aim, we will determine how well the conjugate identifies carcinogenesis in humans. We will analyze at least ten (10) oral squamous cell cancer tissues with surrounding normal margin from patients who are going to the operating room (OR) for surgical removal of an oral squamous cell cancer of moderate to severe dysplasia or invasive cancer and at least 10 patient tissues that were excised for benign conditions (chronic tonsillitis) using the anti-CD44 fluorescently labeled beads.

## 8. EARLY DETECTION FOR SMOKING-ASSOCIATED HEAD AND NECK CANCER

Principal Investigator: Franzmann, Elizabeth J.

Role in Project: Co-Investigator/Biostatistician, 10%

Grant #: 4BB20

Funding Source: FL Biomedical Research, Bankhead-Coley (BHC)

Project Period: 12/1/13 – 11/30/15

Total Award: \$347,826 (DC)

Summary/Aims: The overall goal is to determine variations in solCD44 and total protein levels over time in high-risk participants from a health clinic in Liberty City, Miami, Florida. The specific aims are: (1) To evaluate variations in solCD44 and total protein level over time in 150 high-risk participants from Liberty City. The goal was to follow a previous study cohort of 150 patients annually with oral exam, oral rinse collection and risk assessments. Quantitate changes in individual participant's marker levels were analyzed to determine normal and abnormal variations and associations with risk behavior changes. We determined whether patients with significantly increasing levels developed pre-malignancy or malignancy and cross-checked data with the Florida Cancer Data System (FCDS). (2) To determine whether oral rinse solCD44 and protein marker levels decrease

with smoking cessation. We collected oral rinse and saliva samples in 150 subjects from Liberty City and other regions of South Florida who are newly enrolled in smoking cessation programs. We measured solCD44 and protein. We confirmed smoking cessation using saliva cotinine levels. We compared marker levels before, 3 months and 1 year after completion of smoking cessation in quitters and non-quitters. (3) To examine whether solCD44 and protein levels in oral rinses from HNSCC correlate with disease burden. In this aim, we evaluated 30 cases enrolled in the first 18 months and collected oral rinses before and after treatment to determine if marker levels would drop with decreased tumor burden.

#### 9. METHYLATION PROFILING IN CELL-FREE DNA AS A TEST FOR PROSTATE CANCER DIAGNOSIS

Principal Investigator: Singal, Rakesh  
 Role in Project: Co-Investigator/Biostatistician, 2%  
 Grant #: NA  
 Funding Source: Woman's Cancer Association (WCA)  
 Project Period: 05/1/14 - 5/31/2015  
 Total Award: \$ 50,000 (Total cost)  
 Summary/Aims: To study whole genome methylation patterns in blood of patients who underwent prostate biopsy to identify methylation signatures as biomarkers for detection of prostate cancer.

#### 10. GENOMIC PREDICTION MODELS OF LUNG CANCER SURVIVAL AND TREATMENT RESPONSE

Principal Investigator: Lally, Brian  
 Role in Project: Biostatistician, 10%  
 Grant #: M1200762  
 Funding Source: FL Biomedical Research, Bankhead-Coley (BHC)  
 Project Period: 7/1/12-6/30/15  
 Total Award: \$675,000 (Total DC)  
 Summary/Aims: Prospective multicenter study design recruiting a tri-racial/ethnic cohort of about 600 (200 AA, 200 HW, 200 NHW) newly diagnosed NSCLC patients at 3 VA medical centers within the Veterans Integrated Service Network 8. Specific aims: (1) To evaluate the impact of mental health, physical fitness, and smoking history/status on treatment response and survival in NSCLC. (2) To explore how mental health, smoking history/status, and physical fitness contribute to treatment delays and treatment-associated toxicity in NSCLC. (3) To develop and validate genomic biomarkers in predicting clinical outcomes of NSCLC.

#### 11. HOST DEFENSE REGULATION AND VIRAL ONCOGENESIS (Administration Core (Core A))

Principal Investigator: Barber, Glen  
 Role in Project: Biostatistician, 15% (10% in 2014)  
 Grant #: 1P01CA12811501-A5  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI)  
 Project Period: 8/14/09-7/31/14  
 Total Award: \$5,562,927 (Total Cost)  
 Summary/Aims: The overall objective of this P01 was to understand the basic mechanisms by which different oncogenic viruses evade host innate immunity leading to infection and ultimately cancers. It was composed by the following three strong and interactive research projects: Project 1: Mechanisms of host defense and regulation by oncoviral encoded gene products; Project 2: Host Defense Regulation by HTLV-I; Project 3: Disruption of antiviral signaling pathways by HTLV-I Tax. The P01 was supported by three core facilities: Administrative Core, Tissue & Pathology Core, and Molecular Core. The Administration Core provided the structure that

integrates the various components of the PO1 including organizational, administrative, accounting, biostatistics, informatics, and clinical research support functions. The specific aim of the Biostatistics subcomponent of the Administrative Core was to provide the following biostatistical support: i. Collaborate with investigators in the design and conduct of clinical studies. ii. Consult with investigators on statistical aspects of laboratory experiments. iii. Determine sample size needed to test specific hypotheses at appropriate levels of significance and power. iv. Prepare descriptive summaries and statistical analyses (estimation, testing, and model building) of data obtained from clinical or laboratory investigations.

## 12. IMPACT OF GENOMICS ON DISPARITIES IN BREAST CANCER RADIOSENSITIVITY

Principal Investigator: Hu, Jennifer J

Role in Project: Biostatistician, 10% (5% in 2014)

Grant #: 1R01CA135288-05

Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI)

Project Period: 1/1/10-12/31/14

Total Award: \$2,125,641 (Total DC)

Summary/Aims: It is expected that the findings would enhance the understanding of the genetic susceptibility and molecular mechanisms of EASRs, thus leading to improved preventive strategies. Specific aims: Aim 1. To develop polygenic models of RT-induced EASRs with a comprehensive evaluation of genome-wide nonsynonymous single nucleotide polymorphisms. Aim 2. To evaluate the association between RT-induced EASRs and three functional phenotypes:

(1) the Comet assay for DNA damage, (2) the ionizing radiation (IR)-induced H2AX phosphorylation assay for DNA damage signal transduction, (3) the IR-induced cell cycle G2 delay. Aim 3. To explore polygenic models of genome-wide nsSNPs in predicting RT-induced late side effects (> 4 years) and/or locoregional recurrence in 850 breast cancer patients with a median follow up of 8 years (range 4-12 years).

## 13. IMPACT OF MOLECULAR GENETICS ON DISPARITIES OF BREAST CANCER RISK AND PREVENTION

Principal Investigator: Hu, Jennifer J.

Role in Project: Biostatistician, 10%

Grant #: 1BG04 (EProst 20090481)

Funding Source: FL Biomedical Research, Bankhead-Coley (BHC)

Project Period: 7/1/10 - 6/30/15 (Ended 12/31/13)

Total Award: \$ 1,500,000 (Total Cost)

Summary/Aims: We hypothesized that breast cancer with worse diagnosis occurs most frequently in underserved minorities due to (1) genetic defects in DNA repair, (2) elevated DNA damage, and (3) gene-environment interactions. The goal was to test a new paradigm that genetic and non-genetic regulation of DNA damage/repair contributes to breast cancer disparities in tumor phenotypes and treatment response. Specific aims were: Aim 1: To investigate racial/ethnic specific polygenic models of DNA damage signaling and repair responses in breast cancer risk with a comprehensive evaluation of tagging single nucleotide polymorphisms in 169 genes of 5 candidate pathways. Aim 2: To evaluate whether racial/ethnic-specific breast cancer risk is associated with 3 DNA damage/repair functional phenotypes: (1) BER: oxidative DNA damage, (2) DSB: ionizing radiation-induced H2AX phosphorylation, (3) NER: plasmid-based DNA-repair capacity. Aim 3: To elucidate the racial/ethnic specific molecular mechanisms of genetic (i.e., SNPs) and non-genetic (i.e., alcohol, dietary nutrient deficiencies, and/or smoking exposure) regulations of DNA damage/repair functional phenotypes contributing to breast cancer diagnosis and progression.

#### 14. EARLY DETECTION MARKERS FOR SMOKING-INDUCED HNSCC

Principal Investigator: Franzmann, Elizabeth J.  
 Role in Project: Biostatistician, 10% (5% in 2013)  
 Grant #: 10BG02  
 Funding Source: FL Biomedical Research, Bankhead-Coley (BHC)  
 Project Period: 7/1/10 - 6/30/15 (Ended 12/31/13)  
 Total Award: \$ 1,043,478 (Revised Total DC)

Summary/Aims: Aim 1: To determine the levels of solCD44 and protein in oral rinses from subjects enrolled in a Liberty City head and neck screening clinic and examine a) how they vary with demographic and risk factors and b) how they change over time. Aim 2: to determine changes in oral rinse solCD44 and protein marker status with smoking cessation. In Aim 3: To evaluate perceived acceptability of the test and its likelihood to influence smoking cessation in the population.

#### 15. RESTORING ER EXPRESSION AND ANTI-ESTROGEN RESPONSE IN ER-NEGATIVE BREAST CANCER

Principal Investigator: El-Ashry, Dorraya  
 Role in Project: Biostatistician, 5%  
 Grant #: 09BW04  
 Funding Source: FL Biomedical Research, Bankhead-Coley (BHC)  
 Project Period: 1/1/10 - 12/31/12  
 Total Award: \$ 566,798 (Total DC)

Summary/Aims: The overall goals of this project were (1) to determine if restoration of ER expression and responses to antiestrogen therapies was possible in ERalpha-negative breast cancer in humans and (2) to identify genotypic and/or phospho-proteomic determinants of that subset of ER- breast cancers in which this was possible. Successful completion of this work would lead to a clinical trial testing combination therapy of a MEK inhibitor and an anti-estrogen in ERalpha-negative breast cancer patients.

#### 16. TARGETING OF EBV LATENCY IN BURKITT LYMPHOMA

Principal Investigator: Ramos, Juan Carlos  
 Role in Project: Biostatistician, 5%  
 Grant #: 5-R01-CA-112217-01-05  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI)  
 Project Period: 09/22/06 - 07/31/12  
 Total Award: \$ 937,334 (Total DC, no cost extension)

Summary/Aims: Specific Aim 1: To study EBV viral load in patients with BL enrolled on a therapeutic protocol of chemo/antiviral (AZT, hydrea) therapy. Under this aim, we aimed to determine the following: A) If there was an early phase of EBV reactivation upon initiation of chemotherapy in patients with EBV+ BL. B) If changes in EBV viral load during chemotherapy correlated with response to therapy. C) If EBV viral load could be used as a marker for relapse in patients who achieve remission. Specific Aim 2: To investigate the mechanism of NF-κB activation (canonical vs. non-canonical) and the type of viral latency (I, II, or III) in which each occurs in BL. It was hypothesized that inhibition of NF-κB in BL disrupts EBV latency and results in apoptosis. Primary tumors linked to the aforementioned clinical trial were utilized to determine the following: A) If type I latency was associated with a lack of the canonical NF-κB (p65) activation pathway. B) If a lytic gene expression of EBV was present in primary BL. C) Whether AZT inhibited NF-κB and activated EBV in primary BL cells and if this occurred in type I latency tumors. D) If AZT mediated apoptosis in EBV associated lymphoma was potentiated by the addition of hydroxyurea. Specific Aim 3: To conduct a clinical trial of chemo/antiviral (AZT) therapy for patients with poor prognosis (relapsed, chemo resistant) EBV+ BL. It was

hypothesized that reactivation of EBV induced by conventional chemotherapy would potentiate the unique anti-tumor properties of AZT.

#### 17. A NEOADJUVANT TRIAL OF ANASTRAZOLE AND A NOVEL SRC INHIBITOR, AZD0530, FOR LABC.

Principal Investigator: Pegram, Mark D  
 Role in Project: Biostatistician, 10%  
 Grant #: 1-R21-CA-147163-02  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI)  
 Project Period: 6/1/09 - 5/31/12  
 Total Award: \$ 274,555 (Total DC)

Summary/Aims: This grant supported a clinical trial that combined for the first time a novel molecular Src oncogene, with the antiestrogen anastrozole for women with breast cancer. This was a Phase I/randomized Phase II clinical trial of the Src inhibitor, AZD0530, together with anastrozole. The Phase I part of study was carried out in postmenopausal women with ER positive metastatic disease receiving combined neoadjuvant treatment with anastrozole plus AZD0530. In the phase II part of study, ER+/PgR+ postmenopausal women with locally advanced breast cancer were randomized to either neoadjuvant treatment with anastrozole alone or in combination with AZD0530. Specific aims: (1) To test if Src inhibition can delay or inhibit resistance to aromatase inhibition in ER+ post-menopausal breast cancer. (2) To test the ability of serial MRI to evaluate changes in tumor volume and blood flow as a more reliable clinical measure of response to neoadjuvant hormonal therapy. (3) To define biologic endpoints or predictors of treatment response that may assist in patient selection for subsequent studies. To this end, we conducted assays in molecular targets and upstream regulators of Src using protein and gene expression profiles and quantitate tumor initiating cells in diagnostic samples, tumor biopsies at 12 weeks and resected cancers at mastectomy or lumpectomy after 4-6 months of treatment with anastrozole alone or anastrozole and AZD0530.

#### 18. A SIMPLE TEST FOR PROSTATE CANCER DIAGNOSIS

Principal Investigator: Singal, Rakesh  
 Role in Project: Biostatistician, 2%  
 Grant #: PROPOSALM1101848  
 Funding Source: Woman's Cancer Association (WCA)  
 Project Period: 6/1/11- 5/31/12  
 Total Award: \$ 50,000 (Total DC)

Summary/Aims: This grant proposed to compare spectrophotometric and fluorescence- based quantitation of total fcDNA to that of amplifiable DNA levels determined by qPCR.

#### 19. TARGETED THERAPY FOR BURKITT LYMPHOMA IN RESOURCE POOR SETTINGS

Principal Investigator: Barber, Glen  
 Role in Project: Biostatistician, 5%  
 Grant #: 5-R01-CA-121935-05  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI)  
 Project Period: 09/22/06 - 07/31/11  
 Total Award: \$ 982,630 (Total DC)

Summary/Aims: The goals of this project were to investigate the molecular epidemiology and pathogenesis of primary tumors and prospectively analyze lymphomas derived from patients with EBV+ forms of BL in resource poor settings. This proposal was an opportunity to develop and innovative model of collaboration between diverse organizations to achieve better awareness and access. The hypothesis was that in primary BL, NF- $\kappa$ B activation (and sensitivity to antiviral mediated apoptosis) is dependent upon the form of latency of EBV. We prospectively analyzed

lymphomas derived from Brazilian patients with EBV+ (endemic and HIV associated) forms of BL. Specific aims: (1) To determine the pathway for activation of NF- $\kappa$ B (canonical vs. non canonical) and the context of EBV latency in which each occurs. (2) To determine the transcription profile of EBV+ BLs and to test the hypothesis that some primary EBV+ BLs display viral lytic transcripts including vTK, in the absence of intermediate culture or non-specific amplification. (3) Using primary tumor specimens, to test the hypothesis that inhibition of NF- $\kappa$ B leads to disruption of EBV latency and apoptosis; and to determine the sensitivity of primary EBV positive BLs to AZT alone or in combination with inducers of the viral lytic program and inhibitors of NF- $\kappa$ B.

## 20. SALIVARY SOLUBLE MARKERS IN HEAD AND NECK CANCER

Principal Investigator: Franzmann, Elizabeth J.  
 Role in Project: Biostatistician, 5%  
 Grant #: 5-R01-CA-118584-03  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI)  
 Project Period: 6/4/07 - 5/31/11  
 Total Award: \$1, 299,409 (Total DC)

Summary/Aims: Our long-term goal is to design and perform a definitive screening trial with the outcomes of early detection and most definitely, survival. Specific Aim 1. To determine whether solCD44, HA and HAase levels in oral rinses distinguishes between patients with invasive HNSCC and high-risk controls with favorable sensitivity and specificity. Specific Aim 2. To assess short-term variability of solCD44, HA, and HAase levels in oral rinses from control and HNSCC patients.

## 21. REVERSAL OF 5-FU RESISTANCE BY ARSENIC TRIOXIDE IN COLORECTAL CARCINOMA

Principal Investigator: Ardalan, Bach  
 Role in Project: Biostatistician, 10%  
 Grant #: 5-R21-CA-117116-02  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI)  
 Project Period: 6/4/07 - 5/31/10  
 Total Award: \$ 379,896 (Total DC)

Summary/Aims: The overall goal of this R21 proposal was to conduct a phase I/II to examine whether concurrent administration of low dose ATO would down regulate thymidylate synthase expression and reverse clinical 5-FU resistance in CRC patients. Aim 1: Determine in the Phase I component of a Phase I/II clinical trial the dose of 5-FU/Leucovorin in combination with a fixed dose of ATO that can be safely administered for the treatment of 5-FU-resistant relapsed/refractory colorectal cancer patients. Aim 2: Determine if ATO administration down regulates the expression of thymidylate synthase in tumor and normal tissue (PBMC, oral mucosal epithelium), and correlate expression between intratumoral and normal tissue levels as well as to clinical parameters.

## 22. MOLECULAR EPIDEMIOLOGY AND PREVENTION OF BREAST CANCER

Principal Investigator: Hu, Jennifer J.  
 Role in Project: Biostatistician, 10%  
 Grant #: 5-R01-CA-073629-11  
 Funding Source: National Institutes of Health (NIH), National Cancer Institute (NCI)  
 Project Period: 7/1/06 - 6/30/10.  
 Total Award: \$ 1,300,000 (Total Cost)

Summary/Aims: Aim 1: To investigate polygenic models of DNA damage signaling and repair responses in breast cancer risk with a comprehensive evaluation of haplotype tagging single nucleotide polymorphisms and non-synonymous SNPs in 189 genes of multiple candidate pathways. Aim 2: To evaluate the association between breast cancer risk and three functional

phenotypes: (1) the ionizing radiation (IR)-induced H2AX phosphorylation assay for DNA damage signal transduction, (2) the IR-induced cell cycle G2 delay, and (3) the Comet assay for DNA damage. Aim 3: To apply a candidate-pathway approach in assessing genetic (i.e., SNPs) and non-genetic (i.e., alcohol, dietary deficiencies, and/or smoking exposure) regulations of DNA damage/repair functional phenotypes in driving breast carcinogenesis and progression.

### 23. PPARGAMMA: BIOMARKER FOR BREAST CANCER IN OLDER WOMEN

Principal Investigator: Pearl, Seo  
 Role in Project: Biostatistician, 5%  
 Grant #: 7-K08-AG-026744-03  
 Funding Source: National Institutes of Health (NIH), National Institute on Aging (NIA)  
 Project Period: 08/15/07-06/30/10  
 Total Award: \$ 481,351 (Total DC).

Summary/Aims: The goal of this project was to determine whether the aberrant methylation of selected genes in serum DNA is associated with the presence of breast cancer and whether this association is influenced by age, family history and breast cancer risk factors. Specific aims: (1a) To determine if methylation of five genes (RASSF1A, APC, GSTP1, RARb and Twist) in plasma correlate with methylation of these genes in tumor tissue of women with breast cancer (cases). (1b) To compare methylation of these five genes measured in plasma between breast cancer cases and controls (women without breast cancer). (1c) To determine if methylation of these five genes measured in plasma and in tumor tissue of breast cancer cases and in plasma of controls vary by potential breast cancer prognostic factors, such as age, menopause status, family history, and smoking history. (2) To develop a test using methylation expression of the five pre-selected genes (RASSF1A, APC, GSTP1, RARb and Twist) in plasma to predict the presence of breast cancer.

### 24. RESISTANCE TO INTERFERON-BASED THERAPY IN ADULT T-CELL LEUKEMIA

Principal Investigator: Ramos, Juan Carlos  
 Role in Project: Biostatistician, 5%  
 Grant #: 3707  
 Funding Source: Damon Runyon Cancer Research Foundation  
 Project Period: 07/01/07-06/30/10  
 Total Award: \$ 450,000 (Total DC)

Summary/Aims: The overall goal of this proposal was to investigate the role of IRF-4 in primary ATLL focusing on mechanisms involved in IFN resistance. These studies would clarify the mechanisms of antiviral therapy in this unique viral associated malignancy and help identify the subset of patients most likely to benefit from this treatment. Ultimately this work would have great potential to define the molecular processes contributing to the neoplastic growth of ATLL. Specific Aims: Aim 1: We studied the role IRF-4 plays in interferon resistance in Adult T-cell leukemia. To accomplish this, we studied whether a) IRF-4 suppression by RNA interference restores sensitivity to IFN-based therapy in an established ATLL NOD/SCID mouse model and b) whether targeting of NF-kB with pharmacologic inhibitors (bortezomib) restores IFN- $\alpha$  sensitivity. Aim 2: We conducted a clinical trial to test the hypotheses that a) weekly peg-IFN- $\alpha$  is an effective alternative to daily dosing in ATLL, b) whether specific molecular markers (IRF-4, c-Rel) are predictive of antiviral response and, c) whether IRF-4 expression, alterations in NF-kB, or other molecular events common in ATLL such as defective tumor suppressors, are associated with disease progression or recurrence after treatment.

## 25. PATHOGENESIS AND THERAPY OF VIRAL RELATED LYMPHOMAS

(Administration, Core A of this pre-SPORE grant)

Principal Investigator: Lossos, Izidoros

Role in Project: Biostatistician, 10%

Grant #: 07BR01

Funding Source: FL Biomedical Research, Bankhead-Coley (BHC)

Project Period: 7/1/07-6/30/10

Total Award: \$925,924 (Total DC)

Summary/Aims: The main goal of this project was to host activities that would serve as unique platforms for training of young investigators in both clinical and basic aspects of AIDS oncology and to promote collaborative efforts in anticipation of submission of an NCI SPORE application.

## 26. ABERRANT PROMOTER METHYLATION IN SERUM DNA AS A BIOMARKER FOR PROSTATE CANCER.

Principal Investigator: Singal, Rakesh

Role in Project: Co-PI, 5%

Grant #: W81XWH-04-1-0241

Funding Source: Department of Defense (DOD)

Project Period: 5/1/04-5/31/09

Total Award: \$ 354,637 (Total DC)

Summary/Aims: The main objective of this study was to develop a serum-based test for prostate cancer using DNA methylation of one or more candidate genes to improve the predictive value of prostate screening.

## 27. CYTOCHLOR/ CYTOFLUOR: NEW TUMOR TARGETED RADIOSENSITIZERS

Principal Investigator: Abdel-Wahab, May

Role in Project: Biostatistician, 5%

Grant #: 5R42CA079272-03

Funding Source: National Institutes of Health (NIH), NCI-SBIR-STTR

Project Period: 7/10/04-5/31/07

Total Award: \$110,391 (Total DC)

Summary/Aims: The specific aims were as follows: (1) To determine the levels of the critical enzymes, dCK and dCMP in tumors and associated normal tissue, (2) to simplify the protocol from 3 biomodulators to 1, (3) the determination of the % of cells of human tumors growing in nude mice incorporating 5-chlorouracil in their DNA, (4) the determination of the dose enhancement ratio utilizing human tumors growing in nude mice (PC-3 prostate), (5) to compare CldC + H4U vs. IdU as a radiosensitizer of human tumors in nude mice, and (6) to determine the minimal effective dose of CldC as a radiosensitizer.

## 28. ARSENIC TRIOXIDE + ASCORBIC ACID FOR MULTIPLE MYELOMA.

Principal Investigator: Kelvin Lee

Role in Project: Biostatistician, 5%

Grant #: 5R01CA97243-05

Funding Source: National Institutes of Health (NIH)

Project Period: 7/1/99-9/28/06

Total Award: \$1,698,731 (Total DC)

Summary/Aims: Aims: To conduct a phase II clinical trial of arsenic + ascorbic acid for refractory/relapsed multiple myeloma and develop correlates of response and toxicity.



## 29. PROSTATE CANCER AND VITAMIN D: RECEPTORS, RESPONSE AND RACE

Principal Investigator: Schwartz, Gary G

Role in Project: Biostatistician, 20%

Grant #: R01 CA-94-028

Funding Source: National Institutes of Health (NIH)

Project Period: 07/01/99 - 06/30/00

Total Award: \$112,265 (Total DC)

Summary/Aims: The ultimate goal of this study in prostate cancer was to understand the roles played by vitamin D and calcium and how these factors could be manipulated to develop preventive and therapeutic strategies.

**20d. STATISTICIAN in clinical trials, letters of intent (LOIs), and other research studies conducted at UM/Sylvester** (84 studies, including 10 LOIs)

1. EPROST 2021xxxx: A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma. PI: Peter Hosein.
2. EPROST 2021xxxx: A multicenter, Phase Ib/II study that combines Luspatercept and Lenalidomide (L2) in lower-risk, non-del(5q) MDS Patients. PI: Mikkael A. Sekeres
3. EPROST 2021xxxx: Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR/MSS Recurrent/Unresectable Endometrial Carcinoma. PI Aaron Wolfson / Marilyn Huang.
4. EPROST 2021xxxx: A Phase 3, Randomized, Comparative Effectiveness Clinical Trial of Early Continence comparing Continence Hood (CH) versus Retzius Sparing (RS) Robot-Assisted Radical Prostatectomy (RALP) for patient with localized prostate cancer (Hood-RS Trial). PI: Bruno Nahar.
5. EPROST 2021xxxx: A phase 1/2 study of zanubrutinib and tafasitamab in mantle cell lymphoma. PI: Alvaro Alencar.
6. EPROST 2021xxxx: A Randomized Phase 2 Study of Neoadjuvant mFOLFIRINOX and IL-1 Inhibition with or without Immune Checkpoint Inhibition in Resectable Pancreatic Cancer. PI: Nipun B. Merchant.
7. Phase 1b/2 trial of AMG 900 in combination with docetaxel for patients with previously treated, metastatic, histologically documented gastric and gastroesophageal junction (GEJ) cancers. PI: Nkiruka, Ezenwajiaku / Albert Craig Lockhart.
8. LOI 2021-03: A phase 2, open-label, study evaluating safety and efficacy of the Lenalidomide in relapsed extranodal marginal zone lymphoma. PI: Izidore Lossos.
9. EPROST 2021xxxx: A phase 2, open-label, study evaluating safety and efficacy of the loncastuximab in relapsed/refractory marginal zone lymphoma. PI: Izidore Lossos.
10. EPROST 2021xxxx: PET/CT-based prognostication in patients with relapsed and refractory diffuse large B cell lymphoma treated with loncastuximab tesirine PI: Juan Alderuccio.
11. EProst 2020xxxx: Single-arm, open-label Phase 2 study of loncastuximab tesirine in combination with rituximab in patients with advanced stage follicular lymphoma. PI: Juan Alderuccio.
12. EProst 2020xxxx: Phase 2 Single Agent Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia (GTN). PI: Marilyn Huang.
13. EProst 2020xxxx: A Randomized Phase 2 Study of Neoadjuvant mFOLFIRINOX and IL-1 Inhibition with or without Immune Checkpoint Inhibition in Resectable Pancreatic Cancer. PI: Nipun B. Merchant.
14. EProst 2020xxxx: A Pilot Safety Trial of STING-dependent Adjuvants (STAVs) and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias. PI: Juan Carlos Ramos.
15. LOI 2020-May: Phase 2 study of RAMIRI plus Checkpoint Inhibition in Patients with Metastatic Gastroesophageal Cancers. PI: Craig Lochart.
16. LOI 2020-Feb: A Randomized Phase 2 Study of Neoadjuvant mFOLFIRINOX and IL-1 Inhibition with or without Immune Checkpoint Inhibition in Resectable Pancreatic Cancer. PI: Nipun B. Merchant.

17. EProst 20200543: Phase II Trial of Maintenance Cemiplimab-rwlc after Concurrent Chemoradiotherapy (CRT) in Intermediate and High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC). PI: Cesar A. Perez.
18. LOI 2020-02: A phase 2, open-label, study evaluating safety and efficacy of the combination of Lenalidomide and Tafasitamab (MOR208) in untreated extranodal marginal zone lymphoma. PI: Izidore Lossos.
19. LOI 2020-08: Phase 1/2 Study of R-CHOP (Rituximab-Cyclophosphamide-Adriamycin-Vincristine-Prednisone) with Olaparib (Ola-R-CHOP) in patients with untreated Diffuse Large B-Cell Lymphoma (DLBCL) expressing high LMO2. PI: Izidore Lossos.
20. LOI 2020-06: Phase 1 Study of R-CHOP (Rituximab-Cyclophosphamide-adriamycin-vincristine-prednisone) with Pamiparib (Pami-R-ICE) in patients with untreated Diffuse Large B-Cell Lymphoma (DLBCL) PI: Izidore Lossos.
21. LOI 2019-2020: Phase 2 Trial of Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for Patients with Recurrent/Unresectable Endometrial Carcinoma. PI: Aaron H Wolfson.
22. LOI 2019: Simple-arm, Phase 2 study of Loncastuximab tesirine in combination with rituximab in untreated patients with follicular lymphoma and marginal zone lymphoma. PI: Crag Moskowitz & Juan Alderuccio.
23. LOI 2019: A Phase 2, open-label, study evaluating safety and efficacy of the combination of duvelisib and Ibrutinib in relapsed and refractory marginal zone lymphoma. PI: Izidore Lossos & Juan Alderuccio.
24. LOI 2019: Phase 1/2 Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Olaparib (Ola-R-ICE) in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). PI: Izidore Lossos & Juan Alderuccio.
25. EProst 20190283: "Phase I Study to Evaluate the Safety and Feasibility of Preoperative Ablative Breast Radiotherapy (SABER) for Selected Early Stage Breast Cancer". PI: Cristiane Takita.
26. EProst 2018xxxx: "An exploratory phase II, randomized, controlled, open label, study of tadalafil, a PDE5 inhibitor, with nivolumab, a check point inhibitor, and the enhanced anti-tumor MUC1 vaccine for the treatment of recurrent head and neck squamous cell cancer (HNSCC)". PI: Donald Weed.
27. EProst 2018xxxx: "A randomized, open-label, phase II study of FOLFIRINOX versus FLOT chemotherapies for previously untreated advanced gastric, gastro-esophageal junction, and esophageal tumors". PI: A. Craig Lockhart.
28. EProst 2018xxxx: "A phase II study of neoadjuvant therapy with 5-FU, leucovorin, oxaliplatin and docetaxel (FLOT) concurrent with radiation therapy (RT) in patients with resectable esophageal cancer". PI: A. Craig Lockhart.
29. Eprost 20150952: "Miami Membrane for Potency (MMeP) Trial to Assess the Impact of Dehydrated Human Amnion Membrane Allograft Placement during Robotic Radical Prostatectomy on Early Return of Erectile Function." PI: Sanoj Punnen.
30. EProst 2017xxxx: "A phase I, open-label, dose-escalation, study of trabectedin [T] in combination with doxorubicin [D] and olaratumab [O] in patients with metastatic or recurrent leiomyosarcoma". PI: Marilyn Huang.

31. 2017 LOI: "Combination of daratumumab and bendamustine in non-transplant eligible patients with relapse/refractory multiple myeloma." PI: James Hoffman.
32. 2016 LOI: "A phase II open-label study to assess the efficacy of first line ibrutinib in newly diagnosed patients with marginal zone lymphoma of the ocular adnexa." PI: Izidore Lossos.
33. 2016 LOI: "Single-center phase I study of intratumoral talimogene laherparepvec in combination with low-dose irradiation in patients with pancreatic adenocarcinoma." PI: Nicolas Acquavella.
34. EProst 20160653: "Proof of concept study of vorinostat, a histone deacetylase inhibitor, in patients with class 2 high risk uveal melanoma." PI: Lynn Feun (prior PI: Nicolas Acquavella).
35. EProst 20170846: "Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients with Recurrent, Persistent, or Metastatic Cervical Cancer." PI: Marilyn Huang.
36. EProst 20160477: "Phase II single arm study of combination pembrolizumab, paclitaxel, and carboplatin in patients with advanced stage ovarian, fallopian tube, or peritoneal carcinoma receiving neoadjuvant chemotherapy". PI: Marilyn Huang.
37. EProst 20151012: "The validity of sentinel lymph node dissection (SLND) in patients with apparent early stage endometrial cancer (EC)". PI: Brian Slomovitz.
38. EProst 20150989: "DePICT: Defining Platforms for Individualized Cancer Treatment." PI: Jonathan Trent.
39. EProst 20150567: "A Phase II trial of Belinostat as consolidation therapy with zidovudine for adult T-cell leukemia-lymphoma (ATLL)." PI: Juan Carlos Ramos.
40. 2014 LOI: "An open-label single-arm phase 2 study of azacitidine plus pembrolizumab (MK-3475) in patients with high-risk myeloid malignancies who are unfit for intensive chemotherapy". PI: Justin Watts.
41. EProst 20140960: "PDE5 Inhibition via tadalafil (Cialis®) to enhance anti-tumor MUC1 vaccine efficacy in patients with resectable, and recurrent or second primary head and neck squamous cell carcinoma (HNSCC): A phase I/II clinical trial". PI: Donald Weed.
42. EProst 2014x: "Overcoming 5-FU resistance with arsenical trioxide: A single-arm phase II trial in metastatic colon cancer". PI: Bach Ardalan.
43. EProst 2014x: "A Randomized, Open-label, phase I trial of continuous, intermittent, and pulsatile selumetinib (AZD6244) plus nab-paclitaxel as second-line treatment for stage IIIB or IV non-small cell lung cancer (NSCLC)". PI: Khaled Tolba.
44. EProst 20140460: "Phase I trial of intratumoral administration of recombinant vesicular stomatitis virus expressing human interferon beta (VSV-hIFN- $\beta$ ) in patients with recurrent/metastatic squamous cell carcinoma of the head and neck". PI: Jaime Merchan.
45. EProst 20130200: "Overcoming 5-FU resistance with arsenical trioxide: phase II, colon cancer trial". PI: Bach Ardalan.
46. EProst 20110069: "Phase II study to evaluate fenofibrate therapy in patients with relapsed/refractory multiple myeloma who have failed at least two prior therapies". PI: Denise Pereira & Theodore J Lampidis. (active)
47. LOI 2010: "Treatment of multiple myeloma with fenofibrate". PI: Denise Pereira.
48. EProst 20100389 "A Phase I Trial of MRI-guided lattice extreme ablative dose radiotherapy for prostate cancer." (LEAD study) PI: Allan Pollack. (active)

49. EProst 20100153: "A phase I study of nelfinavir added to cisplatin chemotherapy concurrent with pelvic radiation for locally advanced cervical cancer (II-IVA)". PI: Matt Pearson (previously Fiona Simpkins).(active)
50. EProst 20100252: "Evaluation of the use of AZD6244 to induce increased ER expression and anti-estrogen response in ER-negative/low breast cancer". PI: Mark Pegram & Dorraya El-Ashry.
51. EProst 20100156: "Mechanisms and control of head and neck (HN) cancer". PI: Elizabeth Franzmann.
52. LOI Jul/Aug 2009 for Bill and Melissa Gates Foundation: "Use of N-acetyl cysteine for the treatment of Kaposi's Sarcoma in Sub-Saharan Africa". PIs: Pascal J. Goldschmidt-Clermont, MD and Enrique Mesri, PhD. (In collaboration with Bob Duncan, I developed statistical considerations -- study design, sample size justification and methods of analysis -- for this grant LOI.)
53. LOI Jul 2009: "Phase I/II study of cetuximab-irinotecan-panobinostat combination in patients with metastatic colorectal adenocarcinoma who failed at least one line of systemic chemotherapy". PI: Caio Max Rocha-Lima.
54. LOI Jan 2009: "Clinical evaluation of docetaxel in combination with platinum salts as neoadjuvant therapy for triple negative breast cancer". PI: Judith Hurley.
55. EProst 20090462: "Phase II clinical trial of bortezomib (Velcade<sup>TM</sup>) in combination with tamoxifen in the treatment of patients with metastatic triple negative breast cancer previously treated with chemotherapy". PI: Stefan Gluck.
56. LOI Nov 2008: "A phase II study of temsirolimus in patients with advanced urothelial carcinoma". PI: Rakesh Singal.
57. EProst 20090229: "A phase I trial assessing the safety and feasibility of prophylactic nipple-areola complex (NAC) irradiation after nipple-sparing mastectomy and immediate reconstruction in patients with in-situ or invasive breast cancer." PI: Cristiane Takita.
58. SCCC 2009003: "A Phase I/II study of combination of gemcitabine, oxaliplatin, and sorafenib (GEMOX-Sorafenib) in patients with advanced biliary tract cancer. " PI: Caio M Rocha-Lima.
59. LOI for SCCC 2009003: "A Phase I/II study of combination of gemcitabine, oxaliplatin, and sorafenib (GEMOX-Sorafenib) in patients with advanced biliary tract cancer". PI: Caio M Rocha-Lima.
60. Eprost 20090166, SCCC 2009002: "Phase II study of chemotherapy (doxorubicin, methotrexate and leucovorin) in combination with antiviral-based therapy (zidovudine + hydroxyurea) for relapsed Epstein Barr virus associated non-Hodgkin's lymphoma". PI: Juan Carlos Ramos.
61. IRB 20080130: "Pathologic and molecular prognostic factors in adult renal cell carcinoma". PI: Merce Jorda.
62. 2008: "Comparison of two visual examinations (white light v. Velscope enhanced) for early detection of SCCA of the head and neck. New protocol amended to project SCCC 2006117 "Salivary soluble markers in head and neck cancer". PI: Elizabeth Franzmann.
63. IRB 20080325 (SCCC 2008002, IND 102,186): "A phase I pharmacokinetic and randomized phase II trial of neoadjuvant treatment with anastrozole plus AZD0530 in postmenopausal patients with hormone receptor positive breast cancer". PI: Joyce Slingerland.

64. SCCC 2008077: "Phase II trial of PET-guided neoadjuvant chemotherapy with FLOD in the management of previously untreated advanced esophago-gastric carcinoma" PI: Dr. Ardalan.
65. LOI for SCCC 2008077: "Phase II trial of PET-guided neoadjuvant chemotherapy with FLOD in the management of previously untreated advanced esophago-gastric carcinoma" PI: Dr. Ardalan.
66. SCCC 2008017: "A phase II trial of photodynamic therapy with gemcitabine and oxaliplatin in nonresectable biliary tract cancer". PI: Afonso Ribeiro.
67. 2007: "Pilot study of dietary intervention in indigent breast cancer patients". PI: Judith Hurley.
68. 2007: "Are circulating tumor cells (CTCs) predictive of pCR, DFS, PFS, and OS in locally advanced breast cancer". PI: Orlando Silva.
69. 2007: "Retrospective study of correlation between MRI and pathology in breast cancer patients". PI: Stefan Gluck & Maria Manzanares. (Retrospective chart review.)
70. 2007: "The effect of HAART on cervical cancer outcomes in HIV-infected women with cervical cancer as compared to non-infected women". PI: Nathalie Dauphin-McKenzie and Joseph Lucci. (Retrospective chart review.)
71. SCCC 2007096: "Phase II trial of Abraxane® in the treatment of patients with pancreatic cancer who failed first-line treatment with Gemcitabine-based therapy". PI: Caio Max Rocha- Lima & Gilberto Lopez.
72. SCCC 2007079: "Predictors of response and resistance to neoadjuvant therapy in breast cancer". PI: Judith Hurley. (Retrospective chart review.)
73. EProst 20070805, SCCC 2007055 "Prospective study of the molecular characteristics of sensitive and resistant disease in patients with HTLV-I associated adult T cell leukemia treated with zidovudine (AZT) plus interferon alpha-2B". PI: Juan Carlos Ramos. (Part of a Damon Runyon grant.)
74. SCCC 2006987: Racial disparities in acute toxicities of adjuvant chemotherapy with FEC 100 and their impact on the outcomes of patients with breast cancer". PI: Stefan Glück.
75. SCCC 2006081: "A Phase II Study of gemcitabine, abraxane and bevacizumab for first line metastatic breast cancer". PI: Stefan Glück.
76. SCCC 2006080: "A Phase I/II Study of azacitidine (Vidaza®), docetaxel and prednisone for patients with metastatic hormone refractory metastatic prostate cancer. PI: Rakesh Singal.
77. SCCC 2004162 (2006 amendment): "A Phase I Study of 5-FU (plus leucovorin) and arsenic trioxide for patients with refractory/relapsed metastatic colorectal carcinoma". PI: Bach Ardalan.
78. SCCC 2006059: "Phase II randomized double-blind study of hectoral in patients undergoing salvage or post-operative ionizing radiation (IR) for localized prostate cancer after prostatectomy". PI: May Abdel-Wahab. (Updated version, April 2006 -- "Phase II randomized double-blind study of Cholecalciferol, in conjunction with ionizing radiation (IR) post-prostatectomy or salvage therapy for prostate cancer".)
79. SCCC 2006049: "Phase II study of antiviral-based therapy (zidovudine + hydroxyurea) in combination with chemotherapy (doxorubin, methotrexate, and leucovorin) for relapsed endemic Burkitt lymphoma". PI: William Harrington.
80. SCCC 2005155: "An open-label study of the efficacy and safety of oral CEP-701 (80mg BID) for the treatment of patients with advanced melanoma". PI: Oluwatoyin Shonukan.

81. SCCC 2005145: "Phase II study of avastin, irinotecan, high dose 24 hour continuous intravenous infusion of floxuridine and leucovorin in patients with previously untreated metastatic colorectal cancer". PI: Bach Ardalan.
82. SCCC 2005097: "Translational Phase I trial of escalating doses of 5-chloro-2'-deoxycytidine (CldC) with a fixed dose of tetrahydrouridine combined with external beam brain radiation for metastatic carcinoma to the brain". PI: May Abdel-Wahab.
83. SCCC 2005030: "Phase II clinical trial of Thalidomide + arsenic trioxide + liposomal doxorubicin + ascorbic acid (ThAD-C) consolidation followed by arsenic trioxide + prednisone maintenance post high-dose chemotherapy/stem cell transplantation for multiple myeloma". PI: Kelvin Lee.
84. SCCC 2004066: "Evaluation of genetic risk in Bahamian women with breast/ovarian cancer". PI: Judith Hurley.
85. SCCC 2004162: "A phase I/II study of 5-FU, arsenic trioxide, and leucovorin for patients with refractory/relapsed metastatic colorectal carcinoma". (PI: Bach Ardalan)
86. SCCC 2004064: "Phase II study of dose dense carboplatin, taxotere, and herceptin as primary systemic therapy in breast cancer". PI: Judith Hurley.
87. SCCC 2004035: "A pilot study to assess vaginal quality and psychosexual function with the use of vaginal estrogen therapy in women undergoing pelvic irradiation for cervical cancer". PI: Nicholas Lambrou.
88. SCCC 2004136: "Pharmacogenomics approach to chemotherapy response in NSCLC". PI: Luis Raez.
89. SCCC 2003160: "An open-label phase II study of capecitabine, docetaxel and herceptin as first line treatment for patients with metastatic breast cancer whose tumors overexpress Her-2/neu". PI: Shou-Ching Tang.
90. SCCC 2003151: "A non-randomized Phase II study: Feasibility and outcome of neo-adjuvant chemotherapy with oxaliplatin, fluorodeoxyuridine (FudR), taxotere and leucovorin in the treatment of previously untreated advanced esophago-gastric carcinoma". PI: Dr Ardalan Bach.
91. SCCC 2003149: "Phase II Study of oxaliplatin, high-dose 24-hour continuous intravenous infusion of floxuridine, and leucovorin in patients with previously untreated advanced metastatic colorectal cancer". PI: Dr Ardalan Bach.
92. SCCC 2003083: "Open label phase II trial of docetaxel, epirubicin and cyclophosphamide (TEC) in HER2/neu-negative metastatic breast cancer (GIA# 11224)". PI: Shou-Ching Tang.
93. SCCC 2003053: "Phase II Trial of docetaxel and capecitabine in the treatment of HER2/neu-negative metastatic breast cancer (GIA# 11203)". .PIs: Orlando Silva.
94. SCCC 2003041: "A Phase II Study of neoadjuvant Docetaxel and estramustine in high-risk prostate cancer". .PI: Gustavo Fernandez.
95. SCCC 2002076: "Phase II study of high-dose, 24-hour continuous intravenous infusion of floxuridine, camptosar and leucovorin for advanced previously untreated colorectal cancer". .PI: Bach Ardalan.
96. SCCC 2002053: "Phase II Trial of docetaxel and capecitabine in the treatment of HE2/neu-negative metastatic breast cancer (GIA# 11203)". PI: Orlando Silva.

97. SCCC 2002033: "Translational phase I trial of escalating dose of 5-chloro-2'-deoxycytidine (CldC) with a fixed dose of tetrahydrouridine combined with a fixed dose of 3240 cGy external radiation in once a day fractionation, followed by only external radiation with concomitant boost in patient with advanced squamous cell carcinoma of the oral cavity and oropharynx". Supporting Agency: NCI, Division of Cancer Treatment and Diagnosis. .PIs: Luis Raez, May Wahab.
98. SCCC 2001071: "Combination chemotherapy with docetaxel and captosar for patients with newly diagnosed or relapsed, locally advanced or metastatic non-small cell lung cancer". PI: Luis Raez.
99. SCCC 2001040: "Phase II trial of hepatic intra-arterial cisplatin chemotherapy with systemic octreotide for unresectable hepatocellular carcinoma (HCC)" PI: Luis Raez.
100. SCCC 2001032: "Phase II study of arsenic trioxide and ascorbic acid therapy in metastatic colorectal cancer refractory to chemotherapy. PI: Bach Ardalan.
101. SCCC 2001013: "Phase II trial of neoadjuvant carboplatin and taxotere in the treatment of locally advanced and inflammatory breast cancers that do not overexpress Her-2". PI: Judith Hurley.
102. SCCC 2000082: "Phase I trial of hycamtin, adriamycin and oncovin in advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)". PI: Kasi Sridhar.
103. SCCC 2000010: "Phase I/II trial of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) with ascorbic acid in the treatment of relapsed/refractory multiple myeloma". Supporting Agency: NIH/NCI, Division of Cancer Treatment. PI: Kevin Lee.
104. SCCC 2000: "Phase I study of topotecan in combination with fixed doses of doxorubicin and vincristine in patients with advanced NSCLC or advanced SCLC". PI: Kasi Sridhar.
105. SCCC 1999064: "A phase II study of lipiodol chemoembolization therapy with cisplatin and thiotepa followed by oral thalidomide for primary liver cancer and liver metastases". PI: Lynn Feun.
106. SCCC 1999056: "Phase II trial of neoadjuvant herceptin, taxotere and cisplatin in the treatment of locally advanced and inflammatory breast cancer". PI: Judith Hurley.
107. SCCC 1999022: "Phase I study of oral eniluracil/5-FU with cisplatin in patients with locally recurrent or metastatic carcinomas of the aerodigestive tract (head and neck, lung or esophagus)". PIs: Lini Bartlett-Pandite, Kasi Sridhar.
108. SCCC 1999009: "Elicitation of a cellular immune response in non-small cell lung cancer (NSCLC) patients by immunogenic tumor cell vaccination: a phase I/II study". PIs: Eckhard R. Podack, Kasi Sridhar, Peter A. Cassileth.



**21. Editorial responsibilities:**

PLOS ONE	2015-present
BMC Medical Research Methodology	2015-present

**22. Professional and Honorary Organizations:**

*Member of the following organizations:*

Member of the American Statistics Association (ASA)	1984-present
Member of the Brazilian Statistics Association [Associação Brasileira de Estatística (ABE)]	1989-1999
Member of the International Association of Survey Statisticians (IASS)	1984-1999
Member of the Delta Omega Society, Iota Chapter of the Delta Omega Society at UCLA	1995-1999
Member of the Delta Omega Society	1995-1999
Member of the Iota Chapter of the Delta Omega Society at UCLA	1995-1999

**23. Honors and Awards:**

Excellence in Teaching, University of Miami, Miami, FL	2008
One-year Dissertation fellowship award, University of California at Los Angeles.	09/1995-03/1996
Elected a member of the Iota Chapter of The Delta Omega Society at UCLA and a member of the National Society.	1995
<i>Doctoral program fellowship.</i>	08/1991-08/1995
<i>Master program fellowship.</i>	1984-1985
CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazilian Ministry of Science and Technology	
<i>Fellowship</i> for summer course <i>Statistics in Health</i> , Statistical Service Centre, University of Reading, Reading, United Kingdom. WHO/PAHO - World Health Organization / Pan American Health Organization.	07-09/1989

**24. Post-Doctoral Fellowships: N/A**

## 25. Other Professional Activities:

### 25a. Service on National Scientific Review Panels, Study Section, Committees

*Member of scientific review panels at the National Institutes of Health (NIH):*

**PAR-11-151: “Strategic Partnering to Evaluate Cancer Signatures [SPECS III] (U01)”** 10/2011

The emphasis of PAR-11-151 was on the late translational stage of existing signatures (DNA, RNA, protein etc.), moving them forward to potential clinical usefulness. If along the way, additional signatures were discovered this would be fine. Thus, an application which was focuses only on discovery or technology development would not be deemed responsive to this RFA (request for applications) targeting multidisciplinary research groups. A total of 40 U01 applications were evaluated.

**PAR-10-126: “Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01)”** 11/2010

A total of 44 U01 applications were evaluated for the potential clinical usefulness of molecular signatures (DNA, RNA, protein etc.) that have already been developed. The emphasis was on the late translational stage into the potential clinical trial rather than a focus on discovery. The goal was the confirmation and evaluation of clinically useful multi-analyte molecular signatures. Applications were from multidisciplinary groups and featured analytical technologies, oncology, pathology, assay development, biostatistics and bioinformatics.

**PAR-06-294: “Small Grants Program for Cancer Epidemiology (R03)”** 11/2007

**PAR-06-313: “Cancer Prevention Research Small Grants Program (R03)”** 11/2007

**Small Business Innovation Research (SBIR) Topic 214 “Systems to Enhance Data Collection and Medication Compliance in Clinical Trials”** 03/2005

**RFA-CA-04-015: “Strategic Partnering to Evaluate Cancer Signatures [SPECS I] (U01)”** 11/2004

The grant funding mechanism was a multi-institutional award *U01 Research Project - Cooperative Agreements*. NCI invited investigators to form strategic partnerships that would bring together the multidisciplinary expertise and resources needed to determine how the information derived from comprehensive molecular analyses can be used to improve patient care and ultimately, patient outcomes. The applications addressed the potential usefulness for clinical decision making of molecular signatures that were already developed, focusing on the gap between initial signature molecule discovery and the integration into clinical practice. In response to NCI, applications submitted addressed well-defined clinical needs such as identification of sub-stages in a tumor's development, risk of progression, differential responses to target therapies or prediction of responses to selected therapies.

**25b. Seminars, lectures, workshops.**

UM SCCC Annual Zubrod Memorial Lecture and Poster Session at UM SCCC, Miami, FL. ( <i>Attendance and poster presentations</i> )	1999-2021
2018 Joint Statistical Meetings (JSM) of the American Statistical Association (ASA) Vancouver, BC, Canada ( <i>Poster presentation</i> )	07/28-08/02/2018
2017 Spring Meeting of the Eastern North America Region (ENAR) of the International Biometrics Society (IBS), Washington, DC ( <i>Poster presentation</i> )	03/12-15/2017
2016 Spring Meeting of the Eastern North America Region (ENAR) of the International Biometrics Society (IBS), Austin, Texas ( <i>Poster presentation</i> )	03/06-09/2016
2015 Spring Meeting of the Eastern North America Region (ENAR) of the International Biometrics Society (IBS), Miami, FL ( <i>Poster presentation</i> )	03/15-18/2015
2011 Spring Meeting of the Eastern North America Region (ENAR) of the International Biometrics Society (IBS), Miami, FL ( <i>Attend and provided support as volunteer.</i> )	03/20-23/2011
Regular attendance to the UM/Sylvester Distinguished Lecture Seminar Series.	1999-present
Regular attendance to seminars at the department of Public Health Sciences	1999-present
Attend VIII Annual Landon Foundation - America Association for "Cancer Research (AACR) Awards Lectures", at UM SCCC, Miami, FL.	01/22/2010
Attend VII Annual Landon Foundation-America Association for "Cancer Research (AACR) Awards Lectures", at UM SCCC, Miami, FL.	01/23/2009
Attend Second annual meeting on Molecular Markers in Cancer, ASCO, NCI, and EORTC. Hollywood, FL.	10/30 & 11/1/2008
Attend VI Annual Landon Foundation - America Association for "Cancer Research (AACR) Awards Lectures, at UM SCCC, Miami, FL.	01/18/2008
2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, IL. ( <i>Attendance and poster presentation</i> )	05/1-5/2007
Attend Cancer Biology of the Eye Workshop Bascom Palmer Eye Institute and Sylvester Comprehensive Cancer Center.	02/15/2007
Attend V Annual Landon Foundation - America Association for "Cancer Research (AACR) Awards Lectures", at UM SCCC, Miami, FL.	01/19/2007

2006 Annual Meeting of the American Society of Clinical Oncology (ASCO) Atlanta, GA. (Attendance and poster presentation)	06/2-6/2006
Attend IV Annual Landon Foundation - America Association for "Cancer Research (AACR) Awards Lectures", at UM SCCC, Miami, FL.	01/20/2006
Attend III Annual Landon Foundation - America Association for "Cancer Research (AACR) Awards Lectures", at UM SCCC, Miami, FL.	01/19/2005
Attend Second Annual Landon Foundation - America Association for "Cancer Research (AACR) Awards Lecture", at UM SCCC.	01/16/2004
Attend Novel Therapeutic Approaches in the Treatment of Multiple Myeloma, sponsored by IM SCCC and Multiple Myeloma Research Foundation.	02/2003
Participation on Workshop Workshop "Operational Research for the Control of Tropical Diseases" Pan American Group of Health, Program of Communicable Diseases, Brazilian Ministry of Health, SENEPE e DNDS. Goiânia, Brazil.	Jul-Aug/1997
Invited lecturer "Analysis of contingency tables " In biostatistics course offered by the Federal University of Goiás, Institute of Tropical Pathology and Public Health, Department of Community Health; Goiânia, Goiás, Brazil.	06/1990

## **VI. TEACHING**

### **26. Teaching Awards Received:**

- Certificate of Appreciation for outstanding service to the Public Health Student Association as Faculty Advisor.** 08/2010  
The University of Miami Miller School of Medicine Public Health Student Association.
- Fall 2008 "Lecturer of the Semester"** 12/2008  
The University of Miami Miller School of Medicine, Public Health Student Association.

### **27. Teaching Specialization:**

- EPH 751: Survival Analysis in Clinical Trials** (former EPH651) 2017-22, 2010-2015  
Department of Public Health Sciences 2000-2008  
University of Miami School of Medicine

Developed during 1999-2000. A three-credit course offered yearly for graduate students in epidemiology, and biostatistics and also allowing students of other department of the University of Miami. Students learn statistical methods for analysis and interpretation of time to event data. The topics covered in ten lectures of 3 hours duration are: survival curves (functions of survival time, relationships among the several survival functions), estimation of the survival curve by the Kaplan-Meier method, parametric models for estimating survival, comparison of two survival curves (log-rank or Mantel-Haenszel test), estimation of sample size for survival studies, Cox's proportional-hazards models (variable selection, inclusion of interactions, assessment of model fit and diagnostics for the proportional hazards assumption), development of prognostic indices, and time-dependent variables. Students are expected to participate actively in classroom discussions, complete written reports for assigned exercises, make classroom presentations of assigned exercises, and complete a final term assignment involving survival data analysis.

- Lecture on Biostatistics** Nov 15, 2019  
**Multidisciplinary Clinical Research Symposium**  
Hematology Oncology Fellowship Training Program at the  
Sylvester Comprehensive Cancer Center and Jackson Memorial Hospital, University of Miami  
School of Medicine

- Biostatistics in Clinical Research** Aug 26 & 30, Sep 3 & 4, 2019  
**Radiation Oncology Lecture Series 2019**  
Residency Program of the Department of Radiation Oncology,  
Sylvester Comprehensive Cancer Center, University of Miami School of Medicine

- Biostatistics in Clinical Research** 2015-2019  
Didactic Lecture for the Division of Hematology/Oncology, Core Curriculum,  
Sylvester Comprehensive Cancer Center, University of Miami School of Medicine

- Survival Analysis** 2015, 2016  
Didactic Lecture for the Division of Hematology/Oncology, Core Curriculum,  
Sylvester Comprehensive Cancer Center, University of Miami School of Medicine

**Biostatistics for Clinical Research**

Apr 9, 2013

Didactic Lecture for Residents in the  
Residency Program of the Department of Radiation Oncology,  
Sylvester Comprehensive Cancer Center, University of Miami School of Medicine

**Biostatistics in Clinical Research**

Feb 21, 2013

Didactic Lecture for the Division of Hematology/Oncology, Core Curriculum,  
Sylvester Comprehensive Cancer Center, University of Miami School of Medicine

**Biostatistics for Clinical Research Workshop**

2001-2008

UM/Sylvester Biostatistics Core Resource (BCR),  
Sylvester Comprehensive Cancer Center, University of Miami School of Medicine

The objective of this workshop was to familiarize oncology residents and fellows in oncology programs of the SCCC with statistical methods commonly found in the research literature and applicable to their future research activities in the area of clinical oncology studies. The lectures were taught by members of the UM/Sylvester Biostatistics Core Resource (BCR). My participation was to give lectures on survival analysis in cancer studies, and on clinical trials.

**Categorical data analysis applied to epidemiologic studies**

1997

University of São Paulo, School of Public Health  
Course developed to be offered to epidemiology or other public health graduate programs.

**Biostatistics**

1985-1991, 1997-1998

University of São Paulo, School of Public Health  
A required course in the several programs of specialization in public health.

**Biostatistics**

1987-1989

University of São Paulo, School of School of Nutrition  
A four-credit course for students in graduate programs.

**Biostatistics**

08/1987

Rondonia Federal University Foundation; Porto Velho, Rondonia, Brazil.

**Biostatistics**

07/1988

Rondonia Federal University Foundation; Porto Velho, Rondonia, Brazil.

**Biostatistics**

12/1989

Brazilian Health Ministry, Department of Especial Health Programs,  
National Division of Sexually Transmitted Diseases and AIDS, Brasilia, Brazil.

**Biostatistics**

04/1997

Federal University of Goiás, Institute of Tropical Pathology and Public Health,  
Department of Community Health; Goiânia, Goiás, Brazil.

## 28. Thesis and Dissertation Advising/Post-doctoral Student Supervision

### 28a. Thesis or Dissertation Advisor

**George Ruochen Yang:** Doctoral degree in Public Health at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Dissertation Tentative Title: “MOLECULAR MECHANISMS OF BREAST CANCER PROGNOSIS”. Dissertation Defense: 10/2021. (Committee member, Faculty advisor jointly with Dr Jennifer J. Hu).

**Xiaozhuang Hu:** Master of Science in Public Health (MSPH) at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Thesis Title: Immune-cell profiling among female breast cancer patients with different clinical characteristics. 11/20/2020. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Hankun Xie:** Master of Science in Public Health (MSPH) at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Thesis Title: Combined effects of transforming growth factor-beta and C-reactive protein on radiotherapy-induced skin toxicities in breast cancer patients. 08/03/2020. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Caroline Ripat:** Master of Science in Public Health (MSPH) at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Thesis Title: Evaluation of risk factors associated with in-hospital pediatric acute moderate-to-severe pain and pain management. 06/20/2019. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Kaichen Wang:** Master of Public Health (MPH) at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Capstone project Title: Breast cancer survival disparities in a tri-race/ethnic populations. May 2019. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Yindi Li:** Master of Science in Public Health (MSPH) at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Thesis title: Metabolomics Analyses and RT-induced Skin Toxicity among Breast Cancer Patients. 07/27/2018. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Mohamed Mihyu, MD:** Master of Science in Public Health at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Thesis title: Association between DNA Oxidative Damage Biomarker 8-hydroxy-2-deoxyguanosine (8-OHdG) and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population. 07/18/2018. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Chaonan Wang:** Master of Science in Public Health at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Thesis title: Racial/Ethnic Disparities in Breast Cancer Survival. Thesis defense: 12/05/2016. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Abzal Zhumagaliuly, MD:** Master of Science in Public Health at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Thesis title: Radiotherapy-Induced Immune Cell Type Changes in Breast Cancer Patients. Thesis defense: 07/04/2017. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Nurila Aryntayeva, MD:** Master of Science in Public Health at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Thesis title: “Immune-Cell Profiling In Breast Cancer Risk”. Thesis defense: 06/04/2017. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Saltanat Sapargaliyeva, MD:** Master of Science in Public Health at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Thesis title: Transforming Growth Factor-Beta (Tgf-B) in Radiation Therapy-Induced Early Skin Toxicity in Breast Cancer Patients. Thesis defense: 05/14/2017. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Raed Jannadi, MD:** Master of Science in Public Health at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Thesis title: “Racial/ethnic disparities in lung cancer survival”. Thesis defense: 08/15/2016. (Faculty advisor jointly with Dr Jennifer J. Hu, Ph.D.)

**Eunkyung (Muriel) Lee:** Doctoral degree in Public Health at University of Miami, Miller School of Medicine, Department of Public Health Sciences. Dissertation Title: “Genetic/molecular biomarkers of cancer pain in breast cancer patients undergoing radiation therapy”. Dissertation Defense: 02/2017. (Committee member).

**Julie Kornfeld:** Doctoral degree in Public Health at University of Miami, Miller School of Medicine, Department of Epidemiology and Public Health. Dissertation Title: “Factors that are associated with acceptance of Human Papillomavirus Vaccines: A Study of Spanish Information Seekers”. Dissertation Defense: 11/2009. (Committee member)

**Nicole Cook:** Doctoral degree in Public Health at University of Miami, Miller School of Medicine, Department of Epidemiology and Public Health. Dissertation Title: “A multi-level approach to understanding Pap smear compliance at Community Health Centers including patient, provider and organizational variables”. Dissertation Defense: 10/2008. (Committee member)

**Kimberly Nhu-Mai Hoang:** Bachelor’s thesis submitted in partial fulfillment of requirements for the distinction of *summa cum laude* at University of Miami, Miller School of Medicine. Thesis title: “Genetic polymorphisms of multiple DNA-repair pathways and breast cancer risk”. Thesis date: 05/2008. (Committee member)

**Hermes Flores:** Doctoral degree in Public Health at University of Miami, Miller School of Medicine, Department of Epidemiology and Public Health. Dissertation Title: “Genetic polymorphisms associated with dyslipidemia and subclinical inflammation in subjects with the metabolic syndrome: A case control study in South Florida”. Dissertation Defense: 04/2006. (Committee member)

**Guillermo Prado:** Doctoral degree in Epidemiology at University of Miami, Miller School of Medicine, Department of Epidemiology and Public Health. Dissertation Title: “The efficacy of three interventions to prevent substance use and sexual behavior in subgroups of Hispanic adolescents”. Dissertation Defense: --/4/2005. (Committee member)

**Helena dos Santos:** Doctoral degree in Public Health - Nutrition, University of São Paulo School of Public Health. Dissertation Title: “Prevalência, distribuição e determinantes do retardo do crescimento infantil na população urbana do estado do Pará, Brasil”. Dissertation Defense: 04/1998. (Committee member)



**Denise Costa Coitinho:** Doctoral degree in Public Health - Nutrition, University of São Paulo School of Public Health. Dissertation Title: “A influência da história reprodutiva no Índice de massa corporal de mulheres brasileiras”. Dissertation Defense: 03/1998. (Committee member)

**Adriana Souza de Toledo Piza:** Master of Science in Public health – Epidemiology, University of São Paulo School of Public Health. Dissertation Title: “Adaptação do método imunoenzimático (ELISA) para detecção de anticorpos anti-rábitos neutralizantes em soros humanos. Comparação com a prova de soroneutralização em cultura celular”. Dissertation Defense: 06/1997. (Committee member)

**Fátima Cristina Minari:** Master of Science in Public health – Epidemiology, University of São Paulo School of Public Health. Dissertation Title: “Morbidade: um estudo conceitual e empírico”. Dissertation Defense: 01/1997. (Committee member)

**Lenise Mondini:** Doctoral degree in Public Health - Nutrition, University of São Paulo School of Public Health. Dissertation Title: “Desnutrição e obesidade no Brasil: relevância epidemiológica e padrões de distribuição intra-familiar em diferentes estratos econômicos e regionais”. Dissertation Defense: 12/1996. (Committee member)

## **28b. Committee Member ONLY for Qualifying Exam of Master/Doctoral students**

**Wander Ricardo Mingardi:** candidate for a master’s degree in Public health – Epidemiology, University of São Paulo School of Public Health. Dissertation Title: “Prevalência de carie e fatores de risco: estudo realizado entre escolares de 12 anos da região administrativa do Ipiranga, município de São Paulo, 1998”. Qualifying exam: 03/1998. (Committee member)

**Miguel Veses Cataluña:** candidate for a doctoral degree in Public Health - Epidemiology, University of Caxias do Sul and University of São Paulo School of Public Health. Dissertation Title: “Duração da vida segundo a relação da ocupação com o mercado de trabalho”. Qualifying exam: 12/1997. (Committee member)

**Maria Teresa Cera Sanches:** candidate for a master’s degree in Public health – Maternal-Infant, University of São Paulo School of Public Health. Dissertation Title: “Disfunções motoras-orais e suas repercussões no aleitamento materno”. Qualifying exam: 11/1997. (Committee member)

**Ligia Beatriz Bento Franz:** candidate for a master’s degree in Public health - Nutrition, University of São Paulo School of Public Health. Dissertation Title: “Bioimpedância Elétrica como método de avaliação da composição corporal de indivíduos adultos e idosos”. Qualifying exam: 11/1996. (Committee member)

**Nélida Antonia Schmid de Fornés:** candidate for a doctoral degree in Public Health - Nutrition, University of São Paulo School of Public Health. Dissertation Title: “Padrões alimentares e fatores de risco para doenças cardiovasculares ateroscleróticas em população da área metropolitana na região sudeste do Brasil”. Qualifying exam: 10/1996. (Committee member)

**Ana Lúcia Medeiros de Souza:** candidate for a master’s degree in Public health - Nutrition, University of São Paulo School of Public Health. Dissertation Title: “Estratificação social e obesidade no Brasil” [Social class and obesity in Brazil]. Qualifying exam: 10/1996. (Committee member)

**28c. Academic Advisor**

Department of Epidemiology and Public Health  
University of Miami, Miller School of Medicine  
MPH (Master in Public Health)

Diego Perilla	2008 - 1010
Brad Coyle	2005 - 2007
Angel Loor	2005 - 2010
Jeffrey Simmons	2004 - 2007
Daniel Torres	2001 - 2002
Enrique Molina	2001 - 2002

**28d. Mentor of PhD student**

Department of Public Health Sciences  
University of Miami, Miller School of Medicine

Evan Wu	2013 - 2014
Eric M Hecht	2015 – 2016
George Ruochen Yang	2019 - present

**28e. Mentor of Young Investigators and Medical Residents or Fellows** in specific training programs at UM Sylvester.

*Guide and teach trainees in their research projects with respect to research methods, biostatistics, presentations and interpretation of results for manuscripts and oral/poster presentations in scientific meetings.*

Azad A. Jabiev, M.D.	Division of Endocrine surgery, UMSOM
Gil Ascunce, M.D.	Division of Gastroenterology
Alexandra Gomez	Resident, Division of Internal Medicine, University of Miami /Jackson Memorial Hospital.
Agustin Pimentel, M.D. Carmen Calfa, M.D. Christopher Lobo, M.D. Gilberto de Lima Lopes, M.D. Hyo Sook Han, M.D. Juan Pablo Alderuccio, M.D. Nizar J. Bahlis, M.D. Partha M. Das, M.D. Peter J Hosein, M.D. Tadeu Ambros, M.D.	Department of Medicine, Division of Hematology and Oncology
Jennifer McCafferty-Grad, Ph.D.	Department of Microbiology and Immunology
Fiona Simpkins, M.D. J. Matthew Pearson, M.D. Joseph De La Garza, M.D. Nathalie Dauphin-McKenzie, M.D.	Department of Obstetrics and Gynecology
Erin R. Cohen, M.D. Gia Hoosien, M.D. Joyson Kodiyan, M.D.	Department of Otolaryngology

Turki M. AlMohimmed, M.D. Drew. H Smith, M.D. Shahm Raslan, MD.	
Claudia P. Rojas, M.D. Loren Herrera, M.D. Yasir, Saba M.D.	Department of Pathology
Faisal FM Alotaibi, M.D. Saltanat Sapargaliyeva, MD	Department of Public Health Sciences
Daniel Arsenault, M.D. Dayssy Alexandra Diaz, M.D. Joseph E Panoff, M.D. Kelly La Favre, M.D. Kunal Saigal, M.D. Omar Mahmoud, M.D. Nicholas R Cnossen, M.D. Benjamin James Rich	Department of Radiation Oncology
George JS Kallingal, M.D. Murugesan Manoharan, M.D.	Department of Urology

**28f. Statistical consultant** on master/doctoral dissertations 1982-1990, 1996-1998  
School of Public Health, University of São Paulo, Brazil.

## **VII. SERVICE**

### **29. University of Miami Committee and Administrative Responsibilities:**

#### **29a. Administrative responsibilities**

<b>Director</b>	04/2012 - 06/2015
<b>Interim co-Director</b>	04/2008 - 11/2008
<b>Interim co-Director</b>	07/2004 - 12/2006
Division of Biostatistics, Sylvester Biostatistics and Bioinformatics Shared Resource Sylvester Comprehensive Cancer Center Leonard M. Miller School of Medicine, University of Miami	

#### **29b. Standing Committees**

Member of the UM/Sylvester Data and Safety Monitoring Committee	2013 - present
Alternate member of the UM/Sylvester Data and Safety Monitoring Committee	2004– 2012
Alternative member of the UM/Sylvester Protocol Review Committee	2012– 2018
Member of the UM/Sylvester Protocol Review Committee	1999 – 2012
Member of the Curriculum Committee for MPH and Ph.D. Programs,	11/2007-2010

Department of Epidemiology and Public Health.

Affiliated member of the UM/Sylvester Biobehavioral Oncology and Cancer Epidemiology (BOCE) research program 2007-2009, 2011-present

Affiliated member of the UM/Sylvester Cancer Epidemiology and Prevention (CEP) research program 2013-present

## 29c. Ad Hoc Committees

**Participation in the 2017 accreditation of the Epidemiology Doctoral Program of the Department of Public Health Sciences (PHS)** 2017  
Participated as a faculty member and course instructor.

**Participation in the 2014 accreditation of the academic programs of the Department of Public Health Sciences (PHS)** 2013/2014  
Participated as a faculty member and course instructor.

**Faculty Advisor for the Public Health Student Association** 2010 – 2011  
Department of Epidemiology and Public Health

**Reviewer Committee Member** of grant applications to the 11/ 2010  
“2010 Sylvester Pap Corps Cancer Health Disparities Pilot Grants Competition”  
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine

**Participation in the 2006 accreditation of the academic programs of the Department of Epidemiology and Public Health** 2006  
Participated as a faculty member and course instructor.

**Faculty Peer Evaluations** 2004, 2006, 2009, 2010  
Department of Epidemiology and Public Health (DEPH)

Member, **Committee for Ph.D. Biostatistics Comprehensive Exam** 2005-09, 2011-2019  
Department of Public Health Sciences (PHS)

Member, **Search Committee** for Chief of Biostatistics Division 2004-2005  
Department of Epidemiology and Public Health (DEPH)

Member, **MPH and Ph.D. Curriculum Committee** 2000-2002  
Department of Epidemiology and Public Health (DEPH)

Member, **Information and Technology Committee** 2000-2003  
Department of Epidemiology and Public Health (DEPH)

### 30. Community Activities:

#### Participant of activities in the following organizations

Fraternidade PAX Universal (Brotherhood for Universal Peace) 1996-present  
A non-profit, metaphysical organization in São Paulo, Brazil, that exists for 22 years to gather people to meditate for Universal Peace and Healing, with the objective of awakening people's consciousness for the Third Millennium.

Theosophical Society, member at large 2000-present  
Miami-Dade Blavatsky Theosophical Lodge 2002-present  
(<http://www.logiablavatsky.com>)

The Theosophical Society, founded in 1875, is a worldwide body whose primary object is "Universal Brotherhood based on the realization that life, and all its diverse forms, human and non-human, is indivisibly One". The Society imposes no belief on its members, who are united by a common search for Truth and desire to learn the meaning and purpose of existence through study, reflection, self-responsibility and loving service. Theosophy is the wisdom underlying all religions when they are stripped of accretions and superstitions. It offers a philosophy which renders life intelligible and demonstrates that justice and love guide the cosmos. Its teachings aid the unfoldment of the latent spiritual nature in the human being, without dependence. The Society is composed of students belonging to any religion or to none. Its members are united by their approval of the Society's Three Objects, by their wish to remove religious antagonisms and to draw together people of goodwill whatsoever their religious opinions, and by their desire to study religious truths and to share the results of their studies with others. Theosophists respect the different beliefs. They see each religion as an expression of the Divine Wisdom, adapted to the needs of a particular time and place.

Headquarters: Chennai, Madras, India ([www.ts-adyar.org](http://www.ts-adyar.org)); In USA: The Theosophical Society in America (<http://www.theosophical.org>).